AstraZeneca (AZN) 6-K 30 Jul 21 2021 Q2 Current report (foreign) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2021
Document and Entity Information
Entity Registrant Name	ASTRAZENECA PLC
Entity Central Index Key	0000901832
Document Type	6-K
Document Period End Date	Jun. 30, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Consolidated Statement of Comprehensive Income
Total Revenue	$ 8,220	$ 6,275	$ 15,540	$ 12,629
Product Sales	8,045	6,048	15,302	12,359
Collaboration Revenue	175	227	238	270
Cost of sales	(2,191)	(984)	(4,055)	(2,404)
Gross Profit	6,029	5,291	11,485	10,225
Distribution costs	(103)	(104)	(202)	(191)
Research and development expense	(1,829)	(1,389)	(3,542)	(2,777)
Selling, general and administrative costs	(3,098)	(2,635)	(6,027)	(5,354)
Other operating income and expense	128	121	1,308	601
Operating Profit	1,127	1,284	3,022	2,504
Finance income	7	22	27	73
Finance expense	(326)	(329)	(629)	(661)
Share of after-tax losses in associates and joint ventures	(44)	(16)	(48)	(20)
Profit Before Tax	764	961	2,372	1,896
Taxation	(214)	(223)	(260)	(408)
Profit for the period	550	738	2,112	1,488
Other comprehensive income:
Remeasurement of the defined benefit pension liability	211	(645)	692	(205)
Net (losses)/gains on equity investments measured at fair value through other comprehensive income	81	898	(27)	1,069
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss	1	(15)	2	6
Tax on items that will not be reclassified to profit or loss	146	(13)	52	(79)
Total other comprehensive income that will not be reclassified to profit or loss, net of tax	439	225	719	791
Foreign exchange arising on consolidation	166	114	59	(494)
Foreign exchange arising on designated borrowings in net investment hedges	72	363	(230)	(17)
Fair value movements on cash flow hedges	27	56	(59)	(131)
Fair value movements on cash flow hedges transferred to profit or loss	(48)	(46)	73	(1)
Fair value movements on derivatives designated in net investment hedges	(6)		7	60
Costs of hedging	(1)	9	(2)	4
Tax on items that may be reclassified subsequently to profit or loss	(8)	(44)	18	29
Other comprehensive income that may be reclassified to profit or loss, net of tax	202	452	(134)	(550)
Other comprehensive income for the period, net of tax	641	677	585	241
Total comprehensive income for the period	1,191	1,415	2,697	1,729
Owners of the Parent	550	756	2,111	1,536
Non-controlling interests		(18)	1	(48)
Total comprehensive income attributable to:
Owners of the Parent	1,190	1,432	2,696	1,777
Non-controlling interests	1	(17)	1	(48)
Total comprehensive income for the period	$ 1,191	$ 1,415	$ 2,697	$ 1,729
Basic earnings loss per (in dollars per share)	$ 0.42	$ 0.58	$ 1.61	$ 1.17
Diluted earnings loss per Share (in dollars per share)	$ 0.42	$ 0.58	$ 1.60	$ 1.17
Weighted average number of Ordinary Shares in issue for basic earnings	1,312	1,312	1,312	1,312
Diluted weighted average number of Ordinary Shares in issue (millions)	1,318	1,313	1,319	1,313

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income (Parenthetical) - $ / shares	Jun. 30, 2021	Jun. 30, 2020
Consolidated Statement of Comprehensive Income
Par value per ordinary share	$ 0.25	$ 0.25

Consolidated Statement of Finan

Consolidated Statement of Financial Position - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Non-current assets
Property, plant and equipment	$ 8,357	$ 8,251	$ 7,475
Right-of-use assets	674	666	634
Goodwill	11,798	11,845	11,645
Intangible assets	20,006	20,947	19,728
Derivative financial instruments	124	171	122
Investments in associates and joint ventures	48	39	41
Other investments	1,072	1,108	1,577
Other receivables	565	720	644
Deferred tax assets	3,723	3,438	3,133
Total non-current assets	46,367	47,185	44,999
Current assets
Inventories	4,762	4,024	3,562
Trade and other receivables	6,356	7,022	5,024
Other investments	62	160	442
Derivative financial instruments	41	142	16
Income tax receivable	486	364	213
Cash and cash equivalents	15,567	7,832	5,673
Total current assets	27,274	19,544	14,930
Total assets	73,641	66,729	59,929
Current liabilities
Interest-bearing loans and borrowings	(2,696)	(2,194)	(3,958)
Lease liabilities	(198)	(192)	(174)
Trade and other payables	(17,729)	(15,785)	(12,028)
Derivative financial instruments	(17)	(33)	(35)
Provisions	(802)	(976)	(612)
Income tax payable	(780)	(1,127)	(1,376)
Current liabilities	(22,222)	(20,307)	(18,183)
Non-current liabilities
Interest-bearing loans and borrowings	(24,109)	(17,505)	(15,150)
Lease liabilities	(492)	(489)	(465)
Derivative financial instruments	(3)	(2)	(121)
Deferred tax liabilities	(2,927)	(2,918)	(2,526)
Retirement benefit obligations	(2,383)	(3,202)	(2,847)
Provisions	(620)	(584)	(835)
Other payables	(5,192)	(6,084)	(6,144)
Total non-current liabilities	(35,726)	(30,784)	(28,088)
Total liabilities	(57,948)	(51,091)	(46,271)
Net assets	15,693	15,638	13,658
Equity
Share capital	328	328	328
Share premium account	7,980	7,971	7,950
Other reserves	2,033	2,024	2,046
Retained earnings	5,335	5,299	1,913
Total equity attributable to owners of parent	15,676	15,622	12,237
Non-controlling interests	17	16	1,421
Total equity	$ 15,693	$ 15,638	$ 13,658

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - USD ($) $ in Millions	Share Capital	Share Premium account	Other reserves	Retained earnings.	Total attributable to owners of the parent	Non-controlling interests.	Total
Equity at beginning of period at Dec. 31, 2019	$ 328	$ 7,941	$ 2,046	$ 2,812	$ 13,127	$ 1,469	$ 14,596
Profit for the period				1,536	1,536	(48)	1,488
Other comprehensive income				241	241		241
Dividends				(2,489)	(2,489)		(2,489)
Issue of Ordinary Shares		9			9		9
Share-based payments charge for the period				118	118		118
Settlement of share plan awards				(305)	(305)		(305)
Net movement		9		(899)	(890)	(48)	(938)
Equity at end of period at Jun. 30, 2020	328	7,950	2,046	1,913	12,237	1,421	13,658
Equity at beginning of period at Dec. 31, 2020	328	7,971	2,024	5,299	15,622	16	15,638
Profit for the period				2,111	2,111	1	2,112
Other comprehensive income				585	585		585
Transfer to other reserves			9	(9)
Dividends				(2,490)	(2,490)		(2,490)
Issue of Ordinary Shares		9			9		9
Share-based payments charge for the period				160	160		160
Settlement of share plan awards				(321)	(321)		(321)
Net movement		9	9	36	54	1	55
Equity at end of period at Jun. 30, 2021	$ 328	$ 7,980	$ 2,033	$ 5,335	$ 15,676	$ 17	$ 15,693

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Profit Before Tax	$ 2,372	$ 1,896
Finance income and expense	602	588
Share of after-tax losses of associates and joint ventures	48	20
Depreciation, amortisation and impairment	1,550	1,551
Decrease/(increase) in working capital and short-term provisions	857	(780)
Gains on disposal of intangible assets	(354)	(411)
Gains on disposal of investments in associates and joint ventures	(776)
Fair value movements on contingent consideration arising from business combinations	82	(44)
Non-cash and other movements	(363)	(511)
Cash generated from operations	4,018	2,309
Interest paid	(323)	(338)
Tax paid	(869)	(792)
Net cash outflow from operating activities	2,826	1,179
Cash flows from investing activities
Payment of contingent consideration from business combinations	(309)	(353)
Purchase of property, plant and equipment	(508)	(370)
Disposal of property, plant and equipment	4	67
Purchase of intangible assets	(314)	(983)
Disposal of intangible assets	573	474
Purchase of non-current asset investments	(10)	(119)
Disposal of non-current asset investments		949
Movement in short-term investments, fixed deposits and other investing instruments	135	463
Payments to associates and joint ventures	(55)	(8)
Disposal of investments in associates and joint ventures	776
Interest received	27	37
Net cash outflow from investing activities	319	157
Net cash inflow before financing activities	3,145	1,336
Cash flows from financing activities
Proceeds from issue of share capital	9	9
Repayment of loans	(611)
Issue of loans	7,944
Dividends paid	(2,469)	(2,398)
Hedge contracts relating to dividend payments	(22)	(93)
Repayment of obligations under leases	(111)	(107)
Movement in short-term borrowings	(182)	1,353
Net cash inflow/(outflow) from financing activities	4,558	(1,236)
Net increase in cash and cash equivalents in the period	7,703	100
Cash and cash equivalents at the beginning of the period	7,546	5,223
Exchange rate effects	(52)	(18)
Cash and cash equivalents at the end of the period	15,197	5,305
Cash and cash equivalents	15,567	5,673
Overdrafts	$ (370)	$ (368)

Basis of Preparation and Accoun

Basis of Preparation and Accounting Policies	6 Months Ended
	Jun. 30, 2021
Basis of Presentation and Accounting Policies
Basis of Presentation and Accounting Policies	1) Basis of preparation and accounting policies These unaudited Interim Financial Statements for the six months ended 30 June 2021 have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34, and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority. On 31 December 2020, EU-adopted IFRS at that date was brought into UK law and became UK-adopted international accounting standards, with future changes being subject to endorsement by the UK Endorsement Board. The Interim Financial Statements have transitioned to UK-adopted international accounting standards from financial periods beginning 1 January 2021. There was no impact or changes in accounting policies from the transition. ​ The unaudited Interim Financial Statements for the six months ended 30 June 2021 were approved by the Board of Directors for publication on 29 July 2021. ​ The annual financial statements of the group for the year ended 31 December 2020 were prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006, International Financial Reporting Standards (IFRSs) adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the EU and IFRSs as issued by the International Accounting Standards Board (IASB). Except as noted below and for the estimation of the interim income tax charge, the Interim Financial Statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2020. ​ IFRS 9 and IFRS 7 The replacement of benchmark interest rates, such as the London Inter-bank Offered Rate (LIBOR) and other interbank offered rates (IBORs) has been a priority for global regulators and is expected to be largely completed in 2021, although some benchmark rates will be continued to be published until mid-2023. To prepare for this, the Group adopted the Phase 1 amendments to IFRS 9 ‘Financial Instruments’ and IFRS 7 ‘Financial Instruments: Disclosures’ in 2019 and has adopted the Phase 2 amendments in 2021. These amendments provide relief from applying specific hedge accounting requirements to hedge relationships directly affected by IBOR reform and have the effect that the reform should generally not cause hedge accounting to terminate. ​ The Group has one IFRS 9 designated hedge relationship that is impacted by IBOR reform, namely a €300m cross currency interest rate swap in a fair value hedge relationship with €300m of a €750m 0.875% 2021 non-callable bond. This swap references three-month USD LIBOR; uncertainty arising from the Group’s exposure to IBOR reform will cease when the swap matures in November 2021. The implications on the wider business of IBOR reform have been assessed and the Group is working on moving to new benchmark rates in the second half of 2021. ​ COVID-19 AstraZeneca has assessed the impact of the uncertainty presented by the COVID-19 pandemic on the Interim Financial Statements comprising the financial results to 30 June 2021 and the financial position as at 30 June 2021, specifically considering the impact on key judgements and significant estimates as detailed on page 180 of the Annual Report and 20-F Information 2020 along with several other areas of elevated risk during the pandemic period. A detailed assessment has been performed, focussing on the following areas: - recoverable value of goodwill, intangible assets and property, plant and equipment - impact on key assumptions used to estimate contingent consideration liabilities - key assumptions used in estimating the Group’s defined benefit pension obligations - basis for estimating clinical trial accruals - key assumptions used in estimating rebates, chargebacks and returns for US Product Sales - valuations of unlisted equity investments - expected credit losses associated with changes in credit risk relating to trade and other receivables - net realisable value of inventories - fair value of certain financial instruments - recoverability of deferred tax assets - effectiveness of hedge relationships ​ There were no material accounting impacts identified relating to the above areas during the six-month period ended 30 June 2021. The Group will continue to monitor these areas of increased judgement, estimation and risk for material changes. Going concern The Group has considerable financial resources available. As at 30 June 2021, the Group had $19.7bn in financial resources (cash and cash-equivalent balances of $15.6bn and undrawn committed bank facilities of $4.1bn, of which $3.4bn is available until April 2024, $0.7bn is available until November 2021 (with a one-year extension option, exercisable by the Group), with only $2.9bn of borrowings due within one year). Additionally, as at 30 June 2021, to support the financing of the acquisition of Alexion, the Group had committed bank facilities totalling $9.5bn. All facilities contain no financial covenants and were undrawn at 30 June 2021. On 21 July 2021, cash consideration of $13.3bn was paid on completion of the acquisition of Alexion. $2.0bn of two year and $2.0bn of three-year term loans were drawn on 21 July 2021 under the committed bank facilities of $9.5bn, which may be repaid at the Group’s option before maturity and a further $4.5bn of facilities were cancelled. The remaining $1.0bn of revolving credit facility is available until July 2023. On acquisition date and after repaying its $2.3bn bank loans from existing cash resources, Alexion contributed $1.7bn of cash and cash equivalents, and no The directors have considered the impact of COVID-19 on AstraZeneca’s operations and mitigations to these risks. Overall, the impact of these items would heighten certain risks, such as those relating to the delivery of the pipeline or launch of new medicines, the execution of AstraZeneca’s commercial strategy, the manufacturing and supply of medicines and reliance on third-party goods and services. The Group is continuously monitoring and mitigating where possible impacts of these risks. The Group’s revenues are largely derived from sales of medicines covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to affect adversely revenues in many of the mature markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well-placed to manage its business risks successfully. Accordingly, the going concern basis has been adopted in these Interim Financial Statements. Legal proceedings The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 2020 ​ Financial information The comparative figures for the financial year ended 31 December 2020 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the registrar of companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006

Intangible assets

Intangible assets	6 Months Ended
	Jun. 30, 2021
Intangible assets
Intangible assets	2) Intangible assets In accordance with IAS 36 ‘Impairment of Assets’, reviews for triggers at an individual asset or cash-generating-unit level were conducted, and impairment tests carried out where triggers were identified. This resulted in a total net impairment charge of $55m being recorded against an intangible asset during the six months ended 30 June 2021 (H1 2020: $119m). Net impairment charges in respect of launched products and products in development were $nil

Net Debt

Net Debt	6 Months Ended
	Jun. 30, 2021
Net Debt
Net Debt	3) Net Debt The table below provides an analysis of Net Debt and a reconciliation of Net Cash Flow to the movement in Net Debt. The Group monitors Net Debt as part of its capital-management policy as described in Note 27 of the Annual Report and Form 20-F Information 2020 . Net Debt is a non-GAAP financial measure. Table 48: Net Debt ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At 1 Jan ​ Cash ​ Non-cash ​ Exchange ​ At 30 Jun ​ ​ 2021 ​ flow ​ & other ​ movements ​ 2021 ​ $m $m $m $m $m Non-current instalments of loans (17,505) ​ (7,944) ​ 1,257 ​ 83 ​ (24,109) Non-current instalments of leases ​ (489) ​ - ​ (9) ​ 6 ​ (492) Total long-term debt (17,994) ​ (7,944) ​ 1,248 ​ 89 ​ (24,601) Current instalments of loans (1,536) ​ 611 ​ (1,248) ​ 37 ​ (2,136) Current instalments of leases (192) ​ 117 ​ (127) ​ 4 ​ (198) Bank collateral (288) ​ 120 ​ - ​ - ​ (168) Other short-term borrowings excluding overdrafts ​ (84) ​ 62 ​ - ​ - ​ (22) Overdraft (286) ​ (91) ​ - ​ 7 ​ (370) Total current debt ​ (2,386) ​ 819 ​ (1,375) ​ 48 ​ (2,894) Gross borrowings ​ (20,380) ​ (7,125) ​ (127) ​ 137 ​ (27,495) Net derivative financial instruments ​ 278 ​ (15) ​ (118) ​ - ​ 145 Net borrowings ​ (20,102) ​ (7,140) ​ (245) ​ 137 ​ (27,350) Cash and cash equivalents ​ 7,832 ​ 7,794 ​ - ​ (59) ​ 15,567 Other investments - current ​ 160 ​ (98) ​ - ​ - ​ 62 Cash and investments ​ 7,992 ​ 7,696 ​ - ​ (59) ​ 15,629 Net Debt ​ (12,110) ​ 556 ​ (245) ​ 78 ​ (11,721) ​ Non-cash movements in the period include fair-value adjustments under IFRS 9. The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions above a predetermined threshold. The carrying value of such cash collateral held by the Group was $168 m (H1 2020: $136 m) and the carrying value of such cash collateral posted by the Group was $1 m (H1 2020: $120 m). Cash collateral posted by the Group is presented within Cash and cash equivalents. Other investments – non-current are included within the balance of $1,072 m (31 December 2020: $1,108 m) in the Condensed consolidated statement of financial position. The equivalent GAAP measure to net debt is ‘liabilities arising from financing activities’, which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes the Acerta Pharma liability of $2,375 m (31 December 2020: $2,297 m), $889 m of which is shown in current other payables and $1,486 m is shown in non-current other payables. In April 2021, AstraZeneca exercised its option to acquire the remaining 45% of shares in Acerta. Net Debt decreased by $389 m in the six months to $11,721 m. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. In May 2021 and June 2021, AstraZeneca issued the following: - $1,400m of fixed-rate notes with a coupon of 0.300%, maturing in May 2023 - $1,600m of fixed-rate notes with a coupon of 0.700%, maturing in May 2024 - $1,250m of fixed-rate notes with a coupon of 1.200%, maturing in May 2026 - $1,250m of fixed-rate notes with a coupon of 1.750%, maturing in May 2028 - $750m of fixed-rate notes with a coupon of 2.250%, maturing in May 2031 - $750m of fixed-rate notes with a coupon of 3.000%, maturing in May 2051 - €800m of fixed-rate notes with a coupon of 0.375%, maturing in June 2029 ​ During the six months to 30 June 2021, there were no changes to the Company’s credit ratings issued by S&P Global Ratings (long term: BBB+, short term A-2) and Moody’s (long term: A3, short term P-2). In July 2021, following the acquisition of Alexion, S&P Global Ratings upgraded AstraZeneca’s long-term credit rating to A- .

Financial Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2021
Financial Instruments
Financial Instruments	4) Financial instruments As detailed in the Group’s most recent annual financial statements, the principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, lease liabilities and interest-bearing loans and borrowings. During the period, equity investments previously categorised as Level 3 in the fair-value hierarchy (carrying value of $108 m at 31 December 2020) are now categorised as Level 1 (carrying value of $133 m at 30 June 2021) on availability of quoted prices in the market. There have been no other changes of significance to the categorisation or fair-value hierarchy classification of financial instruments from those detailed in the Notes to the Group Financial Statements in the Annual Report and Form 20-F Information 2020 . The Group holds certain equity investments that are categorised as Level 3 in the fair-value hierarchy and for which fair-value gains of $nil Financial instruments measured at fair value include $1,134 m of other investments, $13,637 m held in money-market funds, $329 m of loans designated at fair value through profit or loss, $359 m of loans designated in a fair-value hedge relationship and $145 m of derivatives as at 30 June 2021. The total fair value of interest-bearing loans and borrowings at 30 June 2021, which have a carrying value of $27,495 m in the Condensed consolidated statement of financial position, was $30,412 m. Contingent consideration liabilities arising on business combinations have been classified under Level 3 in the fair-value hierarchy and movements in fair value are shown below: Table 49: Financial instruments - contingent consideration ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ 2020 ​ ​ Diabetes ​ ​ ​ ​ ​ ​ ​ alliance ​ Other ​ Total ​ Total ​ ​ $m ​ $m ​ $m ​ $m At 1 January 2,932 ​ 391 ​ 3,323 ​ 4,139 Settlements (304) ​ (5) ​ (309) ​ (353) Revaluations ​ 82 ​ – ​ 82 ​ (44) Discount unwind 99 ​ 13 ​ 112 ​ 141 At 30 June 2,809 ​ 399 ​ 3,208 ​ 3,883 ​ Contingent consideration arising from business combinations is fair-valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues. ​ The contingent consideration balance relating to BMS’s share of the global diabetes alliance of $2,809m (31 December 2020: $2,932m) would increase/decline by $281m with an increase/decline in sales of 10%, as compared with the current estimates.

Legal Proceedings and Contingen

Legal Proceedings and Contingent Liabilities	6 Months Ended
	Jun. 30, 2021
Legal Proceedings and Contingent Liabilities
Legal Proceedings and Contingent Liabilities	5) Legal proceedings and contingent liabilities AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations relating to product liability, commercial disputes, infringement of intellectual property (IP) rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2020 (the Disclosures). Unless noted otherwise below or in the Disclosures, no provisions have been established in respect of the claims discussed below. As discussed in the disclosures, the majority of claims involve highly complex issues. Often these issues are subject to substantial uncertainties and, therefore, the probability of a loss, if any, being sustained and/or an estimate of the amount of any loss is difficult to ascertain. ​ Unless specifically identified below that a provision has been taken, AstraZeneca considers each of the claims to represent a contingent liability and discloses information with respect to the nature and facts of the cases in accordance with IAS 37. ​ There is one matter, which is considered probable that an outflow will be required, but for which we are unable to make an estimate of the possible loss or range of possible losses at this stage. ​ In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected loss. The position could change over time and the estimates that the Company made, and upon which the Company have relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the Disclosures and herein. AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP . Matters disclosed in respect of the second quarter of 2021 and to 29 July 2021 ​ Patent litigation ​ Enhertu US patent proceedings As previously disclosed, in October 2020, Seagen Inc. (Seagen) filed a complaint against Daiichi Sankyo Company, Limited in the US District Court for the Eastern District of Texas (the Texas Court) alleging that Enhertu Enhertu ​ Faslodex Patent Proceedings outside the US As previously disclosed, in Japan, in April 2021, AstraZeneca received notice from the Japan Patent Office that Sandoz K.K. filed a Request for Invalidation Trial to seek invalidation of the Faslodex formulation patent. AstraZeneca is considering its response. ​ Farxiga US patent proceedings As previously disclosed, in 2018, in response to Paragraph IV notices, AstraZeneca initiated ANDA litigation against Zydus Pharmaceuticals (USA) Inc. (Zydus) in the US District Court for the District of Delaware (the District Court). Trial against Zydus proceeded in the District Court in May 2021. A decision is expected in the second half of 2021. Patent proceedings outside the US As previously disclosed, in Canada, in January 2021, Sandoz Canada Inc. served three Notices of Allegation on AstraZeneca alleging invalidity and/or non-infringement of all three patents listed on the Canadian Patent Register in relation to Forxiga ​ As previously disclosed, in Canada, in February 2021, Teva Canada Limited served a Notice of Allegation on AstraZeneca alleging invalidity and/or non-infringement of all three patents listed on the Canadian Patent Register in relation to Forxiga ​ Roxadustat US Patent Proceedings As previously disclosed, in April 2021, Akebia Therapeutics, Inc. and Otsuka America Pharmaceutical, Inc. served AstraZeneca with a complaint seeking a declaration of invalidity and noninfringement for several of FibroGen’s method of use patents (U.S. Patent Nos. 8318703, 8466172, 8614204, 9920011, 8629131, 8604012, 8609646, 8604013, 10626090, 10894774, 10882827, and 10927081) related to HIF prolylhydroxylase inhibitors. AstraZeneca is the exclusive licensee of FibroGen in the United States. AstraZeneca filed a motion to dismiss in June 2021. Symbicort US Patent Proceedings As previously disclosed, AstraZeneca is involved in ongoing ANDA litigation with Mylan Pharmaceuticals Inc. (Mylan) and Kindeva Drug Delivery L.P. (Kindeva) in the US District Court for the Northern District of West Virginia (the District Court). In the action, AstraZeneca alleges that the defendants’ generic versions of Symbicort , if approved and marketed, would infringe various AstraZeneca patents. In September 2020, Mylan and Kindeva stipulated to patent infringement to the extent that the asserted patent claims are found to be valid and enforceable, but reserved the right to seek a vacatur of the stipulation if the U.S. Court of Appeals for the Federal Circuit reverses or modifies the District Court’s claim construction. In March 2021, the District Court decided in favour of AstraZeneca and determined that the asserted patent claims were not invalid or unenforceable. Mylan and Kindeva have appealed to the United States Court of Appeals for the Federal Circuit. Oral argument on the appeal is scheduled for 31 August 2021. ​ Product liability litigation ​ Nexium and Losec / Prilosec US proceedings As previously disclosed, in the US, AstraZeneca is defending various lawsuits brought in federal --and state courts involving multiple plaintiffs claiming that they have been diagnosed with various injuries following treatment with proton pump inhibitors (PPIs), including Nexium and Prilosec. The vast majority of those lawsuits relate to allegations of kidney injuries. In particular, in May 2017, counsel for a group of such plaintiffs claiming that they have been diagnosed with kidney injuries filed a motion with the Judicial Panel on Multidistrict Litigation (JPML) seeking the transfer of any currently pending federal court cases as well as any similar, subsequently filed cases to a coordinated and consolidated pre-trial multidistrict litigation (MDL) proceeding. In August 2017, the JPML granted the motion and consolidated the pending federal court cases in an MDL proceeding in federal court in New Jersey for pre-trial purposes. A trial in the MDL has been scheduled for January 2022. In addition to the MDL cases, there are cases filed in several state courts around the US; a trial in Delaware state court has been scheduled for February 2022. ​ In addition, AstraZeneca has been defending lawsuits involving allegations of gastric cancer following treatment with PPIs. One such claim is filed in the US District Court for the Middle District of Louisiana, where the court has re-scheduled a trial for November 2022. ​ Commercial litigation ​ PARP inhibitor royalty dispute In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline plc (GSK)) entered into two worldwide, royalty-bearing patent license agreements with AstraZeneca related to GSK’s product niraparib. In May 2021, AstraZeneca filed a lawsuit against Tesaro in the Commercial Court of England and Wales alleging that GSK has failed to pay all of the royalties due on niraparib sales under our license agreements. While a case schedule has not yet been set, trial is anticipated in the second half of 2022. ​ Alexion shareholder litigation As previously disclosed, in March 2021, several shareholders of Alexion Pharmaceuticals, Inc (Alexion) filed individual lawsuits against Alexion, its management, and/or AstraZeneca and affiliates in federal district court in New York. The complaints generally allege that the preliminary registration statement filed with the SEC on 19 February 2021, omitted certain allegedly material information in connection with AstraZeneca’s proposed acquisition of Alexion (the Acquisition), and one of the complaints further alleges that the Alexion directors breached their fiduciary duties in connection with the Acquisition and that AstraZeneca and the other entity defendants aided and abetted the alleged breaches. In May 2021, all such complaints were withdrawn and dismissed. ​ AZD1222 securities litigation As previously disclosed, in January 2021, putative securities class action lawsuits were filed in the US District Court for the Southern District of New York against AstraZeneca PLC and certain officers, on behalf of purchasers of AstraZeneca publicly traded securities during the period 21 May 2020 through 20 November 2020. The Court appointed co-lead plaintiffs in April 2021 and they filed an Amended Complaint in July 2021 on behalf of purchasers of AstraZeneca publicly traded securities during the period 15 June 2020 through 29 January 2021. The Amended Complaint alleges that defendants made materially false and misleading statements in connection with the development of AZD1222, AstraZeneca’s vaccine for the prevention of COVID-19. ​ Amplimmune In the US, in June 2017, AstraZeneca was served with a lawsuit filed by the stockholders’ agents for Amplimmune, Inc. (Amplimmune) in Delaware State Court that alleged, among other things, breaches of contractual obligations relating to a 2013 merger agreement between AstraZeneca and Amplimmune. A trial of the matter was held in February and post-trial oral argument was heard in August 2020. In November 2020, the Court decided in AstraZeneca’s favour and subsequently entered a Final Judgment as to all pending claims in favour of AstraZeneca. In December 2020, the plaintiffs filed an appeal to the Delaware Supreme Court. The argument is scheduled to be heard in October 2021. Anti-Terrorism Act civil lawsuit In the US, in July 2020, the US District Court for the District of Columbia granted AstraZeneca’s and certain other pharmaceutical and/or medical device companies’ motion and dismissed a lawsuit filed by US nationals (or their estates, survivors, or heirs) who were killed or wounded in Iraq between 2005 and 2011, which had alleged that the defendants violated the US Anti-Terrorism Act and various state laws by selling pharmaceuticals and medical supplies to the Iraqi Ministry of Health. The plaintiffs are appealing the District Court’s order dismissing the litigation. The DC Circuit Court of Appeals has scheduled oral argument on the plaintiffs’ appeal for September 2021. Government investigations/proceedings ​ Tagrisso In India, in June 2021, the National Pharmaceutical Pricing Authority (NPPA) issued a demand notice (Demand Notice) to AstraZeneca Pharma India Limited (AZPIL), regarding the pricing of Tagrisso . The NPPA has alleged that AZPIL has overcharged Tagrisso , claiming approximately $21 m plus interest. AZPIL has challenged the Demand Notice in the Delhi High Court. US 340B litigations and proceedings As previously disclosed, AstraZeneca is involved in several matters relating to its policy with regard to contract pharmacy recognition under the 340B Drug Pricing Program in the US . In October and November 2020, two lawsuits, one in the US District Court for the District of Columbia and one in the US District Court for the Northern District of California, were filed by covered entities and advocacy groups against the US Department of Health and Human Services, the US Health Resources and Services Administration as well as other US government agencies and their officials. The complaints allege, among other things, that these agencies should enforce an interpretation of the governing statute for the 340B Drug Pricing Program that would require drug manufacturers participating in the program to offer their drugs for purchase at statutorily capped rates by an unlimited number of contract pharmacies. AstraZeneca has sought to intervene in the lawsuits. The case in US District Court for the District of Columbia is currently stayed pending further proceedings and the case in federal court in California has been dismissed. Administrative Dispute Resolution (ADR) proceedings have also been initiated against AstraZeneca before the US Health Resources and Services Administration. In February 2021, AstraZeneca received a Civil Investigative Subpoena from the Attorney General’s Office for the State of Vermont seeking documents and information relating to AstraZeneca’s policy regarding contract pharmacy recognition under the 340B Drug Pricing Program. We continue to cooperate with the inquiry. In addition, in January 2021, AstraZeneca filed a separate lawsuit in federal court in Delaware alleging that a recent Advisory Opinion issued by the Department of Health and Human Services violates the Administrative Procedure Act. I n June 2021, the Court found in favour of AstraZeneca, invalidating the Advisory Opinion. Prior to the Court’s ruling, however, on 17 May 2020, the US government issued new and separate letters to AstraZeneca (and other companies) asserting that the Company’s contract pharmacy policy violates the 340B statute. In July 2021, AstraZeneca amended the complaint filed in federal court in Delaware to include allegations challenging the letter sent on 17 May. Toprol - XL Louisiana Attorney General litigation As previously disclosed, in July 2020, the Louisiana First Circuit Court of Appeals (the Appellate Court) reversed and remanded Trial Toprol-XL patents. August 2020, The Supreme Court heard oral argument on ​ European Commission claim regarding AZD1222 As previously disclosed, in April 2021 and May 2021, the European Commission (acting on behalf of the European Union and its member states) initiated two separate legal proceedings against AstraZeneca AB in the Court of First Instance in Brussels. Both proceedings relate to an Advance Purchase Agreement between the parties dated 27 August 2020 (the APA) for the supply of AZD1222. The allegations include claims that AstraZeneca has failed to meet certain of its obligations under the APA and the European Commission is seeking, among other things, a Court order to compel AstraZeneca to supply a specified number of doses before the end of the second quarter of 2021. In June 2021, the Court issued a decision in the first proceeding finding that AstraZeneca did not meet its Best Reasonable Efforts obligation in the APA because AstraZeneca did not use all of the manufacturers listed in the APA to supply the member states. The Court ordered AstraZeneca to provide an additional 50 million doses of vaccine by the end of September 2021, which AstraZeneca exceeded by the end of June 2021. The Court denied the remainder of the Commission’s claims and requested relief. AstraZeneca is considering its next steps with regard to the first proceeding. The second proceeding filed by the European Commission seeks interim relief, documents, and damages. A hearing is scheduled on the interim relief and documents in September 2021. COVID-19 vaccine supply and manufacturing inquiries In June 2021, Argentina’s Federal Criminal Prosecutor’s Office contacted AstraZeneca Argentina seeking documents and electronic records in connection with a local criminal investigation relating to the public procurement and supply of Vaxzevria in that country. Matters disclosed in respect of the first quarter of 2021 and to 30 April 2021 ​ Patent litigation Enhertu US patent proceedings As previously disclosed, in October 2020, Seagen Inc. (Seagen) filed a complaint against Daiichi Sankyo Company, Limited in the US District Court for the Eastern District of Texas alleging that Enhertu Enhertu ​ In November 2020, AstraZeneca, Daiichi Sankyo Company, Limited and Daiichi Sankyo Inc. filed a complaint ​ Faslodex Patent Proceedings outside the US In Japan, in April 2021, AstraZeneca received notice from the Japan Patent Office that Sandoz K.K. filed a Request for Invalidation Trial to seek invalidation of the Faslodex ​ Farxiga US patent proceedings As previously disclosed, in 2018, in response to Paragraph IV notices, AstraZeneca initiated ANDA litigation against Zydus Pharmaceuticals (USA) Inc. (Zydus) in the US District Court for the District of Delaware. In the complaint, AstraZeneca alleged that Zydus’ generic version of Farxiga Farxiga ​ Patent proceedings outside the US As previously disclosed, in Canada, in January 2021, Sandoz Canada Inc. served three Notices of Allegation on AstraZeneca alleging invalidity and/or non-infringement of all three patents listed on the Canadian Patent Register in relation to Forxiga. AstraZeneca commenced litigation in response. ​ In Canada, in February 2021, Teva Canada Limited served a Notice of Allegation on AstraZeneca alleging invalidity and/or non-infringement of all three patents listed on the Canadian Patent Register in relation to Forxiga ​ Onglyza Patent proceedings outside the US As previously disclosed, in Canada, in November 2019, Sandoz Canada Inc. sent a Notice of Allegation to AstraZeneca challenging the validity of Canadian substance Patent No. 2402894 (expiry March 2021) (the ‘894 patent) and formulation Patent No. 2568391 (expiry May 2025) related to Onglyza ​ Roxadustat US Patent Proceedings In April 2021, Akebia Therapeutics, Inc. and Otsuka America Pharmaceutical, Inc. served AstraZeneca with a complaint seeking a declaration of invalidity and noninfringement for several of FibroGen method of use patents (U.S. Patent Nos. 8318703, 8466172, 8614204, 9920011, 8629131, 8604012, 8609646, 8604013, 10626090, 10894774, 10882827, and 10927081) related to HIF prolylhydroxylase inhibitors. AstraZeneca is the exclusive licensee of FibroGen in the United States. AstraZeneca is considering its response. ​ Patent proceedings outside the US As previously disclosed, in Canada, in May 2018, Akebia Therapeutics, Inc. filed an impeachment action in the Federal Court of Canada alleging invalidity of several of FibroGen’s method of use patents (Canadian Patent Nos. 2467689; 2468083; and 2526496) related to HIF prolylhydroxylase inhibitors. AstraZeneca is the exclusive licensee of FibroGen in Canada. AstraZeneca and FibroGen were defending the action. The parties have settled the action. ​ Symbicort US patent proceedings As previously disclosed, in October 2018, AstraZeneca initiated ANDA litigation against Mylan and subsequently against 3M Company (3M) in the US District Court for the Northern District of West Virginia (the District Court). In the action, AstraZeneca alleges that the defendants’ generic versions of Symbicort 2021, the District Court ​ Product liability litigation ​ Byetta/Bydureon As previously disclosed, in the US, Amylin Pharmaceuticals, LLC, a wholly owned subsidiary of AstraZeneca, and/ or AstraZeneca are among multiple defendants in various lawsuits filed in federal and state courts involving claims of physical injury from treatment with Byetta Bydureon lawsuits in California state courts. In October and December 2020, the District Court and the California Court jointly heard oral argument on renewed motions filed by Defendants seeking summary judgment and dismissal of all claims alleging pancreatic cancer. In March and April 2021, the District Court and the California State Court respectively granted the Defendants’ motions, and dismissed all cases alleging pancreatic cancer with prejudice. The plaintiffs have provided notice that they intend to appeal. The other claims pending in both courts, including those alleging thyroid cancer, remains pending. ​ Nexium and Losec/Prilosec US proceedings As previously disclosed, in the US, AstraZeneca is defending various lawsuits brought in federal and state courts involving multiple plaintiffs claiming that they have been diagnosed with various injuries following treatment with proton pump inhibitors (PPIs), including Nexium Prilosec ​ In addition, AstraZeneca has been defending lawsuits involving allegations of gastric cancer following treatment with PPIs. All but one of these claims is filed in the MDL. One claim is filed in the US District Court for the Middle District of Louisiana, where the court has rescheduled a trial for August 2022. ​ Commercial litigation ​ Alexion shareholder litigation In March 2021, several shareholders of Alexion filed individual lawsuits against Alexion, its management, and/or AstraZeneca and affiliates in federal district court in New York. The complaints generally allege that the preliminary registration statement filed with the SEC on 19 February 2021, omitted certain allegedly material information in connection with AstraZeneca’s proposed acquisition of Alexion (the Acquisition), and one of the complaints further alleges that the Alexion directors breached their fiduciary duties in connection with the Acquisition and that AstraZeneca and the other entity defendants aided and abetted the alleged breaches. ​ AZD1222 securities litigation As previously disclosed, in January 2021, putative securities class action lawsuits were filed in the US District Court for the Southern District of New York against AstraZeneca PLC and certain officers, on behalf of purchasers of AstraZeneca publicly traded securities during the period 21 May 2020 through 20 November 2020. The complaints allege that defendants made materially false and misleading statements in connection with the development of AZD1222 (pandemic COVID-19 vaccine), a potential recombinant adenovirus vaccine for the prevention of COVID-19. In March 2021, motions for consolidation of the pending lawsuits and appointment of a lead plaintiff and its counsel were filed and remain pending. ​ Ocimum lawsuit As previously disclosed, in the US, in December 2017, AstraZeneca was served with a complaint filed by Ocimum Biosciences, Ltd. (Ocimum) in the Superior Court for the State of Delaware (the Delaware Supreme Court) that alleged, among other things, breaches of contractual obligations and misappropriation of trade secrets, relating to a now terminated 2001 licensing agreement between AstraZeneca and Gene Logic, Inc. (Gene Logic), the rights to which Ocimum purports to have acquired from Gene Logic. In February 2021, the Delaware Supreme court affirmed the grant of AstraZeneca’s motion for summary judgment. This matter is now concluded. ​ Government investigations/proceedings ​ Toprol-XL Louisiana Attorney General litigation As previously disclosed, in July 2020, the Louisiana First Circuit Court of Appeals (the Appellate Court) reversed and remanded a Louisiana state trial court (the Trial Court) ruling that had granted AstraZeneca’s motion for summary judgment and dismissed a state court complaint, brought by the Attorney General for the State of Louisiana (the State), alleging that AstraZeneca engaged in unlawful monopolisation and unfair trade practices in connection with the enforcement of its Toprol-XL ​ US 340B litigations and proceedings As previously disclosed, AstraZeneca is involved in several matters relating to its policy with regard to contract pharmacy recognition under the 340B Drug Pricing Program in the US. In October and November 2020, two lawsuits, one in the US District Court for the District of Columbia and one in the US District Court for the Northern District of California, were filed by covered entities and advocacy groups against the US Department of Health and Human Services, the US Health Resources and Services Administration as well as other US government agencies and their officials. The complaints allege, among other things, that these agencies should enforce an interpretation of the governing statute for the 340B Drug Pricing Program that would require drug manufacturers participating in the program to offer their drugs for purchase at statutorily capped rates by an unlimited number of contract pharmacies. ​ AstraZeneca has sought to intervene in the lawsuits. Administrative Dispute Resolution (ADR) proceedings have also been initiated against AstraZeneca before the US Health Resources and Services Administration. In addition, in January 2021, AstraZeneca filed a separate lawsuit in federal court in Delaware alleging that a recent Advisory Opinion issued by the Department of Health and Human Services violates the Administrative Procedure Act. In February 2021, AstraZeneca received a Civil Investigative Subpoena from the Attorney General’s Office for the State of Vermont seeking documents and information relating to AstraZeneca’s policy regarding contract pharmacy recognition under the 340B Drug Pricing Program. ​ European Commission claim regarding AZD1222 In April 2021, the European Commission (acting on behalf of the European Union and its member states) initiated legal proceedings against AstraZeneca AB in the Court of First Instance in Brussels. The proceedings relate to an Advance Purchase Agreement (APA) between the parties dated 27 August 2020 for the supply of AZD1222. The allegations include claims that AstraZeneca has failed to meet certain of its obligations under the APA and the Commission is seeking, among other things, a Court order to compel AstraZeneca to supply a specified number of doses before the end of the second quarter of 2021. Taxation As previously disclosed in the Annual Report and Form 20-F Information 2020, AstraZeneca faces a number of audits and reviews in jurisdictions around the world and, in some cases, is in dispute with the tax authorities. The issues under discussion are often complex and can require many years to resolve. Accruals for tax contingencies require management to make key judgements and significant estimates with respect to the ultimate outcome of current and potential future tax audits, and actual results could vary from these estimates. The total net accrual to cover the worldwide tax exposure for transfer pricing and other international tax contingencies of $98 m (31 December 2020: $287 m) reflected the progress in those tax audits and reviews during the year and for those audits where AstraZeneca and tax authorities are in dispute, AstraZeneca estimates the potential for reasonably possible additional liabilities above and beyond the amount provided to be up to $29 m, including associated interest (31 December 2020: $251 m). There is no material change to other tax exposures.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events
Subsequent Events	6) Subsequent events On 21 July 2021, AstraZeneca completed the acquisition of 100% of the issued shares of Alexion Pharmaceuticals, Inc (Alexion), based in Boston, Massachusetts, US. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. ​ At closing, Alexion shareholders received 2.1243 AstraZeneca American Depository Shares (ADSs) and $60 in cash for each of their Alexion shares. Unvested Alexion employee share awards were converted to equivalent AstraZeneca share awards. The total fair value of the purchase consideration was $40bn, comprising AstraZeneca shares of $27bn and cash of $13bn. ​ The Group has funded the cash element of the acquisition with $8bn of new long-term debt, issued in May and June 2021, $4bn of term loans drawn in July 2021 under the $17.5bn committed bank facilities entered into in December 2020, and existing cash balances. The Group retains access to the revolving facility of $1bn entered into in December 2020 and cancelled the remaining $12.5bn of the facilities in June and July 2021. Changes to financing balances during the reporting period are included in Table 48 on Net Debt. ​ The acquisition will be accounted for as a business combination using the acquisition method of accounting in accordance with IFRS 3 ‘Business Combinations’ and consequently the Alexion assets acquired, and liabilities assumed will be recorded by AstraZeneca at fair value, with any excess of the purchase prices over the fair value of the identifiable assets and liabilities being recognised as goodwill. The majority of the consideration paid of $40bn will be attributed to the intangible assets acquired, primarily related to intellectual property rights over launched products and products under development, to inventory on balance sheet as at the acquisition date, and to the related deferred tax adjustments on these items. It is expected that Alexion’s five launched products comprising Soliris, Ultomiris, Strensiq, Kanuma Andexxa ​ Due to the proximity of the acquisition to the results announcement date, the Group has not completed the initial accounting for the acquisition and hence disclosures related to the fair valuation of the assets and liabilities acquired, including acquired receivables, resultant goodwill (including the factors that make up the goodwill), contingent liabilities, separately recognised transactions and proforma revenue and profit/loss were not determinable by the results announcement date. A purchase price allocation exercise has commenced subsequent to the acquisition date, and these disclosures will be included in subsequent financial information and financial statements once determined. ​ ​

H1 2021 Product Sales year-on-y

H1 2021 Product Sales year-on-year analysis	6 Months Ended
	Jun. 30, 2021
H1 2021 Product Sales year-on-year analysis
H1 2021 Product Sales year-on-year analysis	7) Table 50: H1 2021 - Product Sales year-on-year analysis 74 The CER information in respect of H1 2021 included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ World ​ Emerging Markets ​ US ​ Europe ​ Established RoW ​ ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ CER ​ $m % change % change $m % change % change $m % change $m % change % change $m % change % change Oncology 6,267 ​ 23 ​ 18 ​ 1,626 ​ 11 ​ 6 ​ 2,494 ​ 28 ​ 1,183 ​ 33 ​ 20 ​ 964 ​ 19 ​ 14 Tagrisso 2,454 ​ 22 ​ 17 ​ 697 ​ 17 ​ 10 ​ 853 ​ 18 ​ 468 ​ 44 ​ 30 ​ 436 ​ 18 ​ 13 Imfinzi 1,160 ​ 22 ​ 18 ​ 133 ​ n/m ​ 99 ​ 597 ​ 4 ​ 227 ​ 36 ​ 23 ​ 203 ​ 35 ​ 30 Lynparza 1,131 ​ 39 ​ 34 ​ 186 ​ 54 ​ 50 ​ 523 ​ 29 ​ 301 ​ 52 ​ 38 ​ 121 ​ 32 ​ 26 Calquence ​ 490 ​ n/m ​ n/m ​ 7 ​ n/m ​ n/m ​ 445 ​ n/m ​ 32 ​ n/m ​ n/m ​ 6 ​ n/m ​ n/m Koselugo 48 ​ n/m ​ n/m ​ - ​ - ​ - ​ 47 ​ n/m ​ 1 ​ - ​ - ​ - ​ - ​ - Enhertu ​ 4 ​ n/m ​ n/m ​ 4 ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Zoladex* ​ 466 ​ 5 ​ (1) ​ 296 ​ 3 ​ (3) ​ 8 ​ 58 ​ 74 ​ 9 ​ (1) ​ 88 ​ 9 ​ 3 Faslodex 227 ​ (27) ​ (31) ​ 80 ​ (20) ​ (22) ​ 16 ​ (52) ​ 71 ​ (39) ​ (45) ​ 60 ​ (3) ​ (6) Iressa* ​ 107 ​ (27) ​ (31) ​ 89 ​ (26) ​ (31) ​ 5 ​ (27) ​ 3 ​ (66) ​ (71) ​ 10 ​ (10) ​ (13) Arimidex* ​ 73 ​ (32) ​ (35) ​ 56 ​ (37) ​ (40) ​ - ​ - ​ 2 ​ 26 ​ 12 ​ 15 ​ (10) ​ (13) Casodex* 82 ​ (7) ​ (13) ​ 64 ​ (7) ​ (14) ​ - ​ - ​ 1 ​ (29) ​ (10) ​ 17 ​ (7) ​ (10) Others 25 ​ (1) ​ (4) ​ 14 ​ 4 ​ 1 ​ - ​ - ​ 3 ​ 19 ​ 4 ​ 8 ​ (13) ​ (13) BioPharmaceuticals: CVRM 3,935 ​ 14 ​ 9 ​ 1,921 ​ 19 ​ 14 ​ 987 ​ - ​ 727 ​ 24 ​ 13 ​ 300 ​ 9 ​ 3 Farxiga 1,356 ​ 60 ​ 53 ​ 557 ​ 82 ​ 77 ​ 302 ​ 27 ​ 372 ​ 67 ​ 51 ​ 125 ​ 53 ​ 44 Brilinta 749 ​ (11) ​ (15) ​ 180 ​ (38) ​ (40) ​ 360 ​ 2 ​ 178 ​ 3 ​ (7) ​ 31 ​ 6 ​ (7) Bydureon 198 ​ (9) ​ (10) ​ 2 ​ (6) ​ (7) ​ 162 ​ (12) ​ 29 ​ 20 ​ 7 ​ 5 ​ (9) ​ (22) Onglyza 200 ​ (22) ​ (25) ​ 108 ​ 9 ​ 4 ​ 44 ​ (58) ​ 31 ​ 6 ​ (4) ​ 17 ​ (25) ​ (30) Byetta 32 ​ (9) ​ (12) ​ 8 ​ 72 ​ 79 ​ 15 ​ (20) ​ 5 ​ (27) ​ (38) ​ 4 ​ (17) ​ (26) Other diabetes ​ 29 ​ 23 ​ 17 ​ 8 ​ n/m ​ n/m ​ 11 ​ (15) ​ 9 ​ 53 ​ 35 ​ 1 ​ 25 ​ 18 Lokelma 72 ​ n/m ​ n/m ​ 2 ​ n/m ​ n/m ​ 49 ​ n/m ​ 5 ​ n/m ​ n/m ​ 16 ​ n/m ​ n/m Roxadustat ​ 90 ​ n/m ​ n/m ​ 90 ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ n/m ​ n/m Crestor* 539 ​ (7) ​ (11) ​ 372 ​ 1 ​ (4) ​ 41 ​ (10) ​ 32 ​ (50) ​ (54) ​ 94 ​ (10) ​ (12) Seloken Toprol-XL* 515 ​ 30 ​ 24 ​ 503 ​ 34 ​ 27 ​ 1 ​ (88) ​ 6 ​ (23) ​ (20) ​ 5 ​ 3 ​ (8) Atacand 57 ​ (55) ​ (55) ​ 20 ​ (79) ​ (79) ​ 2 ​ (56) ​ 35 ​ n/m ​ n/m ​ - ​ n/m ​ n/m Others 98 ​ (7) ​ (13) ​ 71 ​ 9 ​ 2 ​ - ​ - ​ 25 ​ (19) ​ (22) ​ 2 ​ (20) ​ (23) BioPharmaceuticals: Respiratory & Immunology 2,961 ​ 11 ​ 6 ​ 885 ​ 17 ​ 10 ​ 1,148 ​ 17 ​ 616 ​ 5 ​ (5) ​ 312 ​ (8) ​ (14) Symbicort 1,371 ​ (5) ​ (9) ​ 306 ​ 5 ​ 2 ​ 530 ​ (5) ​ 344 ​ (3) ​ (12) ​ 191 ​ (20) ​ (26) Pulmicort 497 ​ 4 ​ (2) ​ 405 ​ 9 ​ 2 ​ 35 ​ (2) ​ 34 ​ (15) ​ (25) ​ 23 ​ (24) ​ (30) Fasenra 580 ​ 36 ​ 32 ​ 8 ​ 25 ​ 27 ​ 357 ​ 31 ​ 136 ​ 54 ​ 39 ​ 79 ​ 34 ​ 27 Daliresp 114 ​ 8 ​ 7 ​ 2 ​ 20 ​ 18 ​ 103 ​ 15 ​ 8 ​ (36) ​ (42) ​ 1 ​ (56) ​ (60) Bevespi 26 ​ 20 ​ 18 ​ 2 ​ n/m ​ n/m ​ 20 ​ (5) ​ 4 ​ n/m ​ n/m ​ - ​ - ​ - Breztri ​ 82 ​ n/m ​ n/m ​ 27 ​ n/m ​ n/m ​ 43 ​ n/m ​ 1 ​ n/m ​ n/m ​ 11 ​ n/m ​ n/m Others 291 ​ 58 ​ 47 ​ 135 ​ 69 ​ 55 ​ 60 ​ n/m ​ 89 ​ - ​ (9) ​ 7 ​ (16) ​ (25) Other medicines 1,003 ​ (10) ​ (14) ​ 536 ​ 10 ​ 5 ​ 100 ​ (34) ​ 145 ​ (40) ​ (42) ​ 222 ​ (8) ​ (12) Nexium* 739 ​ 4 ​ - ​ 419 ​ 13 ​ 9 ​ 67 ​ (17) ​ 36 ​ (2) ​ (11) ​ 217 ​ (4) ​ (8) Synagis* ​ 49 ​ (72) ​ (72) ​ - ​ n/m ​ n/m ​ 5 ​ (77) ​ 44 ​ (71) ​ (71) ​ - ​ - ​ - Seroquel XR/ * ​ 50 ​ (21) ​ (21) ​ 25 ​ (9) ​ (8) ​ 10 ​ (29) ​ 14 ​ (4) ​ (3) ​ 1 ​ (88) ​ (88) Losec Prilosec* 100 ​ 1 ​ (5) ​ 84 ​ 4 ​ (4) ​ - ​ (90) ​ 15 ​ 56 ​ 55 ​ 1 ​ (90) ​ (92) FluMist* ​ 3 ​ n/m ​ n/m ​ 1 ​ - ​ - ​ - ​ n/m ​ 2 ​ n/m ​ n/m ​ - ​ - ​ - Others 62 ​ (9) ​ (13) ​ 7 ​ n/m ​ n/m ​ 18 ​ (46) ​ 34 ​ 20 ​ 11 ​ 3 ​ (16) ​ (14) COVID-19 ​ 1,136 ​ n/m ​ n/m ​ 455 ​ n/m ​ n/m ​ - ​ - ​ 572 ​ n/m ​ n/m ​ 109 ​ n/m ​ n/m Pandemic COVID-19 vaccine ​ 1,136 ​ n/m ​ n/m ​ 455 ​ n/m ​ n/m ​ - ​ - ​ 572 ​ n/m ​ n/m ​ 109 ​ n/m ​ n/m Total Product Sales 15,302 ​ 24 ​ 19 ​ 5,423 ​ 26 ​ 20 ​ 4,729 ​ 16 ​ 3,243 ​ 41 ​ 28 ​ 1,907 ​ 15 ​ 9 74

Q2 2021 Product Sales year-on-y

Q2 2021 Product Sales year-on-year analysis (Unreviewed)	6 Months Ended
	Jun. 30, 2021
Q2 2021 Product Sales year-on-year analysis (Unreviewed)
Q2 2021 Product Sales year-on-year analysis (Unreviewed)	8) Table 51: Q2 2021 - Product Sales year-on-year analysis (Unreviewed) 75 The Q2 2021 information in respect of the three months ended 30 June 2021 included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ World ​ Emerging Markets ​ US ​ Europe ​ Established RoW ​ ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ CER ​ $m % change % change $m % change % change $m % change $m % change % change $m % change % change Oncology 3,286 ​ 26 ​ 21 ​ 864 ​ 15 ​ 8 ​ 1,301 ​ 33 ​ 608 ​ 38 ​ 23 ​ 513 ​ 18 ​ 15 Tagrisso 1,306 ​ 26 ​ 21 ​ 390 ​ 24 ​ 15 ​ 438 ​ 24 ​ 244 ​ 49 ​ 34 ​ 234 ​ 16 ​ 13 Imfinzi 604 ​ 23 ​ 19 ​ 75 ​ n/m ​ n/m ​ 305 ​ 6 ​ 118 ​ 28 ​ 15 ​ 106 ​ 30 ​ 26 Lynparza 588 ​ 40 ​ 35 ​ 99 ​ 54 ​ 47 ​ 269 ​ 29 ​ 153 ​ 59 ​ 43 ​ 67 ​ 35 ​ 30 Calquence ​ 280 ​ n/m ​ n/m ​ 5 ​ n/m ​ n/m ​ 250 ​ n/m ​ 22 ​ n/m ​ n/m ​ 3 ​ n/m ​ n/m Koselugo ​ 26 ​ n/m ​ n/m ​ - ​ - ​ - ​ 26 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - Enhertu ​ 3 ​ n/m ​ n/m ​ 3 ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Zoladex* ​ 244 ​ 12 ​ 5 ​ 159 ​ 14 ​ 7 ​ 3 ​ 2 ​ 37 ​ 12 ​ (1) ​ 45 ​ 6 ​ 2 Faslodex* 105 ​ (28) ​ (31) ​ 38 ​ (28) ​ (30) ​ 7 ​ (35) ​ 30 ​ (43) ​ (49) ​ 30 ​ (1) ​ (2) Iressa* 47 ​ (34) ​ (38) ​ 36 ​ (38) ​ (43) ​ 3 ​ (30) ​ 1 ​ (61) ​ (68) ​ 7 ​ 30 ​ 27 Arimidex* ​ 29 ​ (50) ​ (53) ​ 20 ​ (58) ​ (60) ​ - ​ - ​ 1 ​ 14 ​ (22) ​ 8 ​ (10) ​ (11) Casodex* ​ 41 ​ (14) ​ (19) ​ 32 ​ (14) ​ (21) ​ - ​ - ​ - ​ - ​ - ​ 9 ​ (12) ​ (14) Others 13 ​ 12 ​ 6 ​ 7 ​ 24 ​ 18 ​ - ​ n/m ​ 2 ​ 46 ​ (8) ​ 4 ​ (26) ​ (20) BioPharmaceuticals: CVRM 2,023 ​ 15 ​ 9 ​ 975 ​ 16 ​ 9 ​ 525 ​ 6 ​ 363 ​ 31 ​ 18 ​ 160 ​ 9 ​ 3 Farxiga ​ 732 ​ 65 ​ 56 ​ 297 ​ 80 ​ 70 ​ 171 ​ 38 ​ 198 ​ 86 ​ 67 ​ 66 ​ 41 ​ 33 Brilinta 375 ​ (14) ​ (18) ​ 74 ​ (52) ​ (55) ​ 194 ​ 4 ​ 90 ​ 13 ​ 1 ​ 17 ​ 19 ​ - Bydureon 95 ​ (18) ​ (20) ​ 1 ​ 97 ​ 77 ​ 77 ​ (24) ​ 15 ​ 17 ​ 1 ​ 2 ​ (19) ​ (34) Onglyza 99 ​ (14) ​ (18) ​ 51 ​ (3) ​ (9) ​ 26 ​ (33) ​ 15 ​ 12 ​ - ​ 7 ​ (31) ​ (39) Byetta 16 ​ 6 ​ - ​ 4 ​ n/m ​ n/m ​ 7 ​ (6) ​ 3 ​ (19) ​ (35) ​ 2 ​ (16) ​ (25) Other diabetes 15 ​ 49 ​ 40 ​ 4 ​ n/m ​ n/m ​ 6 ​ (4) ​ 5 ​ 71 ​ 47 ​ - ​ - ​ - Lokelma ​ 39 ​ n/m ​ n/m ​ 1 ​ 79 ​ 78 ​ 25 ​ n/m ​ 3 ​ n/m ​ n/m ​ 10 ​ n/m ​ n/m Roxadustat ​ 51 ​ n/m ​ n/m ​ 51 ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Crestor* 265 ​ (6) ​ (11) ​ 182 ​ 3 ​ (3) ​ 19 ​ 10 ​ 12 ​ (61) ​ (67) ​ 52 ​ (8) ​ (10) Seloken Toprol-XL* 266 ​ 22 ​ 14 ​ 260 ​ 24 ​ 15 ​ - ​ (83) ​ 3 ​ (20) ​ (12) ​ 3 ​ 25 ​ 14 Atacand* 23 ​ (62) ​ (61) ​ 15 ​ (67) ​ (68) ​ - ​ n/m ​ 8 ​ 31 ​ 32 ​ - ​ n/m ​ n/m Others 47 ​ (1) ​ (9) ​ 35 ​ 20 ​ 10 ​ - ​ n/m ​ 11 ​ (30) ​ (33) ​ 1 ​ (57) ​ (60) BioPharmaceuticals: Respiratory & Immunology 1,420 ​ 27 ​ 21 ​ 343 ​ 56 ​ 45 ​ 597 ​ 27 ​ 318 ​ 19 ​ 7 ​ 162 ​ 3 ​ (5) Symbicort 680 ​ 4 ​ (1) ​ 141 ​ 5 ​ - ​ 264 ​ 6 ​ 176 ​ 9 ​ (2) ​ 99 ​ (9) ​ (17) Pulmicort 167 ​ 72 ​ 59 ​ 119 ​ n/m ​ 88 ​ 18 ​ 40 ​ 18 ​ 23 ​ 7 ​ 12 ​ 5 ​ (1) Fasenra 320 ​ 41 ​ 36 ​ 5 ​ n/m ​ n/m ​ 201 ​ 32 ​ 73 ​ 72 ​ 55 ​ 41 ​ 28 ​ 21 Daliresp 54 ​ 3 ​ 3 ​ 1 ​ 29 ​ 23 ​ 49 ​ 10 ​ 4 ​ (37) ​ (36) ​ - ​ (85) ​ (80) Bevespi 13 ​ 34 ​ 33 ​ 1 ​ n/m ​ n/m ​ 10 ​ 6 ​ 2 ​ n/m ​ n/m ​ - ​ - ​ - Breztri ​ 56 ​ n/m ​ n/m ​ 17 ​ n/m ​ n/m ​ 31 ​ n/m ​ 1 ​ n/m ​ n/m ​ 7 ​ n/m ​ n/m Others 130 ​ 85 ​ 70 ​ 59 ​ n/m ​ n/m ​ 24 ​ n/m ​ 44 ​ 5 ​ (6) ​ 3 ​ 37 ​ 9 Other medicines 454 ​ (19) ​ (23) ​ 239 ​ 1 ​ (4) ​ 47 ​ (27) ​ 68 ​ (41) ​ (45) ​ 100 ​ (31) ​ (32) Nexium* 336 ​ (11) ​ (14) ​ 185 ​ 1 ​ (4) ​ 35 ​ (14) ​ 18 ​ 23 ​ 11 ​ 98 ​ (29) ​ (31) Synagis* ​ 24 ​ (73) ​ (73) ​ - ​ - ​ - ​ 3 ​ (78) ​ 21 ​ (72) ​ (72) ​ - ​ - ​ - Seroquel XR/ * ​ 21 ​ (23) ​ (19) ​ 11 ​ (26) ​ (27) ​ 3 ​ n/m ​ 7 ​ (5) ​ 2 ​ - ​ n/m ​ (87) Losec Prilosec* 46 ​ 2 ​ (6) ​ 38 ​ 2 ​ (7) ​ - ​ (68) ​ 8 ​ 49 ​ 42 ​ - ​ (82) ​ (87) FluMist* ​ 1 ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ 1 ​ n/m ​ n/m Others 26 ​ 10 ​ 1 ​ 5 ​ n/m ​ n/m ​ 6 ​ (30) ​ 14 ​ 14 ​ (3) ​ 1 ​ 39 ​ 55 COVID-19 ​ 862 ​ n/m ​ n/m ​ 413 ​ n/m ​ n/m ​ - ​ - ​ 347 ​ n/m ​ n/m ​ 102 ​ n/m ​ n/m Pandemic COVID-19 vaccine ​ 862 ​ n/m ​ n/m ​ 413 ​ n/m ​ n/m ​ - ​ - ​ 347 ​ n/m ​ n/m ​ 102 ​ n/m ​ n/m Total Product Sales 8,045 ​ 33 ​ 27 ​ 2,834 ​ 38 ​ 31 ​ 2,470 ​ 23 ​ 1,704 ​ 55 ​ 39 ​ 1,037 ​ 17 ​ 12 ​ 75

Q2 2021 Product Sales quarterly

Q2 2021 Product Sales quarterly sequential analysis (Unreviewed)	6 Months Ended
	Jun. 30, 2021
Q2 2021 Product Sales quarterly sequential analysis (Unreviewed)
Q2 2021 Product Sales quarterly sequential analysis (Unreviewed)	9) Table 52: Q2 2021 - Product Sales quarterly sequential analysis (Unreviewed) 76 The sequential quarterly information in respect of the three months ended 30 June 2021 included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Q1 2021 ​ Q2 2021 ​ ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ CER ​ ​ ​ $m ​ % change ​ % change ​ $m ​ % change ​ % change Oncology ​ 2,981 ​ 3 ​ 1 ​ 3,286 ​ 10 ​ 11 Tagrisso ​ 1,149 ​ (1) ​ (3) ​ 1,306 ​ 14 ​ 14 Imfinzi ​ 556 ​ - ​ (1) ​ 604 ​ 9 ​ 10 Lynparza ​ 543 ​ 9 ​ 8 ​ 588 ​ 8 ​ 9 Calquence ​ ​ 209 ​ 15 ​ 15 ​ 280 ​ 34 ​ 34 Koselugo ​ ​ 21 ​ 23 ​ 23 ​ 26 ​ 23 ​ 22 Enhertu ​ ​ 1 ​ n/m ​ n/m ​ 3 ​ n/m ​ n/m Zoladex* ​ 221 ​ 2 ​ - ​ 244 ​ 10 ​ 11 Faslodex* ​ 122 ​ (6) ​ (8) ​ 105 ​ (14) ​ (12) Iressa* ​ ​ 61 ​ (9) ​ (11) ​ 47 ​ (23) ​ (22) Arimidex* ​ ​ 44 ​ 22 ​ 18 ​ 29 ​ (34) ​ (33) Casodex* ​ 42 ​ 7 ​ 5 ​ 41 ​ (2) ​ (1) Others ​ 12 ​ (4) ​ (6) ​ 13 ​ 13 ​ 11 BioPharmaceuticals: CVRM ​ 1,912 ​ 4 ​ 1 ​ 2,023 ​ 6 ​ 6 Farxiga ​ 624 ​ 6 ​ 4 ​ 732 ​ 17 ​ 18 Brilinta ​ 374 ​ 3 ​ 1 ​ 375 ​ - ​ 1 Bydureon ​ 103 ​ (16) ​ (17) ​ 95 ​ (8) ​ (7) Onglyza ​ 101 ​ (3) ​ (6) ​ 99 ​ (2) ​ (2) Byetta ​ 16 ​ (14) ​ (15) ​ 16 ​ (4) ​ (7) Other diabetes ​ 13 ​ 7 ​ 1 ​ 15 ​ 14 ​ 14 Lokelma ​ ​ 33 ​ 16 ​ 18 ​ 39 ​ 21 ​ 21 Roxadustat ​ 39 ​ n/m ​ n/m ​ 51 ​ 32 ​ 32 Crestor* ​ 274 ​ (8) ​ (9) ​ 265 ​ (3) ​ (3) Seloken Toprol-XL* ​ 250 ​ 25 ​ 21 ​ 266 ​ 6 ​ 7 Atacand* ​ 34 ​ (45) ​ (45) ​ 23 ​ (35) ​ (32) Others ​ 51 ​ 12 ​ 10 ​ 47 ​ (7) ​ (10) BioPharmaceuticals: Respiratory & Immunology ​ 1,541 ​ 1 ​ (1) ​ 1,420 ​ (8) ​ (7) Symbicort ​ 691 ​ 2 ​ - ​ 680 ​ (2) ​ (1) Pulmicort ​ 330 ​ (10) ​ (13) ​ 167 ​ (50) ​ (49) Fasenra ​ 260 ​ (8) ​ (9) ​ 320 ​ 23 ​ 23 Daliresp ​ 60 ​ 11 ​ 10 ​ 54 ​ (10) ​ (9) Bevespi ​ 13 ​ 7 ​ 8 ​ 13 ​ 1 ​ 3 Breztri ​ ​ 27 ​ n/m ​ n/m ​ 56 ​ n/m ​ n/m Others ​ 160 ​ 28 ​ 25 ​ 130 ​ (19) ​ (19) Other medicines ​ 548 ​ (25) ​ (26) ​ 454 ​ (17) ​ (16) Nexium* ​ 403 ​ 7 ​ 5 ​ 336 ​ (17) ​ (15) Synagis* ​ 24 ​ (69) ​ (69) ​ 24 ​ 1 ​ 1 Seroquel XR/ * ​ 29 ​ 51 ​ 38 ​ 21 ​ (29) ​ (22) Losec Prilosec* ​ ​ 54 ​ 39 ​ 36 ​ 46 ​ (14) ​ (15) FluMist* ​ ​ 2 ​ (99) ​ (99) ​ 1 ​ (51) ​ (71) Others ​ ​ 36 ​ (6) ​ (4) ​ 26 ​ (28) ​ (32) COVID-19 ​ 275 ​ n/m ​ n/m ​ 862 ​ n/m ​ n/m Pandemic COVID-19 vaccine ​ 275 ​ n/m ​ n/m ​ 862 ​ n/m ​ n/m Total Product Sales ​ ​ 7,257 ​ 4 ​ 1 ​ 8,045 ​ 11 ​ 12 76

FY 2020 Product Sales quarterly

FY 2020 Product Sales quarterly sequential analysis (Unreviewed)	6 Months Ended
	Jun. 30, 2021
FY 2020 Product Sales quarterly sequential analysis (Unreviewed)
FY 2020 Product Sales quarterly sequential analysis (Unreviewed)	10) Table 53: FY 2020 - Product Sales quarterly sequential analysis (Unreviewed) 77 The sequential quarterly information included in the Interim Financial Statements has not been reviewed by PricewaterhouseCoopers LLP. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Q1 2020 ​ Q2 2020 ​ Q3 2020 ​ Q4 2020 ​ ​ Actual ​ CER ​ Actual CER ​ Actual CER ​ Actual CER ​ ​ $m ​ % change ​ % change ​ $m ​ % change ​ % change ​ $m ​ % change ​ % change ​ $m ​ % change ​ % change Oncology 2,502 ​ 10 ​ 10 ​ 2,609 ​ 4 ​ 6 ​ 2,831 ​ 8 ​ 6 ​ 2,908 ​ 3 ​ 2 Tagrisso 982 ​ 11 ​ 11 ​ 1,034 ​ 5 ​ 7 ​ 1,155 ​ 12 ​ 9 ​ 1,157 ​ - ​ (1) Imfinzi 462 ​ 9 ​ 9 ​ 492 ​ 6 ​ 8 ​ 533 ​ 8 ​ 6 ​ 555 ​ 4 ​ 3 Lynparza 397 ​ 13 ​ 13 ​ 419 ​ 5 ​ 7 ​ 464 ​ 11 ​ 8 ​ 496 ​ 7 ​ 6 Calquence ​ 88 ​ 58 ​ 58 ​ 107 ​ 21 ​ 23 ​ 145 ​ 36 ​ 35 ​ 182 ​ 25 ​ 25 Koselugo ​ - ​ - ​ - ​ 7 ​ n/m ​ n/m ​ 13 ​ 75 ​ 75 ​ 17 ​ 34 ​ 34 Zoladex* ​ 225 ​ 15 ​ 15 ​ 217 ​ (3) ​ - ​ 230 ​ 6 ​ 3 ​ 216 ​ (6) ​ (7) Faslodex* 166 ​ - ​ - ​ 146 ​ (12) ​ (9) ​ 138 ​ (5) ​ (8) ​ 130 ​ (6) ​ (7) Iressa* 77 ​ (3) ​ (4) ​ 70 ​ (9) ​ (7) ​ 54 ​ (23) ​ (24) ​ 67 ​ 24 ​ 19 Arimidex* ​ 50 ​ (1) ​ (2) ​ 58 ​ 17 ​ 16 ​ 42 ​ (28) ​ (27) ​ 36 ​ (14) ​ (16) Casodex* ​ 42 ​ (2) ​ (3) ​ 47 ​ 14 ​ 12 ​ 44 ​ (7) ​ (8) ​ 39 ​ (11) ​ (14) Others 13 ​ (52) ​ (52) ​ 12 ​ (11) ​ (1) ​ 13 ​ 4 ​ 3 ​ 13 ​ 2 ​ 2 BioPharmaceuticals: CVRM 1,701 ​ (5) ​ (5) ​ 1,759 ​ 3 ​ 6 ​ 1,794 ​ 2 ​ - ​ 1,842 ​ 3 ​ 1 Farxiga 405 ​ (3) ​ (3) ​ 443 ​ 9 ​ 13 ​ 525 ​ 19 ​ 16 ​ 586 ​ 11 ​ 10 Brilinta 408 ​ (5) ​ (5) ​ 437 ​ 7 ​ 9 ​ 385 ​ (12) ​ (13) ​ 363 ​ (6) ​ (6) Onglyza 141 ​ 8 ​ 8 ​ 115 ​ (19) ​ (17) ​ 110 ​ (6) ​ (6) ​ 105 ​ (4) ​ (5) Bydureon 100 ​ (28) ​ (28) ​ 116 ​ 16 ​ 17 ​ 109 ​ (5) ​ (7) ​ 122 ​ 12 ​ 11 Byetta 20 ​ (24) ​ (24) ​ 15 ​ (28) ​ (28) ​ 15 ​ 1 ​ 4 ​ 19 ​ 26 ​ 24 Other diabetes 13 ​ (22) ​ (22) ​ 10 ​ (21) ​ (19) ​ 11 ​ 9 ​ 6 ​ 12 ​ 11 ​ 15 Lokelma ​ 11 ​ 42 ​ 42 ​ 17 ​ 56 ​ 58 ​ 21 ​ 22 ​ 26 ​ 28 ​ 37 ​ 28 Crestor* 301 ​ 2 ​ 1 ​ 281 ​ (7) ​ (4) ​ 300 ​ 7 ​ 5 ​ 298 ​ (1) ​ (4) Seloken Toprol-XL* 177 ​ (6) ​ (6) ​ 218 ​ 23 ​ 27 ​ 225 ​ 4 ​ 3 ​ 200 ​ (11) ​ (13) Atacand* 66 ​ 11 ​ 12 ​ 59 ​ (11) ​ (5) ​ 54 ​ (9) ​ (12) ​ 63 ​ 16 ​ 14 Others 59 ​ (21) ​ (22) ​ 48 ​ (18) ​ (16) ​ 39 ​ (19) ​ (22) ​ 46 ​ 18 ​ 17 BioPharmaceuticals: Respiratory & Immunology 1,551 ​ 1 ​ 1 ​ 1,117 ​ (28) ​ (26) ​ 1,161 ​ 4 ​ 1 ​ 1,528 ​ 32 ​ 29 Symbicort 790 ​ 11 ​ 11 ​ 653 ​ (17) ​ (15) ​ 599 ​ (8) ​ (11) ​ 680 ​ 13 ​ 13 Pulmicort 380 ​ (8) ​ (9) ​ 97 ​ (74) ​ (73) ​ 151 ​ 56 ​ 49 ​ 368 ​ n/m ​ n/m Fasenra 199 ​ (3) ​ (3) ​ 227 ​ 14 ​ 15 ​ 240 ​ 5 ​ 4 ​ 283 ​ 18 ​ 17 Daliresp 53 ​ (8) ​ (8) ​ 53 ​ (1) ​ (3) ​ 57 ​ 8 ​ 11 ​ 54 ​ (4) ​ (6) Bevespi 12 ​ 9 ​ 9 ​ 10 ​ (19) ​ (21) ​ 14 ​ 47 ​ 46 ​ 12 ​ (16) ​ (17) Breztri ​ 4 ​ n/m ​ n/m ​ 7 ​ 58 ​ 64 ​ 10 ​ 45 ​ 48 ​ 6 ​ (39) ​ (38) Others 113 ​ (16) ​ (17) ​ 70 ​ (38) ​ (36) ​ 90 ​ 27 ​ 22 ​ 125 ​ 39 ​ 35 Other medicines 557 ​ (15) ​ (15) ​ 563 ​ 1 ​ 4 ​ 734 ​ 30 ​ 27 ​ 733 ​ - ​ (2) Nexium* 338 ​ (4) ​ (4) ​ 377 ​ 12 ​ 14 ​ 401 ​ 6 ​ 4 ​ 377 ​ (6) ​ (7) Synagis* 85 ​ 35 ​ 35 ​ 90 ​ 6 ​ 7 ​ 118 ​ 31 ​ 29 ​ 78 ​ (34) ​ (33) FluMist* ​ - ​ n/m ​ n/m ​ - ​ n/m ​ n/m ​ 116 ​ n/m ​ n/m ​ 179 ​ 55 ​ 50 Losec Prilosec* ​ 54 ​ 18 ​ 17 ​ 45 ​ (15) ​ (15) ​ 45 ​ - ​ - ​ 39 ​ (15) ​ (18) Seroquel XR/ * ​ 36 ​ (12) ​ (12) ​ 27 ​ (26) ​ (23) ​ 35 ​ 32 ​ 29 ​ 19 ​ (45) ​ (42) Others 44 ​ (71) ​ (70) ​ 24 ​ (46) ​ (42) ​ 19 ​ (17) ​ (19) ​ 41 ​ n/m ​ n/m Total Product Sales 6,311 ​ 1 ​ 1 ​ 6,048 ​ (4) ​ (2) ​ 6,520 ​ 8 ​ 6 ​ 7,011 ​ 8 ​ 6 77

Collaboration Revenue

Collaboration Revenue	6 Months Ended
	Jun. 30, 2021
Collaboration Revenue
Collaboration Revenue	Table 54: Collaboration Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ H1 2021 ​ H1 2020 ​ FY 2020 ​ FY 2019 ​ $m $m $m $m Initial Collaboration Revenue ​ ​ ​ ​ ​ ​ ​ ​ Nexium ​ 75 ​ - ​ - ​ - Ongoing Collaboration Revenue ​ ​ ​ ​ ​ ​ ​ ​ Lynparza ​ - ​ 135 ​ 160 ​ 60 Lynparza ​ - ​ - ​ 300 ​ 450 Lynparza/Koselugo: ​ - ​ - ​ - ​ 100 Crestor ​ - ​ - ​ - ​ 39 Enhertu: s ​ 83 ​ 36 ​ 94 ​ - Roxadustat: ​ 3 ​ 11 ​ 30 ​ - Royalty income ​ 69 ​ 34 ​ 62 ​ 62 Other Ongoing Collaboration Revenue ​ 8 ​ 54 ​ 81 ​ 108 Total ​ 238 ​ 270 ​ 727 ​ 819 ​

Other Operating Income and Expe

Other Operating Income and Expense	6 Months Ended
	Jun. 30, 2021
Other Operating Income and Expense
Schedule of other operating income and expense	​ Table 55: Other Operating Income and Expense The table below provides an analysis of Reported Other Operating Income and Expense. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ H1 2021 H1 2020 FY 2020 FY 2019 ​ ​ $m ​ $m ​ $m ​ $m Divestment of Viela Bio, Inc. shareholding ​ 776 ​ - ​ - ​ - Crestor ​ 309 ​ - ​ - ​ - Oxra Oxramet ​ 40 ​ - ​ - ​ - Hypertension medicines (ex-US, India and Japan) ​ - ​ 350 ​ 350 ​ - Monetisation of an asset previously licensed ​ - ​ - ​ 120 ​ - Brazikumab licence termination funding ​ 51 ​ - ​ 107 ​ - Inderal Tenormin Seloken Omepral ​ - ​ 51 ​ 51 ​ - Synagis ​ - ​ - ​ - ​ 515 Losec ​ - ​ - ​ - ​ 243 Seroquel and Seroquel XR ​ - ​ - ​ - ​ 213 Arimidex Casodex ​ - ​ - ​ - ​ 181 Nexium Vimovo ​ - ​ - ​ 54 ​ - Atacand ​ - ​ - ​ 400 ​ - Other ​ 132 ​ 200 ​ 446 ​ 389 Total ​ 1,308 ​ 601 ​ 1,528 ​ 1,541 ​

Basis of Preparation and Acco_2

Basis of Preparation and Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Basis of Presentation and Accounting Policies
Basis of preparation and accounting policies	These unaudited Interim Financial Statements for the six months ended 30 June 2021 have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34, and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority. On 31 December 2020, EU-adopted IFRS at that date was brought into UK law and became UK-adopted international accounting standards, with future changes being subject to endorsement by the UK Endorsement Board. The Interim Financial Statements have transitioned to UK-adopted international accounting standards from financial periods beginning 1 January 2021. There was no impact or changes in accounting policies from the transition. ​ The unaudited Interim Financial Statements for the six months ended 30 June 2021 were approved by the Board of Directors for publication on 29 July 2021. ​ The annual financial statements of the group for the year ended 31 December 2020 were prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006, International Financial Reporting Standards (IFRSs) adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the EU and IFRSs as issued by the International Accounting Standards Board (IASB). Except as noted below and for the estimation of the interim income tax charge, the Interim Financial Statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2020.
Adoption of new accounting standards	​ IFRS 9 and IFRS 7 The replacement of benchmark interest rates, such as the London Inter-bank Offered Rate (LIBOR) and other interbank offered rates (IBORs) has been a priority for global regulators and is expected to be largely completed in 2021, although some benchmark rates will be continued to be published until mid-2023. To prepare for this, the Group adopted the Phase 1 amendments to IFRS 9 ‘Financial Instruments’ and IFRS 7 ‘Financial Instruments: Disclosures’ in 2019 and has adopted the Phase 2 amendments in 2021. These amendments provide relief from applying specific hedge accounting requirements to hedge relationships directly affected by IBOR reform and have the effect that the reform should generally not cause hedge accounting to terminate. ​ The Group has one IFRS 9 designated hedge relationship that is impacted by IBOR reform, namely a €300m cross currency interest rate swap in a fair value hedge relationship with €300m of a €750m 0.875% 2021 non-callable bond. This swap references three-month USD LIBOR; uncertainty arising from the Group’s exposure to IBOR reform will cease when the swap matures in November 2021. The implications on the wider business of IBOR reform have been assessed and the Group is working on moving to new benchmark rates in the second half of 2021.
COVID-19	COVID-19 AstraZeneca has assessed the impact of the uncertainty presented by the COVID-19 pandemic on the Interim Financial Statements comprising the financial results to 30 June 2021 and the financial position as at 30 June 2021, specifically considering the impact on key judgements and significant estimates as detailed on page 180 of the Annual Report and 20-F Information 2020 along with several other areas of elevated risk during the pandemic period. A detailed assessment has been performed, focussing on the following areas: - recoverable value of goodwill, intangible assets and property, plant and equipment - impact on key assumptions used to estimate contingent consideration liabilities - key assumptions used in estimating the Group’s defined benefit pension obligations - basis for estimating clinical trial accruals - key assumptions used in estimating rebates, chargebacks and returns for US Product Sales - valuations of unlisted equity investments - expected credit losses associated with changes in credit risk relating to trade and other receivables - net realisable value of inventories - fair value of certain financial instruments - recoverability of deferred tax assets - effectiveness of hedge relationships ​ There were no material accounting impacts identified relating to the above areas during the six-month period ended 30 June 2021. The Group will continue to monitor these areas of increased judgement, estimation and risk for material changes.
Basis for preparation of Financial Statements on a going concern basis	Going concern The Group has considerable financial resources available. As at 30 June 2021, the Group had $19.7bn in financial resources (cash and cash-equivalent balances of $15.6bn and undrawn committed bank facilities of $4.1bn, of which $3.4bn is available until April 2024, $0.7bn is available until November 2021 (with a one-year extension option, exercisable by the Group), with only $2.9bn of borrowings due within one year). Additionally, as at 30 June 2021, to support the financing of the acquisition of Alexion, the Group had committed bank facilities totalling $9.5bn. All facilities contain no financial covenants and were undrawn at 30 June 2021. On 21 July 2021, cash consideration of $13.3bn was paid on completion of the acquisition of Alexion. $2.0bn of two year and $2.0bn of three-year term loans were drawn on 21 July 2021 under the committed bank facilities of $9.5bn, which may be repaid at the Group’s option before maturity and a further $4.5bn of facilities were cancelled. The remaining $1.0bn of revolving credit facility is available until July 2023. On acquisition date and after repaying its $2.3bn bank loans from existing cash resources, Alexion contributed $1.7bn of cash and cash equivalents, and no The directors have considered the impact of COVID-19 on AstraZeneca’s operations and mitigations to these risks. Overall, the impact of these items would heighten certain risks, such as those relating to the delivery of the pipeline or launch of new medicines, the execution of AstraZeneca’s commercial strategy, the manufacturing and supply of medicines and reliance on third-party goods and services. The Group is continuously monitoring and mitigating where possible impacts of these risks. The Group’s revenues are largely derived from sales of medicines covered by patents which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to affect adversely revenues in many of the mature markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well-placed to manage its business risks successfully. Accordingly, the going concern basis has been adopted in these Interim Financial Statements.
Litigation and environmental liabilities	Legal proceedings The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the Group’s Annual Report and Form 20-F Information 2020
Financial information	Financial information The comparative figures for the financial year ended 31 December 2020 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered to the registrar of companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006

Net Debt (Tables)

Net Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Net Debt
Schedule of Net Debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At 1 Jan ​ Cash ​ Non-cash ​ Exchange ​ At 30 Jun ​ ​ 2021 ​ flow ​ & other ​ movements ​ 2021 ​ $m $m $m $m $m Non-current instalments of loans (17,505) ​ (7,944) ​ 1,257 ​ 83 ​ (24,109) Non-current instalments of leases ​ (489) ​ - ​ (9) ​ 6 ​ (492) Total long-term debt (17,994) ​ (7,944) ​ 1,248 ​ 89 ​ (24,601) Current instalments of loans (1,536) ​ 611 ​ (1,248) ​ 37 ​ (2,136) Current instalments of leases (192) ​ 117 ​ (127) ​ 4 ​ (198) Bank collateral (288) ​ 120 ​ - ​ - ​ (168) Other short-term borrowings excluding overdrafts ​ (84) ​ 62 ​ - ​ - ​ (22) Overdraft (286) ​ (91) ​ - ​ 7 ​ (370) Total current debt ​ (2,386) ​ 819 ​ (1,375) ​ 48 ​ (2,894) Gross borrowings ​ (20,380) ​ (7,125) ​ (127) ​ 137 ​ (27,495) Net derivative financial instruments ​ 278 ​ (15) ​ (118) ​ - ​ 145 Net borrowings ​ (20,102) ​ (7,140) ​ (245) ​ 137 ​ (27,350) Cash and cash equivalents ​ 7,832 ​ 7,794 ​ - ​ (59) ​ 15,567 Other investments - current ​ 160 ​ (98) ​ - ​ - ​ 62 Cash and investments ​ 7,992 ​ 7,696 ​ - ​ (59) ​ 15,629 Net Debt ​ (12,110) ​ 556 ​ (245) ​ 78 ​ (11,721)

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2021
Financial Instruments
Schedule of Contingent consideration	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ 2020 ​ ​ Diabetes ​ ​ ​ ​ ​ ​ ​ alliance ​ Other ​ Total ​ Total ​ ​ $m ​ $m ​ $m ​ $m At 1 January 2,932 ​ 391 ​ 3,323 ​ 4,139 Settlements (304) ​ (5) ​ (309) ​ (353) Revaluations ​ 82 ​ – ​ 82 ​ (44) Discount unwind 99 ​ 13 ​ 112 ​ 141 At 30 June 2,809 ​ 399 ​ 3,208 ​ 3,883

H1 2021 Product Sales year-on_2

H1 2021 Product Sales year-on-year analysis (Tables)	6 Months Ended
	Jun. 30, 2021
H1 2021 Product Sales year-on-year analysis
H1 2021 Product Sales year-on-year analysis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ World ​ Emerging Markets ​ US ​ Europe ​ Established RoW ​ ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ CER ​ $m % change % change $m % change % change $m % change $m % change % change $m % change % change Oncology 6,267 ​ 23 ​ 18 ​ 1,626 ​ 11 ​ 6 ​ 2,494 ​ 28 ​ 1,183 ​ 33 ​ 20 ​ 964 ​ 19 ​ 14 Tagrisso 2,454 ​ 22 ​ 17 ​ 697 ​ 17 ​ 10 ​ 853 ​ 18 ​ 468 ​ 44 ​ 30 ​ 436 ​ 18 ​ 13 Imfinzi 1,160 ​ 22 ​ 18 ​ 133 ​ n/m ​ 99 ​ 597 ​ 4 ​ 227 ​ 36 ​ 23 ​ 203 ​ 35 ​ 30 Lynparza 1,131 ​ 39 ​ 34 ​ 186 ​ 54 ​ 50 ​ 523 ​ 29 ​ 301 ​ 52 ​ 38 ​ 121 ​ 32 ​ 26 Calquence ​ 490 ​ n/m ​ n/m ​ 7 ​ n/m ​ n/m ​ 445 ​ n/m ​ 32 ​ n/m ​ n/m ​ 6 ​ n/m ​ n/m Koselugo 48 ​ n/m ​ n/m ​ - ​ - ​ - ​ 47 ​ n/m ​ 1 ​ - ​ - ​ - ​ - ​ - Enhertu ​ 4 ​ n/m ​ n/m ​ 4 ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Zoladex* ​ 466 ​ 5 ​ (1) ​ 296 ​ 3 ​ (3) ​ 8 ​ 58 ​ 74 ​ 9 ​ (1) ​ 88 ​ 9 ​ 3 Faslodex 227 ​ (27) ​ (31) ​ 80 ​ (20) ​ (22) ​ 16 ​ (52) ​ 71 ​ (39) ​ (45) ​ 60 ​ (3) ​ (6) Iressa* ​ 107 ​ (27) ​ (31) ​ 89 ​ (26) ​ (31) ​ 5 ​ (27) ​ 3 ​ (66) ​ (71) ​ 10 ​ (10) ​ (13) Arimidex* ​ 73 ​ (32) ​ (35) ​ 56 ​ (37) ​ (40) ​ - ​ - ​ 2 ​ 26 ​ 12 ​ 15 ​ (10) ​ (13) Casodex* 82 ​ (7) ​ (13) ​ 64 ​ (7) ​ (14) ​ - ​ - ​ 1 ​ (29) ​ (10) ​ 17 ​ (7) ​ (10) Others 25 ​ (1) ​ (4) ​ 14 ​ 4 ​ 1 ​ - ​ - ​ 3 ​ 19 ​ 4 ​ 8 ​ (13) ​ (13) BioPharmaceuticals: CVRM 3,935 ​ 14 ​ 9 ​ 1,921 ​ 19 ​ 14 ​ 987 ​ - ​ 727 ​ 24 ​ 13 ​ 300 ​ 9 ​ 3 Farxiga 1,356 ​ 60 ​ 53 ​ 557 ​ 82 ​ 77 ​ 302 ​ 27 ​ 372 ​ 67 ​ 51 ​ 125 ​ 53 ​ 44 Brilinta 749 ​ (11) ​ (15) ​ 180 ​ (38) ​ (40) ​ 360 ​ 2 ​ 178 ​ 3 ​ (7) ​ 31 ​ 6 ​ (7) Bydureon 198 ​ (9) ​ (10) ​ 2 ​ (6) ​ (7) ​ 162 ​ (12) ​ 29 ​ 20 ​ 7 ​ 5 ​ (9) ​ (22) Onglyza 200 ​ (22) ​ (25) ​ 108 ​ 9 ​ 4 ​ 44 ​ (58) ​ 31 ​ 6 ​ (4) ​ 17 ​ (25) ​ (30) Byetta 32 ​ (9) ​ (12) ​ 8 ​ 72 ​ 79 ​ 15 ​ (20) ​ 5 ​ (27) ​ (38) ​ 4 ​ (17) ​ (26) Other diabetes ​ 29 ​ 23 ​ 17 ​ 8 ​ n/m ​ n/m ​ 11 ​ (15) ​ 9 ​ 53 ​ 35 ​ 1 ​ 25 ​ 18 Lokelma 72 ​ n/m ​ n/m ​ 2 ​ n/m ​ n/m ​ 49 ​ n/m ​ 5 ​ n/m ​ n/m ​ 16 ​ n/m ​ n/m Roxadustat ​ 90 ​ n/m ​ n/m ​ 90 ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ n/m ​ n/m Crestor* 539 ​ (7) ​ (11) ​ 372 ​ 1 ​ (4) ​ 41 ​ (10) ​ 32 ​ (50) ​ (54) ​ 94 ​ (10) ​ (12) Seloken Toprol-XL* 515 ​ 30 ​ 24 ​ 503 ​ 34 ​ 27 ​ 1 ​ (88) ​ 6 ​ (23) ​ (20) ​ 5 ​ 3 ​ (8) Atacand 57 ​ (55) ​ (55) ​ 20 ​ (79) ​ (79) ​ 2 ​ (56) ​ 35 ​ n/m ​ n/m ​ - ​ n/m ​ n/m Others 98 ​ (7) ​ (13) ​ 71 ​ 9 ​ 2 ​ - ​ - ​ 25 ​ (19) ​ (22) ​ 2 ​ (20) ​ (23) BioPharmaceuticals: Respiratory & Immunology 2,961 ​ 11 ​ 6 ​ 885 ​ 17 ​ 10 ​ 1,148 ​ 17 ​ 616 ​ 5 ​ (5) ​ 312 ​ (8) ​ (14) Symbicort 1,371 ​ (5) ​ (9) ​ 306 ​ 5 ​ 2 ​ 530 ​ (5) ​ 344 ​ (3) ​ (12) ​ 191 ​ (20) ​ (26) Pulmicort 497 ​ 4 ​ (2) ​ 405 ​ 9 ​ 2 ​ 35 ​ (2) ​ 34 ​ (15) ​ (25) ​ 23 ​ (24) ​ (30) Fasenra 580 ​ 36 ​ 32 ​ 8 ​ 25 ​ 27 ​ 357 ​ 31 ​ 136 ​ 54 ​ 39 ​ 79 ​ 34 ​ 27 Daliresp 114 ​ 8 ​ 7 ​ 2 ​ 20 ​ 18 ​ 103 ​ 15 ​ 8 ​ (36) ​ (42) ​ 1 ​ (56) ​ (60) Bevespi 26 ​ 20 ​ 18 ​ 2 ​ n/m ​ n/m ​ 20 ​ (5) ​ 4 ​ n/m ​ n/m ​ - ​ - ​ - Breztri ​ 82 ​ n/m ​ n/m ​ 27 ​ n/m ​ n/m ​ 43 ​ n/m ​ 1 ​ n/m ​ n/m ​ 11 ​ n/m ​ n/m Others 291 ​ 58 ​ 47 ​ 135 ​ 69 ​ 55 ​ 60 ​ n/m ​ 89 ​ - ​ (9) ​ 7 ​ (16) ​ (25) Other medicines 1,003 ​ (10) ​ (14) ​ 536 ​ 10 ​ 5 ​ 100 ​ (34) ​ 145 ​ (40) ​ (42) ​ 222 ​ (8) ​ (12) Nexium* 739 ​ 4 ​ - ​ 419 ​ 13 ​ 9 ​ 67 ​ (17) ​ 36 ​ (2) ​ (11) ​ 217 ​ (4) ​ (8) Synagis* ​ 49 ​ (72) ​ (72) ​ - ​ n/m ​ n/m ​ 5 ​ (77) ​ 44 ​ (71) ​ (71) ​ - ​ - ​ - Seroquel XR/ * ​ 50 ​ (21) ​ (21) ​ 25 ​ (9) ​ (8) ​ 10 ​ (29) ​ 14 ​ (4) ​ (3) ​ 1 ​ (88) ​ (88) Losec Prilosec* 100 ​ 1 ​ (5) ​ 84 ​ 4 ​ (4) ​ - ​ (90) ​ 15 ​ 56 ​ 55 ​ 1 ​ (90) ​ (92) FluMist* ​ 3 ​ n/m ​ n/m ​ 1 ​ - ​ - ​ - ​ n/m ​ 2 ​ n/m ​ n/m ​ - ​ - ​ - Others 62 ​ (9) ​ (13) ​ 7 ​ n/m ​ n/m ​ 18 ​ (46) ​ 34 ​ 20 ​ 11 ​ 3 ​ (16) ​ (14) COVID-19 ​ 1,136 ​ n/m ​ n/m ​ 455 ​ n/m ​ n/m ​ - ​ - ​ 572 ​ n/m ​ n/m ​ 109 ​ n/m ​ n/m Pandemic COVID-19 vaccine ​ 1,136 ​ n/m ​ n/m ​ 455 ​ n/m ​ n/m ​ - ​ - ​ 572 ​ n/m ​ n/m ​ 109 ​ n/m ​ n/m Total Product Sales 15,302 ​ 24 ​ 19 ​ 5,423 ​ 26 ​ 20 ​ 4,729 ​ 16 ​ 3,243 ​ 41 ​ 28 ​ 1,907 ​ 15 ​ 9

Q2 2021 Product Sales year-on_2

Q2 2021 Product Sales year-on-year analysis (Unreviewed) (Table)	6 Months Ended
	Jun. 30, 2021
Q2 2021 Product Sales year-on-year analysis (Unreviewed)
Q2 2021 Product Sales year-on-year analysis (Unreviewed)	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ World ​ Emerging Markets ​ US ​ Europe ​ Established RoW ​ ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ CER ​ $m % change % change $m % change % change $m % change $m % change % change $m % change % change Oncology 3,286 ​ 26 ​ 21 ​ 864 ​ 15 ​ 8 ​ 1,301 ​ 33 ​ 608 ​ 38 ​ 23 ​ 513 ​ 18 ​ 15 Tagrisso 1,306 ​ 26 ​ 21 ​ 390 ​ 24 ​ 15 ​ 438 ​ 24 ​ 244 ​ 49 ​ 34 ​ 234 ​ 16 ​ 13 Imfinzi 604 ​ 23 ​ 19 ​ 75 ​ n/m ​ n/m ​ 305 ​ 6 ​ 118 ​ 28 ​ 15 ​ 106 ​ 30 ​ 26 Lynparza 588 ​ 40 ​ 35 ​ 99 ​ 54 ​ 47 ​ 269 ​ 29 ​ 153 ​ 59 ​ 43 ​ 67 ​ 35 ​ 30 Calquence ​ 280 ​ n/m ​ n/m ​ 5 ​ n/m ​ n/m ​ 250 ​ n/m ​ 22 ​ n/m ​ n/m ​ 3 ​ n/m ​ n/m Koselugo ​ 26 ​ n/m ​ n/m ​ - ​ - ​ - ​ 26 ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - Enhertu ​ 3 ​ n/m ​ n/m ​ 3 ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Zoladex* ​ 244 ​ 12 ​ 5 ​ 159 ​ 14 ​ 7 ​ 3 ​ 2 ​ 37 ​ 12 ​ (1) ​ 45 ​ 6 ​ 2 Faslodex* 105 ​ (28) ​ (31) ​ 38 ​ (28) ​ (30) ​ 7 ​ (35) ​ 30 ​ (43) ​ (49) ​ 30 ​ (1) ​ (2) Iressa* 47 ​ (34) ​ (38) ​ 36 ​ (38) ​ (43) ​ 3 ​ (30) ​ 1 ​ (61) ​ (68) ​ 7 ​ 30 ​ 27 Arimidex* ​ 29 ​ (50) ​ (53) ​ 20 ​ (58) ​ (60) ​ - ​ - ​ 1 ​ 14 ​ (22) ​ 8 ​ (10) ​ (11) Casodex* ​ 41 ​ (14) ​ (19) ​ 32 ​ (14) ​ (21) ​ - ​ - ​ - ​ - ​ - ​ 9 ​ (12) ​ (14) Others 13 ​ 12 ​ 6 ​ 7 ​ 24 ​ 18 ​ - ​ n/m ​ 2 ​ 46 ​ (8) ​ 4 ​ (26) ​ (20) BioPharmaceuticals: CVRM 2,023 ​ 15 ​ 9 ​ 975 ​ 16 ​ 9 ​ 525 ​ 6 ​ 363 ​ 31 ​ 18 ​ 160 ​ 9 ​ 3 Farxiga ​ 732 ​ 65 ​ 56 ​ 297 ​ 80 ​ 70 ​ 171 ​ 38 ​ 198 ​ 86 ​ 67 ​ 66 ​ 41 ​ 33 Brilinta 375 ​ (14) ​ (18) ​ 74 ​ (52) ​ (55) ​ 194 ​ 4 ​ 90 ​ 13 ​ 1 ​ 17 ​ 19 ​ - Bydureon 95 ​ (18) ​ (20) ​ 1 ​ 97 ​ 77 ​ 77 ​ (24) ​ 15 ​ 17 ​ 1 ​ 2 ​ (19) ​ (34) Onglyza 99 ​ (14) ​ (18) ​ 51 ​ (3) ​ (9) ​ 26 ​ (33) ​ 15 ​ 12 ​ - ​ 7 ​ (31) ​ (39) Byetta 16 ​ 6 ​ - ​ 4 ​ n/m ​ n/m ​ 7 ​ (6) ​ 3 ​ (19) ​ (35) ​ 2 ​ (16) ​ (25) Other diabetes 15 ​ 49 ​ 40 ​ 4 ​ n/m ​ n/m ​ 6 ​ (4) ​ 5 ​ 71 ​ 47 ​ - ​ - ​ - Lokelma ​ 39 ​ n/m ​ n/m ​ 1 ​ 79 ​ 78 ​ 25 ​ n/m ​ 3 ​ n/m ​ n/m ​ 10 ​ n/m ​ n/m Roxadustat ​ 51 ​ n/m ​ n/m ​ 51 ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - Crestor* 265 ​ (6) ​ (11) ​ 182 ​ 3 ​ (3) ​ 19 ​ 10 ​ 12 ​ (61) ​ (67) ​ 52 ​ (8) ​ (10) Seloken Toprol-XL* 266 ​ 22 ​ 14 ​ 260 ​ 24 ​ 15 ​ - ​ (83) ​ 3 ​ (20) ​ (12) ​ 3 ​ 25 ​ 14 Atacand* 23 ​ (62) ​ (61) ​ 15 ​ (67) ​ (68) ​ - ​ n/m ​ 8 ​ 31 ​ 32 ​ - ​ n/m ​ n/m Others 47 ​ (1) ​ (9) ​ 35 ​ 20 ​ 10 ​ - ​ n/m ​ 11 ​ (30) ​ (33) ​ 1 ​ (57) ​ (60) BioPharmaceuticals: Respiratory & Immunology 1,420 ​ 27 ​ 21 ​ 343 ​ 56 ​ 45 ​ 597 ​ 27 ​ 318 ​ 19 ​ 7 ​ 162 ​ 3 ​ (5) Symbicort 680 ​ 4 ​ (1) ​ 141 ​ 5 ​ - ​ 264 ​ 6 ​ 176 ​ 9 ​ (2) ​ 99 ​ (9) ​ (17) Pulmicort 167 ​ 72 ​ 59 ​ 119 ​ n/m ​ 88 ​ 18 ​ 40 ​ 18 ​ 23 ​ 7 ​ 12 ​ 5 ​ (1) Fasenra 320 ​ 41 ​ 36 ​ 5 ​ n/m ​ n/m ​ 201 ​ 32 ​ 73 ​ 72 ​ 55 ​ 41 ​ 28 ​ 21 Daliresp 54 ​ 3 ​ 3 ​ 1 ​ 29 ​ 23 ​ 49 ​ 10 ​ 4 ​ (37) ​ (36) ​ - ​ (85) ​ (80) Bevespi 13 ​ 34 ​ 33 ​ 1 ​ n/m ​ n/m ​ 10 ​ 6 ​ 2 ​ n/m ​ n/m ​ - ​ - ​ - Breztri ​ 56 ​ n/m ​ n/m ​ 17 ​ n/m ​ n/m ​ 31 ​ n/m ​ 1 ​ n/m ​ n/m ​ 7 ​ n/m ​ n/m Others 130 ​ 85 ​ 70 ​ 59 ​ n/m ​ n/m ​ 24 ​ n/m ​ 44 ​ 5 ​ (6) ​ 3 ​ 37 ​ 9 Other medicines 454 ​ (19) ​ (23) ​ 239 ​ 1 ​ (4) ​ 47 ​ (27) ​ 68 ​ (41) ​ (45) ​ 100 ​ (31) ​ (32) Nexium* 336 ​ (11) ​ (14) ​ 185 ​ 1 ​ (4) ​ 35 ​ (14) ​ 18 ​ 23 ​ 11 ​ 98 ​ (29) ​ (31) Synagis* ​ 24 ​ (73) ​ (73) ​ - ​ - ​ - ​ 3 ​ (78) ​ 21 ​ (72) ​ (72) ​ - ​ - ​ - Seroquel XR/ * ​ 21 ​ (23) ​ (19) ​ 11 ​ (26) ​ (27) ​ 3 ​ n/m ​ 7 ​ (5) ​ 2 ​ - ​ n/m ​ (87) Losec Prilosec* 46 ​ 2 ​ (6) ​ 38 ​ 2 ​ (7) ​ - ​ (68) ​ 8 ​ 49 ​ 42 ​ - ​ (82) ​ (87) FluMist* ​ 1 ​ n/m ​ n/m ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ - ​ 1 ​ n/m ​ n/m Others 26 ​ 10 ​ 1 ​ 5 ​ n/m ​ n/m ​ 6 ​ (30) ​ 14 ​ 14 ​ (3) ​ 1 ​ 39 ​ 55 COVID-19 ​ 862 ​ n/m ​ n/m ​ 413 ​ n/m ​ n/m ​ - ​ - ​ 347 ​ n/m ​ n/m ​ 102 ​ n/m ​ n/m Pandemic COVID-19 vaccine ​ 862 ​ n/m ​ n/m ​ 413 ​ n/m ​ n/m ​ - ​ - ​ 347 ​ n/m ​ n/m ​ 102 ​ n/m ​ n/m Total Product Sales 8,045 ​ 33 ​ 27 ​ 2,834 ​ 38 ​ 31 ​ 2,470 ​ 23 ​ 1,704 ​ 55 ​ 39 ​ 1,037 ​ 17 ​ 12

Q2 2021 Product Sales quarter_2

Q2 2021 Product Sales quarterly sequential analysis (Unreviewed) (Tables)	6 Months Ended
	Jun. 30, 2021
Q2 2021 Product Sales quarterly sequential analysis (Unreviewed)
Q2 2021 Product Sales quarterly sequential analysis (Unreviewed)	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Q1 2021 ​ Q2 2021 ​ ​ ​ ​ Actual ​ CER ​ ​ ​ Actual ​ CER ​ ​ ​ $m ​ % change ​ % change ​ $m ​ % change ​ % change Oncology ​ 2,981 ​ 3 ​ 1 ​ 3,286 ​ 10 ​ 11 Tagrisso ​ 1,149 ​ (1) ​ (3) ​ 1,306 ​ 14 ​ 14 Imfinzi ​ 556 ​ - ​ (1) ​ 604 ​ 9 ​ 10 Lynparza ​ 543 ​ 9 ​ 8 ​ 588 ​ 8 ​ 9 Calquence ​ ​ 209 ​ 15 ​ 15 ​ 280 ​ 34 ​ 34 Koselugo ​ ​ 21 ​ 23 ​ 23 ​ 26 ​ 23 ​ 22 Enhertu ​ ​ 1 ​ n/m ​ n/m ​ 3 ​ n/m ​ n/m Zoladex* ​ 221 ​ 2 ​ - ​ 244 ​ 10 ​ 11 Faslodex* ​ 122 ​ (6) ​ (8) ​ 105 ​ (14) ​ (12) Iressa* ​ ​ 61 ​ (9) ​ (11) ​ 47 ​ (23) ​ (22) Arimidex* ​ ​ 44 ​ 22 ​ 18 ​ 29 ​ (34) ​ (33) Casodex* ​ 42 ​ 7 ​ 5 ​ 41 ​ (2) ​ (1) Others ​ 12 ​ (4) ​ (6) ​ 13 ​ 13 ​ 11 BioPharmaceuticals: CVRM ​ 1,912 ​ 4 ​ 1 ​ 2,023 ​ 6 ​ 6 Farxiga ​ 624 ​ 6 ​ 4 ​ 732 ​ 17 ​ 18 Brilinta ​ 374 ​ 3 ​ 1 ​ 375 ​ - ​ 1 Bydureon ​ 103 ​ (16) ​ (17) ​ 95 ​ (8) ​ (7) Onglyza ​ 101 ​ (3) ​ (6) ​ 99 ​ (2) ​ (2) Byetta ​ 16 ​ (14) ​ (15) ​ 16 ​ (4) ​ (7) Other diabetes ​ 13 ​ 7 ​ 1 ​ 15 ​ 14 ​ 14 Lokelma ​ ​ 33 ​ 16 ​ 18 ​ 39 ​ 21 ​ 21 Roxadustat ​ 39 ​ n/m ​ n/m ​ 51 ​ 32 ​ 32 Crestor* ​ 274 ​ (8) ​ (9) ​ 265 ​ (3) ​ (3) Seloken Toprol-XL* ​ 250 ​ 25 ​ 21 ​ 266 ​ 6 ​ 7 Atacand* ​ 34 ​ (45) ​ (45) ​ 23 ​ (35) ​ (32) Others ​ 51 ​ 12 ​ 10 ​ 47 ​ (7) ​ (10) BioPharmaceuticals: Respiratory & Immunology ​ 1,541 ​ 1 ​ (1) ​ 1,420 ​ (8) ​ (7) Symbicort ​ 691 ​ 2 ​ - ​ 680 ​ (2) ​ (1) Pulmicort ​ 330 ​ (10) ​ (13) ​ 167 ​ (50) ​ (49) Fasenra ​ 260 ​ (8) ​ (9) ​ 320 ​ 23 ​ 23 Daliresp ​ 60 ​ 11 ​ 10 ​ 54 ​ (10) ​ (9) Bevespi ​ 13 ​ 7 ​ 8 ​ 13 ​ 1 ​ 3 Breztri ​ ​ 27 ​ n/m ​ n/m ​ 56 ​ n/m ​ n/m Others ​ 160 ​ 28 ​ 25 ​ 130 ​ (19) ​ (19) Other medicines ​ 548 ​ (25) ​ (26) ​ 454 ​ (17) ​ (16) Nexium* ​ 403 ​ 7 ​ 5 ​ 336 ​ (17) ​ (15) Synagis* ​ 24 ​ (69) ​ (69) ​ 24 ​ 1 ​ 1 Seroquel XR/ * ​ 29 ​ 51 ​ 38 ​ 21 ​ (29) ​ (22) Losec Prilosec* ​ ​ 54 ​ 39 ​ 36 ​ 46 ​ (14) ​ (15) FluMist* ​ ​ 2 ​ (99) ​ (99) ​ 1 ​ (51) ​ (71) Others ​ ​ 36 ​ (6) ​ (4) ​ 26 ​ (28) ​ (32) COVID-19 ​ 275 ​ n/m ​ n/m ​ 862 ​ n/m ​ n/m Pandemic COVID-19 vaccine ​ 275 ​ n/m ​ n/m ​ 862 ​ n/m ​ n/m Total Product Sales ​ ​ 7,257 ​ 4 ​ 1 ​ 8,045 ​ 11 ​ 12

FY 2020 Product Sales quarter_2

FY 2020 Product Sales quarterly sequential analysis (Unreviewed) (Tables)	6 Months Ended
	Jun. 30, 2021
FY 2020 Product Sales quarterly sequential analysis (Unreviewed)
FY 2020 Product Sales quarterly sequential analysis (Unreviewed)	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Q1 2020 ​ Q2 2020 ​ Q3 2020 ​ Q4 2020 ​ ​ Actual ​ CER ​ Actual CER ​ Actual CER ​ Actual CER ​ ​ $m ​ % change ​ % change ​ $m ​ % change ​ % change ​ $m ​ % change ​ % change ​ $m ​ % change ​ % change Oncology 2,502 ​ 10 ​ 10 ​ 2,609 ​ 4 ​ 6 ​ 2,831 ​ 8 ​ 6 ​ 2,908 ​ 3 ​ 2 Tagrisso 982 ​ 11 ​ 11 ​ 1,034 ​ 5 ​ 7 ​ 1,155 ​ 12 ​ 9 ​ 1,157 ​ - ​ (1) Imfinzi 462 ​ 9 ​ 9 ​ 492 ​ 6 ​ 8 ​ 533 ​ 8 ​ 6 ​ 555 ​ 4 ​ 3 Lynparza 397 ​ 13 ​ 13 ​ 419 ​ 5 ​ 7 ​ 464 ​ 11 ​ 8 ​ 496 ​ 7 ​ 6 Calquence ​ 88 ​ 58 ​ 58 ​ 107 ​ 21 ​ 23 ​ 145 ​ 36 ​ 35 ​ 182 ​ 25 ​ 25 Koselugo ​ - ​ - ​ - ​ 7 ​ n/m ​ n/m ​ 13 ​ 75 ​ 75 ​ 17 ​ 34 ​ 34 Zoladex* ​ 225 ​ 15 ​ 15 ​ 217 ​ (3) ​ - ​ 230 ​ 6 ​ 3 ​ 216 ​ (6) ​ (7) Faslodex* 166 ​ - ​ - ​ 146 ​ (12) ​ (9) ​ 138 ​ (5) ​ (8) ​ 130 ​ (6) ​ (7) Iressa* 77 ​ (3) ​ (4) ​ 70 ​ (9) ​ (7) ​ 54 ​ (23) ​ (24) ​ 67 ​ 24 ​ 19 Arimidex* ​ 50 ​ (1) ​ (2) ​ 58 ​ 17 ​ 16 ​ 42 ​ (28) ​ (27) ​ 36 ​ (14) ​ (16) Casodex* ​ 42 ​ (2) ​ (3) ​ 47 ​ 14 ​ 12 ​ 44 ​ (7) ​ (8) ​ 39 ​ (11) ​ (14) Others 13 ​ (52) ​ (52) ​ 12 ​ (11) ​ (1) ​ 13 ​ 4 ​ 3 ​ 13 ​ 2 ​ 2 BioPharmaceuticals: CVRM 1,701 ​ (5) ​ (5) ​ 1,759 ​ 3 ​ 6 ​ 1,794 ​ 2 ​ - ​ 1,842 ​ 3 ​ 1 Farxiga 405 ​ (3) ​ (3) ​ 443 ​ 9 ​ 13 ​ 525 ​ 19 ​ 16 ​ 586 ​ 11 ​ 10 Brilinta 408 ​ (5) ​ (5) ​ 437 ​ 7 ​ 9 ​ 385 ​ (12) ​ (13) ​ 363 ​ (6) ​ (6) Onglyza 141 ​ 8 ​ 8 ​ 115 ​ (19) ​ (17) ​ 110 ​ (6) ​ (6) ​ 105 ​ (4) ​ (5) Bydureon 100 ​ (28) ​ (28) ​ 116 ​ 16 ​ 17 ​ 109 ​ (5) ​ (7) ​ 122 ​ 12 ​ 11 Byetta 20 ​ (24) ​ (24) ​ 15 ​ (28) ​ (28) ​ 15 ​ 1 ​ 4 ​ 19 ​ 26 ​ 24 Other diabetes 13 ​ (22) ​ (22) ​ 10 ​ (21) ​ (19) ​ 11 ​ 9 ​ 6 ​ 12 ​ 11 ​ 15 Lokelma ​ 11 ​ 42 ​ 42 ​ 17 ​ 56 ​ 58 ​ 21 ​ 22 ​ 26 ​ 28 ​ 37 ​ 28 Crestor* 301 ​ 2 ​ 1 ​ 281 ​ (7) ​ (4) ​ 300 ​ 7 ​ 5 ​ 298 ​ (1) ​ (4) Seloken Toprol-XL* 177 ​ (6) ​ (6) ​ 218 ​ 23 ​ 27 ​ 225 ​ 4 ​ 3 ​ 200 ​ (11) ​ (13) Atacand* 66 ​ 11 ​ 12 ​ 59 ​ (11) ​ (5) ​ 54 ​ (9) ​ (12) ​ 63 ​ 16 ​ 14 Others 59 ​ (21) ​ (22) ​ 48 ​ (18) ​ (16) ​ 39 ​ (19) ​ (22) ​ 46 ​ 18 ​ 17 BioPharmaceuticals: Respiratory & Immunology 1,551 ​ 1 ​ 1 ​ 1,117 ​ (28) ​ (26) ​ 1,161 ​ 4 ​ 1 ​ 1,528 ​ 32 ​ 29 Symbicort 790 ​ 11 ​ 11 ​ 653 ​ (17) ​ (15) ​ 599 ​ (8) ​ (11) ​ 680 ​ 13 ​ 13 Pulmicort 380 ​ (8) ​ (9) ​ 97 ​ (74) ​ (73) ​ 151 ​ 56 ​ 49 ​ 368 ​ n/m ​ n/m Fasenra 199 ​ (3) ​ (3) ​ 227 ​ 14 ​ 15 ​ 240 ​ 5 ​ 4 ​ 283 ​ 18 ​ 17 Daliresp 53 ​ (8) ​ (8) ​ 53 ​ (1) ​ (3) ​ 57 ​ 8 ​ 11 ​ 54 ​ (4) ​ (6) Bevespi 12 ​ 9 ​ 9 ​ 10 ​ (19) ​ (21) ​ 14 ​ 47 ​ 46 ​ 12 ​ (16) ​ (17) Breztri ​ 4 ​ n/m ​ n/m ​ 7 ​ 58 ​ 64 ​ 10 ​ 45 ​ 48 ​ 6 ​ (39) ​ (38) Others 113 ​ (16) ​ (17) ​ 70 ​ (38) ​ (36) ​ 90 ​ 27 ​ 22 ​ 125 ​ 39 ​ 35 Other medicines 557 ​ (15) ​ (15) ​ 563 ​ 1 ​ 4 ​ 734 ​ 30 ​ 27 ​ 733 ​ - ​ (2) Nexium* 338 ​ (4) ​ (4) ​ 377 ​ 12 ​ 14 ​ 401 ​ 6 ​ 4 ​ 377 ​ (6) ​ (7) Synagis* 85 ​ 35 ​ 35 ​ 90 ​ 6 ​ 7 ​ 118 ​ 31 ​ 29 ​ 78 ​ (34) ​ (33) FluMist* ​ - ​ n/m ​ n/m ​ - ​ n/m ​ n/m ​ 116 ​ n/m ​ n/m ​ 179 ​ 55 ​ 50 Losec Prilosec* ​ 54 ​ 18 ​ 17 ​ 45 ​ (15) ​ (15) ​ 45 ​ - ​ - ​ 39 ​ (15) ​ (18) Seroquel XR/ * ​ 36 ​ (12) ​ (12) ​ 27 ​ (26) ​ (23) ​ 35 ​ 32 ​ 29 ​ 19 ​ (45) ​ (42) Others 44 ​ (71) ​ (70) ​ 24 ​ (46) ​ (42) ​ 19 ​ (17) ​ (19) ​ 41 ​ n/m ​ n/m Total Product Sales 6,311 ​ 1 ​ 1 ​ 6,048 ​ (4) ​ (2) ​ 6,520 ​ 8 ​ 6 ​ 7,011 ​ 8 ​ 6

Collaboration Revenue (Tables)

Collaboration Revenue (Tables)	6 Months Ended
	Jun. 30, 2021
Collaboration Revenue
Schedule of collaboration revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ H1 2021 ​ H1 2020 ​ FY 2020 ​ FY 2019 ​ $m $m $m $m Initial Collaboration Revenue ​ ​ ​ ​ ​ ​ ​ ​ Nexium ​ 75 ​ - ​ - ​ - Ongoing Collaboration Revenue ​ ​ ​ ​ ​ ​ ​ ​ Lynparza ​ - ​ 135 ​ 160 ​ 60 Lynparza ​ - ​ - ​ 300 ​ 450 Lynparza/Koselugo: ​ - ​ - ​ - ​ 100 Crestor ​ - ​ - ​ - ​ 39 Enhertu: s ​ 83 ​ 36 ​ 94 ​ - Roxadustat: ​ 3 ​ 11 ​ 30 ​ - Royalty income ​ 69 ​ 34 ​ 62 ​ 62 Other Ongoing Collaboration Revenue ​ 8 ​ 54 ​ 81 ​ 108 Total ​ 238 ​ 270 ​ 727 ​ 819

Other Operating Income and Ex_2

Other Operating Income and Expense (Tables)	6 Months Ended
	Jun. 30, 2021
Other Operating Income and Expense
Schedule of other operating income and expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ H1 2021 H1 2020 FY 2020 FY 2019 ​ ​ $m ​ $m ​ $m ​ $m Divestment of Viela Bio, Inc. shareholding ​ 776 ​ - ​ - ​ - Crestor ​ 309 ​ - ​ - ​ - Oxra Oxramet ​ 40 ​ - ​ - ​ - Hypertension medicines (ex-US, India and Japan) ​ - ​ 350 ​ 350 ​ - Monetisation of an asset previously licensed ​ - ​ - ​ 120 ​ - Brazikumab licence termination funding ​ 51 ​ - ​ 107 ​ - Inderal Tenormin Seloken Omepral ​ - ​ 51 ​ 51 ​ - Synagis ​ - ​ - ​ - ​ 515 Losec ​ - ​ - ​ - ​ 243 Seroquel and Seroquel XR ​ - ​ - ​ - ​ 213 Arimidex Casodex ​ - ​ - ​ - ​ 181 Nexium Vimovo ​ - ​ - ​ 54 ​ - Atacand ​ - ​ - ​ 400 ​ - Other ​ 132 ​ 200 ​ 446 ​ 389 Total ​ 1,308 ​ 601 ​ 1,528 ​ 1,541

Basis of Preparation and Acco_3

Basis of Preparation and Accounting Policies (Details) € in Millions, $ in Millions	Jul. 21, 2021USD ($)	Jun. 30, 2021USD ($)item	Jun. 30, 2021EUR (€)	Dec. 31, 2020USD ($)	Jun. 30, 2020USD ($)
Application of new accounting standards
Number of hedge relationship instruments effected with LIBOR | item		1
Borrowings		$ 27,495		$ 20,380
Going concern
Financial resources		19,700
Cash and cash equivalents		15,567		7,832	$ 5,673
Undrawn committed bank facilities	$ 9,500	4,100
Borrowings cancelled	4,500
Alexion Pharmaceuticals, Inc.
Application of new accounting standards
Borrowings	4,000	8,000
Going concern
Undrawn committed bank facilities				$ 9,500
Loans paid off	2,300
Cash and cash equivalents acquired	1,700
Oustanding bank borrowings acquired	0
Consideration paid	13,300
Years 2 and 3
Going concern
Undrawn committed bank facilities		3,400
Loans drawn	2,000
Years 1 and 2
Going concern
Undrawn committed bank facilities	1,000	$ 700
Extension option (in years)		1 year
Loans drawn	$ 2,000
Due within one year
Going concern
Short-term borrowings		$ 2,900
0.875% Non-callable bond
Application of new accounting standards
Borrowings | €			€ 750
Interest rate on borrowings		0.875%	0.875%
Instruments in a fair value hedge relationship | 0.875% Non-callable bond
Application of new accounting standards
Borrowings covered by hedges | €			€ 300
Interest rate swaps | Instruments in a fair value hedge relationship | Group's EUR denominated net assets
Application of new accounting standards
Nominal amounts in local currency | €			300

Intangible assets - Summary of

Intangible assets - Summary of impairment charges (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Impairment of intangible assets
Impairment charges	$ 55	$ 119
Carrying value	20,006	19,728	$ 20,947
Launched products
Impairment of intangible assets
Impairment charges	0	85
Products in development
Impairment of intangible assets
Impairment charges	$ 55	$ 34

Net Debt (Details)

Net Debt (Details) € in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2021EUR (€)	Jun. 30, 2020USD ($)	Apr. 30, 2021	Dec. 31, 2020USD ($)
Interest bearing loans and borrowings
Non-current installments of loans	$ (17,505)
Non-current instalments of loans - Cash Flow	(7,944)
Non-current installments of loans - Non-cash & Other	1,257
Non-current installments of loans - Exchange Movements	83
Non-current installments of loans	(24,109)		$ (15,150)
Non-current installments of leases	(489)
Non-current installments of leases - Non-cash & Other	(9)
Non-current installments of leases - Exchange Movements	6
Non-current installments of leases	(492)		(465)
Total long-term debt	(17,994)
Total long-term debt - Cash Flow	(7,944)
Total long-term debt - Non-cash & Other	1,248
Total long-term debt - Exchange Movements	89
Total long-term debt	(24,601)
Current instalments of loans	(1,536)
Current instalments of loans - Cash Flow	611
Current instalments of loans - Non-cash & Other	(1,248)
Current instalments of loans - Exchange Movements	37
Current instalments of loans	(2,136)
Current instalments of leases	(192)
Current instalments of leases - Cash Flow	117
Current instalments of leases - Non-cash & Other	(127)
Current instalments of leases - Exchange Movements	4
Current instalments of leases	(198)		(174)
Interest-bearing loans and borrowings	(2,194)
Interest-bearing loans and borrowings	(2,696)		(3,958)
Total current debt	(2,386)
Total current debt - Cash Flow	819
Total current debt - Non-cash & Other	(1,375)
Total current debt - Exchange Movements	48
Total current debt	(2,894)
Gross borrowings	(20,380)
Gross borrowings - Cash Flow	(7,125)
Gross borrowings - Non-cash & Other	(127)
Gross borrowings - Exchange Movements	137
Gross borrowings	(27,495)
Net derivative financial instruments	278
Net derivative financial instruments - Cash Flow	(15)
Net derivative financial instruments - Non-cash & Other	(118)
Net derivative financial instruments	145
Net borrowings	(20,102)
Net borrowings - Cash Flow	(7,140)
Net borrowings - Non-cash & Other	(245)
Net borrowings - Exchange Movements	137
Net borrowings	(27,350)
Cash and cash equivalents at the beginning of the period	7,832
Cash and cash equivalents - Cash Flow	7,794
Cash and cash equivalents - Exchange Movements	(59)
Cash and cash equivalents at the end of the period	15,567		5,673
Other investments - current	160
Other investments, current - Cash Flow	(98)
Other investments - current	62		442
Cash and investments	7,992
Cash and investments - Cash Flow	7,696
Cash and investments - Exchange Movements	(59)
Cash and investments	15,629
Net Debt	(12,110)
Net Debt - Cash Flow	556
Net Debt - Non-cash & Other	(245)
Net Debt - Exchange Movements	78
Net Debt	(11,721)
Cash collateral on financial derivatives	168		136
Cash collateral posted by the Group	1		120
Other investments - non-current	1,072		1,577		$ 1,108
Potential payable	2,375				$ 2,297
Increase in net debt	(389)
Dividends paid	2,469		2,398
Purchase of intangible assets	314		983
Payment of contingent consideration from business combinations	309		353
Purchase of property, plant and equipment	508		370
Net cash inflow before financing activities	3,145		1,336
Net cash inflow from operating activities	2,826		1,179
Disposal of non-current asset investments			949
Disposal of intangible assets	573		$ 474
Acerta Pharma Acquisition
Interest bearing loans and borrowings
Ownership interest acquired (as a percent)				45.00%
Current other payables
Interest bearing loans and borrowings
Potential payable	889
Non-current other payables
Interest bearing loans and borrowings
Potential payable	1,486
Bank collateral
Interest bearing loans and borrowings
Interest-bearing loans and borrowings	(288)
Current borrowings and current portion of non-current borrowing - Cash Flow	120
Interest-bearing loans and borrowings	(168)
Other Short-term borrowings excluding overdrafts
Interest bearing loans and borrowings
Interest-bearing loans and borrowings	(84)
Current borrowings and current portion of non-current borrowing - Cash Flow	62
Interest-bearing loans and borrowings	(22)
Overdrafts
Interest bearing loans and borrowings
Interest-bearing loans and borrowings	(286)
Current borrowings and current portion of non-current borrowing - Cash Flow	(91)
Current borrowings and current portion of non-current borrowing - Exchange Movements	7
Interest-bearing loans and borrowings	(370)
Fixed-rate notes, 0.300%, maturing in May 2023
Interest bearing loans and borrowings
Gross borrowings	(1,400)
Fixed-rate notes, 0.700%, maturing in May 2024
Interest bearing loans and borrowings
Gross borrowings	(1,600)
Fixed-rate notes, 1.200%, maturing in May 2026
Interest bearing loans and borrowings
Gross borrowings	(1,250)
Fixed-rate notes, 1.750%, maturing in May 2028
Interest bearing loans and borrowings
Gross borrowings	(1,250)
Fixed-rate notes, 2.250%, maturing in May 2031
Interest bearing loans and borrowings
Gross borrowings	(750)
Fixed-rate notes, 3.000%, maturing in May 2051
Interest bearing loans and borrowings
Gross borrowings	$ (750)
Fixed-rate notes, 0.375%, maturing in May 2029
Interest bearing loans and borrowings
Gross borrowings | €		€ (800)

Net Debt (Debt Issued) (Details

Net Debt (Debt Issued) (Details) € in Millions, $ in Millions	Jun. 30, 2021EUR (€)	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Interest bearing loans and borrowings
Borrowings		$ 27,495	$ 20,380
Fixed-rate notes, 0.300%, maturing in May 2023
Interest bearing loans and borrowings
Borrowings		$ 1,400
Interest rate on borrowings	0.30%	0.30%
Fixed-rate notes, 0.700%, maturing in May 2024
Interest bearing loans and borrowings
Borrowings		$ 1,600
Interest rate on borrowings	0.70%	0.70%
Fixed-rate notes, 1.200%, maturing in May 2026
Interest bearing loans and borrowings
Borrowings		$ 1,250
Interest rate on borrowings	1.20%	1.20%
Fixed-rate notes, 1.750%, maturing in May 2028
Interest bearing loans and borrowings
Borrowings		$ 1,250
Interest rate on borrowings	1.75%	1.75%
Fixed-rate notes, 2.250%, maturing in May 2031
Interest bearing loans and borrowings
Borrowings		$ 750
Interest rate on borrowings	2.25%	2.25%
Fixed-rate notes, 3.000%, maturing in May 2051
Interest bearing loans and borrowings
Borrowings		$ 750
Interest rate on borrowings	3.00%	3.00%
Fixed-rate notes, 0.375%, maturing in May 2029
Interest bearing loans and borrowings
Borrowings | €	€ 800
Interest rate on borrowings	0.375%	0.375%

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Financial instruments fair value gains
Fair value movements on equity investments	$ 81	$ 898	$ (27)	$ 1,069
Reconciliation of changes in contingent liabilities in business combination
Contingent liabilities recognised in business combination at beginning of period			3,323	4,139
Settlements			(309)	(353)
Revaluations			82	(44)
Discount unwind			112	141
Contingent liabilities recognised in business combination at end of period	3,208	$ 3,883	3,208	3,883
Diabetes alliance
Reconciliation of changes in contingent liabilities in business combination
Contingent liabilities recognised in business combination at beginning of period			2,932
Settlements			(304)
Revaluations			82
Discount unwind			99
Contingent liabilities recognised in business combination at end of period	2,809		2,809
Increase/decrease in contingent consideration balance with change in current estimates	281		$ 281
The increase/decrease in sales estimates			10.00%
Other
Reconciliation of changes in contingent liabilities in business combination
Contingent liabilities recognised in business combination at beginning of period			$ 391
Settlements			(5)
Discount unwind			13
Contingent liabilities recognised in business combination at end of period	399		399
Interest-Bearing Loans and Borrowings
Financial instruments fair value gains
Total carrying value	27,495		27,495
Fair value	30,412		30,412
Other Investments
Financial instruments fair value gains
Fair value	1,134		1,134
Money market funds
Financial instruments fair value gains
Fair value	13,637		13,637
Loans | Instruments in a fair value hedge relationship
Financial instruments fair value gains
Fair value	359		359
Loans | Instruments designated at fair value through profit and loss
Financial instruments fair value gains
Fair value	329		329
Derivatives
Financial instruments fair value gains
Fair value	$ 145		145
Level 1 | Equity investments
Financial instruments fair value gains
Transfers out			133
Level 3
Financial instruments fair value gains
Fair value movements on equity investments			$ 0	$ 65
Level 3 | Equity investments
Financial instruments fair value gains
Financial assets					$ 108

Legal Proceedings and Conting_2

Legal Proceedings and Contingent Liabilities - Legal proceedings (Details) item in Millions, $ in Millions	1 Months Ended			2 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)agreementitem	Feb. 28, 2021patent	Jan. 31, 2021claimpatent	May 31, 2021case	Nov. 30, 2020lawsuit	Jun. 30, 2021lawsuitagreementitem
Commitments and contingent liabilities
Number of patents infringed or potentially infringed | patent		3
Forxiga | Sandoz
Commitments and contingent liabilities
Number of patents infringed or potentially infringed | patent		3	3
Number of notices received | claim			3
PARP Inhibitor Royalty Dispute
Commitments and contingent liabilities
Number of royalty-bearing patent license agreements | agreement	2					2
US 340B Litigation
Commitments and contingent liabilities
Number of claims filed					2
US 340B Litigation | US District Court for the District of Columbia
Commitments and contingent liabilities
Number of claims filed					1
US 340B Litigation | United States District Court For Northern District Of California
Commitments and contingent liabilities
Number of claims filed					1
European Commission Claim Regarding AZD1222
Commitments and contingent liabilities
Number of claims filed | case				2
Number of doses ordered to supply | item	50					50
Tagrisso | India
Commitments and contingent liabilities
Amount of claim | $	$ 21
Nexium And Prilosec | US District Court for the Middle District of Louisiana
Commitments and contingent liabilities
Number of claims filed						1

Legal Proceedings and Conting_3

Legal Proceedings and Contingent Liabilities Taxation) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Legal Proceedings and Contingent Liabilities
Tax contingency related to transfer pricing audits included in tax accrual	$ 98	$ 287
Maximum amount of possible additional losses, transfer pricing	$ 29	$ 251

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	Jul. 21, 2021	Jul. 21, 2021	Jun. 30, 2021	Apr. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Subsequent events
Borrowings			$ 27,495		$ 20,380
Undrawn committed bank facilities	$ 9,500	$ 9,500	4,100
Borrowings cancelled	4,500
Intangible assets			20,006		20,947	$ 19,728
Alexion Pharmaceuticals, Inc.
Subsequent events
Consideration paid (received)	13,300
Borrowings	$ 4,000	$ 4,000	$ 8,000
Undrawn committed bank facilities					$ 9,500
Acerta Pharma Acquisition
Subsequent events
Ownership interest acquired (as a percent)				45.00%
Major business combination | Alexion Pharmaceuticals, Inc.
Subsequent events
Ownership interest acquired (as a percent)	100.00%	100.00%
Consideration paid (received)	$ 40,000
Cash Alexion shareholders will receive for each of their Alexion shares	$ 60	$ 60
Total amount of cash paid in consideration	$ 13,000
Major business combination | Alexion Pharmaceuticals, Inc. | American Depository Shares
Subsequent events
Number of shares Alexion shareholders will receive for each of their Alexion shares	2.1243	2.1243
Total fair value of shares Alexion shareholders will receive	$ 27,000	$ 27,000
New Borrowing
Subsequent events
Borrowings	17,500	17,500
Undrawn committed bank facilities	$ 1,000	1,000
Borrowings cancelled		$ 12,500

H1 2021 Product Sales year-on_3

H1 2021 Product Sales year-on-year analysis (Details) - USD ($) $ in Millions	3 Months Ended						6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021
Product sales
Product Sales	$ 8,045	$ 7,257	$ 7,011	$ 6,520	$ 6,048	$ 6,311
World
Product sales
Product Sales	$ 8,045						$ 15,302
Actual %, year-on-year	33.00%						24.00%
CER %, year-on-year	27.00%						19.00%
Emerging Markets
Product sales
Product Sales	$ 2,834						$ 5,423
Actual %, year-on-year	38.00%						26.00%
CER %, year-on-year	31.00%						20.00%
US
Product sales
Product Sales	$ 2,470						$ 4,729
Actual %, year-on-year	23.00%						16.00%
Europe
Product sales
Product Sales	$ 1,704						$ 3,243
Actual %, year-on-year	55.00%						41.00%
CER %, year-on-year	39.00%						28.00%
Established ROW
Product sales
Product Sales	$ 1,037						$ 1,907
Actual %, year-on-year	17.00%						15.00%
CER %, year-on-year	12.00%						9.00%
Total Oncology
Product sales
Product Sales	$ 3,286	2,981	2,908	2,831	2,609	2,502
Total Oncology | World
Product sales
Product Sales	$ 3,286						$ 6,267
Actual %, year-on-year	26.00%						23.00%
CER %, year-on-year	21.00%						18.00%
Total Oncology | Emerging Markets
Product sales
Product Sales	$ 864						$ 1,626
Actual %, year-on-year	15.00%						11.00%
CER %, year-on-year	8.00%						6.00%
Total Oncology | US
Product sales
Product Sales	$ 1,301						$ 2,494
Actual %, year-on-year	33.00%						28.00%
Total Oncology | Europe
Product sales
Product Sales	$ 608						$ 1,183
Actual %, year-on-year	38.00%						33.00%
CER %, year-on-year	23.00%						20.00%
Total Oncology | Established ROW
Product sales
Product Sales	$ 513						$ 964
Actual %, year-on-year	18.00%						19.00%
CER %, year-on-year	15.00%						14.00%
Tagrisso
Product sales
Product Sales	$ 1,306	1,149	1,157	1,155	1,034	982
Tagrisso | World
Product sales
Product Sales	$ 1,306						$ 2,454
Actual %, year-on-year	26.00%						22.00%
CER %, year-on-year	21.00%						17.00%
Tagrisso | Emerging Markets
Product sales
Product Sales	$ 390						$ 697
Actual %, year-on-year	24.00%						17.00%
CER %, year-on-year	15.00%						10.00%
Tagrisso | US
Product sales
Product Sales	$ 438						$ 853
Actual %, year-on-year	24.00%						18.00%
Tagrisso | Europe
Product sales
Product Sales	$ 244						$ 468
Actual %, year-on-year	49.00%						44.00%
CER %, year-on-year	34.00%						30.00%
Tagrisso | Established ROW
Product sales
Product Sales	$ 234						$ 436
Actual %, year-on-year	16.00%						18.00%
CER %, year-on-year	13.00%						13.00%
Imfinzi
Product sales
Product Sales	$ 604	556	555	533	492	462
Imfinzi | World
Product sales
Product Sales	$ 604						$ 1,160
Actual %, year-on-year	23.00%						22.00%
CER %, year-on-year	19.00%						18.00%
Imfinzi | Emerging Markets
Product sales
Product Sales	$ 75						$ 133
CER %, year-on-year							99.00%
Imfinzi | US
Product sales
Product Sales	$ 305						$ 597
Actual %, year-on-year	6.00%						4.00%
Imfinzi | Europe
Product sales
Product Sales	$ 118						$ 227
Actual %, year-on-year	28.00%						36.00%
CER %, year-on-year	15.00%						23.00%
Imfinzi | Established ROW
Product sales
Product Sales	$ 106						$ 203
Actual %, year-on-year	30.00%						35.00%
CER %, year-on-year	26.00%						30.00%
Lynparza
Product sales
Product Sales	$ 588	543	496	464	419	397
Lynparza | World
Product sales
Product Sales	$ 588						$ 1,131
Actual %, year-on-year	40.00%						39.00%
CER %, year-on-year	35.00%						34.00%
Lynparza | Emerging Markets
Product sales
Product Sales	$ 99						$ 186
Actual %, year-on-year	54.00%						54.00%
CER %, year-on-year	47.00%						50.00%
Lynparza | US
Product sales
Product Sales	$ 269						$ 523
Actual %, year-on-year	29.00%						29.00%
Lynparza | Europe
Product sales
Product Sales	$ 153						$ 301
Actual %, year-on-year	59.00%						52.00%
CER %, year-on-year	43.00%						38.00%
Lynparza | Established ROW
Product sales
Product Sales	$ 67						$ 121
Actual %, year-on-year	35.00%						32.00%
CER %, year-on-year	30.00%						26.00%
Calquence
Product sales
Product Sales	$ 280	209	182	145	107	88
Calquence | World
Product sales
Product Sales	280						$ 490
Calquence | Emerging Markets
Product sales
Product Sales	5						7
Calquence | US
Product sales
Product Sales	250						445
Calquence | Europe
Product sales
Product Sales	22						32
Calquence | Established ROW
Product sales
Product Sales	3						6
Koselugo
Product sales
Product Sales	26	21	17	13	7
Koselugo | World
Product sales
Product Sales	26						48
Koselugo | US
Product sales
Product Sales	26						47
Koselugo | Europe
Product sales
Product Sales							1
Enhertu
Product sales
Product Sales	3	1
Enhertu | World
Product sales
Product Sales	3						4
Enhertu | Emerging Markets
Product sales
Product Sales	3						4
Zoladex
Product sales
Product Sales	244	221	216	230	217	225
Zoladex | World
Product sales
Product Sales	$ 244						$ 466
Actual %, year-on-year	12.00%						5.00%
CER %, year-on-year	5.00%						(1.00%)
Zoladex | Emerging Markets
Product sales
Product Sales	$ 159						$ 296
Actual %, year-on-year	14.00%						3.00%
CER %, year-on-year	7.00%						(3.00%)
Zoladex | US
Product sales
Product Sales	$ 3						$ 8
Actual %, year-on-year	2.00%						58.00%
Zoladex | Europe
Product sales
Product Sales	$ 37						$ 74
Actual %, year-on-year	12.00%						9.00%
CER %, year-on-year	(1.00%)						(1.00%)
Zoladex | Established ROW
Product sales
Product Sales	$ 45						$ 88
Actual %, year-on-year	6.00%						9.00%
CER %, year-on-year	2.00%						3.00%
Faslodex
Product sales
Product Sales	$ 105	122	130	138	146	166
Faslodex | World
Product sales
Product Sales	$ 105						$ 227
Actual %, year-on-year	(28.00%)						(27.00%)
CER %, year-on-year	(31.00%)						(31.00%)
Faslodex | Emerging Markets
Product sales
Product Sales	$ 38						$ 80
Actual %, year-on-year	(28.00%)						(20.00%)
CER %, year-on-year	(30.00%)						(22.00%)
Faslodex | US
Product sales
Product Sales	$ 7						$ 16
Actual %, year-on-year	(35.00%)						(52.00%)
Faslodex | Europe
Product sales
Product Sales	$ 30						$ 71
Actual %, year-on-year	(43.00%)						(39.00%)
CER %, year-on-year	(49.00%)						(45.00%)
Faslodex | Established ROW
Product sales
Product Sales	$ 30						$ 60
Actual %, year-on-year	(1.00%)						(3.00%)
CER %, year-on-year	(2.00%)						(6.00%)
Iressa
Product sales
Product Sales	$ 47	61	67	54	70	77
Iressa | World
Product sales
Product Sales	$ 47						$ 107
Actual %, year-on-year	(34.00%)						(27.00%)
CER %, year-on-year	(38.00%)						(31.00%)
Iressa | Emerging Markets
Product sales
Product Sales	$ 36						$ 89
Actual %, year-on-year	(38.00%)						(26.00%)
CER %, year-on-year	(43.00%)						(31.00%)
Iressa | US
Product sales
Product Sales	$ 3						$ 5
Actual %, year-on-year	(30.00%)						(27.00%)
Iressa | Europe
Product sales
Product Sales	$ 1						$ 3
Actual %, year-on-year	(61.00%)						(66.00%)
CER %, year-on-year	(68.00%)						(71.00%)
Iressa | Established ROW
Product sales
Product Sales	$ 7						$ 10
Actual %, year-on-year	30.00%						(10.00%)
CER %, year-on-year	27.00%						(13.00%)
Arimidex
Product sales
Product Sales	$ 29	44	36	42	58	50
Arimidex | World
Product sales
Product Sales	$ 29						$ 73
Actual %, year-on-year	(50.00%)						(32.00%)
CER %, year-on-year	(53.00%)						(35.00%)
Arimidex | Emerging Markets
Product sales
Product Sales	$ 20						$ 56
Actual %, year-on-year	(58.00%)						(37.00%)
CER %, year-on-year	(60.00%)						(40.00%)
Arimidex | Europe
Product sales
Product Sales	$ 1						$ 2
Actual %, year-on-year	14.00%						26.00%
CER %, year-on-year	(22.00%)						12.00%
Arimidex | Established ROW
Product sales
Product Sales	$ 8						$ 15
Actual %, year-on-year	(10.00%)						(10.00%)
CER %, year-on-year	(11.00%)						(13.00%)
Casodex
Product sales
Product Sales	$ 41	42	39	44	47	42
Casodex | World
Product sales
Product Sales	$ 41						$ 82
Actual %, year-on-year	(14.00%)						(7.00%)
CER %, year-on-year	(19.00%)						(13.00%)
Casodex | Emerging Markets
Product sales
Product Sales	$ 32						$ 64
Actual %, year-on-year	(14.00%)						(7.00%)
CER %, year-on-year	(21.00%)						(14.00%)
Casodex | Europe
Product sales
Product Sales							$ 1
Actual %, year-on-year							(29.00%)
CER %, year-on-year							(10.00%)
Casodex | Established ROW
Product sales
Product Sales	$ 9						$ 17
Actual %, year-on-year	(12.00%)						(7.00%)
CER %, year-on-year	(14.00%)						(10.00%)
Oncology, Others
Product sales
Product Sales	$ 13	12	13	13	12	13
Oncology, Others | World
Product sales
Product Sales	$ 13						$ 25
Actual %, year-on-year	12.00%						(1.00%)
CER %, year-on-year	6.00%						(4.00%)
Oncology, Others | Emerging Markets
Product sales
Product Sales	$ 7						$ 14
Actual %, year-on-year	24.00%						4.00%
CER %, year-on-year	18.00%						1.00%
Oncology, Others | Europe
Product sales
Product Sales	$ 2						$ 3
Actual %, year-on-year	46.00%						19.00%
CER %, year-on-year	(8.00%)						4.00%
Oncology, Others | Established ROW
Product sales
Product Sales	$ 4						$ 8
Actual %, year-on-year	(26.00%)						(13.00%)
CER %, year-on-year	(20.00%)						(13.00%)
BioPharmaceuticals: total CVRM
Product sales
Product Sales	$ 2,023	1,912	1,842	1,794	1,759	1,701
BioPharmaceuticals: total CVRM | World
Product sales
Product Sales	$ 2,023						$ 3,935
Actual %, year-on-year	15.00%						14.00%
CER %, year-on-year	9.00%						9.00%
BioPharmaceuticals: total CVRM | Emerging Markets
Product sales
Product Sales	$ 975						$ 1,921
Actual %, year-on-year	16.00%						19.00%
CER %, year-on-year	9.00%						14.00%
BioPharmaceuticals: total CVRM | US
Product sales
Product Sales	$ 525						$ 987
Actual %, year-on-year	6.00%
BioPharmaceuticals: total CVRM | Europe
Product sales
Product Sales	$ 363						$ 727
Actual %, year-on-year	31.00%						24.00%
CER %, year-on-year	18.00%						13.00%
BioPharmaceuticals: total CVRM | Established ROW
Product sales
Product Sales	$ 160						$ 300
Actual %, year-on-year	9.00%						9.00%
CER %, year-on-year	3.00%						3.00%
Farxiga
Product sales
Product Sales	$ 732	624	586	525	443	405
Farxiga | World
Product sales
Product Sales	$ 732						$ 1,356
Actual %, year-on-year	65.00%						60.00%
CER %, year-on-year	56.00%						53.00%
Farxiga | Emerging Markets
Product sales
Product Sales	$ 297						$ 557
Actual %, year-on-year	80.00%						82.00%
CER %, year-on-year	70.00%						77.00%
Farxiga | US
Product sales
Product Sales	$ 171						$ 302
Actual %, year-on-year	38.00%						27.00%
Farxiga | Europe
Product sales
Product Sales	$ 198						$ 372
Actual %, year-on-year	86.00%						67.00%
CER %, year-on-year	67.00%						51.00%
Farxiga | Established ROW
Product sales
Product Sales	$ 66						$ 125
Actual %, year-on-year	41.00%						53.00%
CER %, year-on-year	33.00%						44.00%
Brilinta
Product sales
Product Sales	$ 375	374	363	385	437	408
Brilinta | World
Product sales
Product Sales	$ 375						$ 749
Actual %, year-on-year	(14.00%)						(11.00%)
CER %, year-on-year	(18.00%)						(15.00%)
Brilinta | Emerging Markets
Product sales
Product Sales	$ 74						$ 180
Actual %, year-on-year	(52.00%)						(38.00%)
CER %, year-on-year	(55.00%)						(40.00%)
Brilinta | US
Product sales
Product Sales	$ 194						$ 360
Actual %, year-on-year	4.00%						2.00%
Brilinta | Europe
Product sales
Product Sales	$ 90						$ 178
Actual %, year-on-year	13.00%						3.00%
CER %, year-on-year	1.00%						(7.00%)
Brilinta | Established ROW
Product sales
Product Sales	$ 17						$ 31
Actual %, year-on-year	19.00%						6.00%
CER %, year-on-year							(7.00%)
Bydureon
Product sales
Product Sales	$ 95	103	122	109	116	100
Bydureon | World
Product sales
Product Sales	$ 95						$ 198
Actual %, year-on-year	(18.00%)						(9.00%)
CER %, year-on-year	(20.00%)						(10.00%)
Bydureon | Emerging Markets
Product sales
Product Sales	$ 1						$ 2
Actual %, year-on-year	97.00%						(6.00%)
CER %, year-on-year	77.00%						(7.00%)
Bydureon | US
Product sales
Product Sales	$ 77						$ 162
Actual %, year-on-year	(24.00%)						(12.00%)
Bydureon | Europe
Product sales
Product Sales	$ 15						$ 29
Actual %, year-on-year	17.00%						20.00%
CER %, year-on-year	1.00%						7.00%
Bydureon | Established ROW
Product sales
Product Sales	$ 2						$ 5
Actual %, year-on-year	(19.00%)						(9.00%)
CER %, year-on-year	(34.00%)						(22.00%)
Onglyza
Product sales
Product Sales	$ 99	101	105	110	115	141
Onglyza | World
Product sales
Product Sales	$ 99						$ 200
Actual %, year-on-year	(14.00%)						(22.00%)
CER %, year-on-year	(18.00%)						(25.00%)
Onglyza | Emerging Markets
Product sales
Product Sales	$ 51						$ 108
Actual %, year-on-year	(3.00%)						9.00%
CER %, year-on-year	(9.00%)						4.00%
Onglyza | US
Product sales
Product Sales	$ 26						$ 44
Actual %, year-on-year	(33.00%)						(58.00%)
Onglyza | Europe
Product sales
Product Sales	$ 15						$ 31
Actual %, year-on-year	12.00%						6.00%
CER %, year-on-year							(4.00%)
Onglyza | Established ROW
Product sales
Product Sales	$ 7						$ 17
Actual %, year-on-year	(31.00%)						(25.00%)
CER %, year-on-year	(39.00%)						(30.00%)
Byetta
Product sales
Product Sales	$ 16	16	19	15	15	20
Byetta | World
Product sales
Product Sales	$ 16						$ 32
Actual %, year-on-year	6.00%						(9.00%)
CER %, year-on-year							(12.00%)
Byetta | Emerging Markets
Product sales
Product Sales	$ 4						$ 8
Actual %, year-on-year							72.00%
CER %, year-on-year							79.00%
Byetta | US
Product sales
Product Sales	$ 7						$ 15
Actual %, year-on-year	(6.00%)						(20.00%)
Byetta | Europe
Product sales
Product Sales	$ 3						$ 5
Actual %, year-on-year	(19.00%)						(27.00%)
CER %, year-on-year	(35.00%)						(38.00%)
Byetta | Established ROW
Product sales
Product Sales	$ 2						$ 4
Actual %, year-on-year	(16.00%)						(17.00%)
CER %, year-on-year	(25.00%)						(26.00%)
Other diabetes
Product sales
Product Sales	$ 15	13	12	11	10	13
Other diabetes | World
Product sales
Product Sales	$ 15						$ 29
Actual %, year-on-year	49.00%						23.00%
CER %, year-on-year	40.00%						17.00%
Other diabetes | Emerging Markets
Product sales
Product Sales	$ 4						$ 8
Other diabetes | US
Product sales
Product Sales	$ 6						$ 11
Actual %, year-on-year	(4.00%)						(15.00%)
Other diabetes | Europe
Product sales
Product Sales	$ 5						$ 9
Actual %, year-on-year	71.00%						53.00%
CER %, year-on-year	47.00%						35.00%
Other diabetes | Established ROW
Product sales
Product Sales							$ 1
Actual %, year-on-year							25.00%
CER %, year-on-year							18.00%
Lokelma
Product sales
Product Sales	$ 39	33	28	21	17	11
Lokelma | World
Product sales
Product Sales	39						$ 72
Lokelma | Emerging Markets
Product sales
Product Sales	$ 1						2
Actual %, year-on-year	79.00%
CER %, year-on-year	78.00%
Lokelma | US
Product sales
Product Sales	$ 25						49
Lokelma | Europe
Product sales
Product Sales	3						5
Lokelma | Established ROW
Product sales
Product Sales	10						16
Roxadustat
Product sales
Product Sales	51	39
Roxadustat | World
Product sales
Product Sales	51						90
Roxadustat | Emerging Markets
Product sales
Product Sales	51						90
Crestor
Product sales
Product Sales	265	274	298	300	281	301
Crestor | World
Product sales
Product Sales	$ 265						$ 539
Actual %, year-on-year	(6.00%)						(7.00%)
CER %, year-on-year	(11.00%)						(11.00%)
Crestor | Emerging Markets
Product sales
Product Sales	$ 182						$ 372
Actual %, year-on-year	3.00%						1.00%
CER %, year-on-year	(3.00%)						(4.00%)
Crestor | US
Product sales
Product Sales	$ 19						$ 41
Actual %, year-on-year	10.00%						(10.00%)
Crestor | Europe
Product sales
Product Sales	$ 12						$ 32
Actual %, year-on-year	(61.00%)						(50.00%)
CER %, year-on-year	(67.00%)						(54.00%)
Crestor | Established ROW
Product sales
Product Sales	$ 52						$ 94
Actual %, year-on-year	(8.00%)						(10.00%)
CER %, year-on-year	(10.00%)						(12.00%)
Seloken/Toprol-XL
Product sales
Product Sales	$ 266	250	200	225	218	177
Seloken/Toprol-XL | World
Product sales
Product Sales	$ 266						$ 515
Actual %, year-on-year	22.00%						30.00%
CER %, year-on-year	14.00%						24.00%
Seloken/Toprol-XL | Emerging Markets
Product sales
Product Sales	$ 260						$ 503
Actual %, year-on-year	24.00%						34.00%
CER %, year-on-year	15.00%						27.00%
Seloken/Toprol-XL | US
Product sales
Product Sales							$ 1
Actual %, year-on-year	(83.00%)						(88.00%)
Seloken/Toprol-XL | Europe
Product sales
Product Sales	$ 3						$ 6
Actual %, year-on-year	(20.00%)						(23.00%)
CER %, year-on-year	(12.00%)						(20.00%)
Seloken/Toprol-XL | Established ROW
Product sales
Product Sales	$ 3						$ 5
Actual %, year-on-year	25.00%						3.00%
CER %, year-on-year	14.00%						(8.00%)
Atacand
Product sales
Product Sales	$ 23	34	63	54	59	66
Atacand | World
Product sales
Product Sales	$ 23						$ 57
Actual %, year-on-year	(62.00%)						(55.00%)
CER %, year-on-year	(61.00%)						(55.00%)
Atacand | Emerging Markets
Product sales
Product Sales	$ 15						$ 20
Actual %, year-on-year	(67.00%)						(79.00%)
CER %, year-on-year	(68.00%)						(79.00%)
Atacand | US
Product sales
Product Sales							$ 2
Actual %, year-on-year							(56.00%)
Atacand | Europe
Product sales
Product Sales	$ 8						$ 35
Actual %, year-on-year	31.00%
CER %, year-on-year	32.00%
CVRM, Others
Product sales
Product Sales	$ 47	51	46	39	48	59
CVRM, Others | World
Product sales
Product Sales	$ 47						$ 98
Actual %, year-on-year	(1.00%)						(7.00%)
CER %, year-on-year	(9.00%)						(13.00%)
CVRM, Others | Emerging Markets
Product sales
Product Sales	$ 35						$ 71
Actual %, year-on-year	20.00%						9.00%
CER %, year-on-year	10.00%						2.00%
CVRM, Others | Europe
Product sales
Product Sales	$ 11						$ 25
Actual %, year-on-year	(30.00%)						(19.00%)
CER %, year-on-year	(33.00%)						(22.00%)
CVRM, Others | Established ROW
Product sales
Product Sales	$ 1						$ 2
Actual %, year-on-year	(57.00%)						(20.00%)
CER %, year-on-year	(60.00%)						(23.00%)
BioPharmaceuticals: total Respiratory & Immunology
Product sales
Product Sales	$ 1,420	1,541	1,528	1,161	1,117	1,551
BioPharmaceuticals: total Respiratory & Immunology | World
Product sales
Product Sales	$ 1,420						$ 2,961
Actual %, year-on-year	27.00%						11.00%
CER %, year-on-year	21.00%						6.00%
BioPharmaceuticals: total Respiratory & Immunology | Emerging Markets
Product sales
Product Sales	$ 343						$ 885
Actual %, year-on-year	56.00%						17.00%
CER %, year-on-year	45.00%						10.00%
BioPharmaceuticals: total Respiratory & Immunology | US
Product sales
Product Sales	$ 597						$ 1,148
Actual %, year-on-year	27.00%						17.00%
BioPharmaceuticals: total Respiratory & Immunology | Europe
Product sales
Product Sales	$ 318						$ 616
Actual %, year-on-year	19.00%						5.00%
CER %, year-on-year	7.00%						(5.00%)
BioPharmaceuticals: total Respiratory & Immunology | Established ROW
Product sales
Product Sales	$ 162						$ 312
Actual %, year-on-year	3.00%						(8.00%)
CER %, year-on-year	(5.00%)						(14.00%)
Symbicort
Product sales
Product Sales	$ 680	691	680	599	653	790
Symbicort | World
Product sales
Product Sales	$ 680						$ 1,371
Actual %, year-on-year	4.00%						(5.00%)
CER %, year-on-year	(1.00%)						(9.00%)
Symbicort | Emerging Markets
Product sales
Product Sales	$ 141						$ 306
Actual %, year-on-year	5.00%						5.00%
CER %, year-on-year							2.00%
Symbicort | US
Product sales
Product Sales	$ 264						$ 530
Actual %, year-on-year	6.00%						(5.00%)
Symbicort | Europe
Product sales
Product Sales	$ 176						$ 344
Actual %, year-on-year	9.00%						(3.00%)
CER %, year-on-year	(2.00%)						(12.00%)
Symbicort | Established ROW
Product sales
Product Sales	$ 99						$ 191
Actual %, year-on-year	(9.00%)						(20.00%)
CER %, year-on-year	(17.00%)						(26.00%)
Pulmicort
Product sales
Product Sales	$ 167	330	368	151	97	380
Pulmicort | World
Product sales
Product Sales	$ 167						$ 497
Actual %, year-on-year	72.00%						4.00%
CER %, year-on-year	59.00%						(2.00%)
Pulmicort | Emerging Markets
Product sales
Product Sales	$ 119						$ 405
Actual %, year-on-year							9.00%
CER %, year-on-year	88.00%						2.00%
Pulmicort | US
Product sales
Product Sales	$ 18						$ 35
Actual %, year-on-year	40.00%						(2.00%)
Pulmicort | Europe
Product sales
Product Sales	$ 18						$ 34
Actual %, year-on-year	23.00%						(15.00%)
CER %, year-on-year	7.00%						(25.00%)
Pulmicort | Established ROW
Product sales
Product Sales	$ 12						$ 23
Actual %, year-on-year	5.00%						(24.00%)
CER %, year-on-year	(1.00%)						(30.00%)
Fasenra
Product sales
Product Sales	$ 320	260	283	240	227	199
Fasenra | World
Product sales
Product Sales	$ 320						$ 580
Actual %, year-on-year	41.00%						36.00%
CER %, year-on-year	36.00%						32.00%
Fasenra | Emerging Markets
Product sales
Product Sales	$ 5						$ 8
Actual %, year-on-year							25.00%
CER %, year-on-year							27.00%
Fasenra | US
Product sales
Product Sales	$ 201						$ 357
Actual %, year-on-year	32.00%						31.00%
Fasenra | Europe
Product sales
Product Sales	$ 73						$ 136
Actual %, year-on-year	72.00%						54.00%
CER %, year-on-year	55.00%						39.00%
Fasenra | Established ROW
Product sales
Product Sales	$ 41						$ 79
Actual %, year-on-year	28.00%						34.00%
CER %, year-on-year	21.00%						27.00%
Daliresp/Daxas
Product sales
Product Sales	$ 54	60	54	57	53	53
Daliresp/Daxas | World
Product sales
Product Sales	$ 54						$ 114
Actual %, year-on-year	3.00%						8.00%
CER %, year-on-year	3.00%						7.00%
Daliresp/Daxas | Emerging Markets
Product sales
Product Sales	$ 1						$ 2
Actual %, year-on-year	29.00%						20.00%
CER %, year-on-year	23.00%						18.00%
Daliresp/Daxas | US
Product sales
Product Sales	$ 49						$ 103
Actual %, year-on-year	10.00%						15.00%
Daliresp/Daxas | Europe
Product sales
Product Sales	$ 4						$ 8
Actual %, year-on-year	(37.00%)						(36.00%)
CER %, year-on-year	(36.00%)						(42.00%)
Daliresp/Daxas | Established ROW
Product sales
Product Sales							$ 1
Actual %, year-on-year	(85.00%)						(56.00%)
CER %, year-on-year	(80.00%)						(60.00%)
Bevespi
Product sales
Product Sales	$ 13	13	12	14	10	12
Bevespi | World
Product sales
Product Sales	$ 13						$ 26
Actual %, year-on-year	34.00%						20.00%
CER %, year-on-year	33.00%						18.00%
Bevespi | Emerging Markets
Product sales
Product Sales	$ 1						$ 2
Bevespi | US
Product sales
Product Sales	$ 10						$ 20
Actual %, year-on-year	6.00%						(5.00%)
Bevespi | Europe
Product sales
Product Sales	$ 2						$ 4
Breztri
Product sales
Product Sales	56	27	6	10	7	4
Breztri | World
Product sales
Product Sales	56						82
Breztri | Emerging Markets
Product sales
Product Sales	17						27
Breztri | US
Product sales
Product Sales	31						43
Breztri | Europe
Product sales
Product Sales	1						1
Breztri | Established ROW
Product sales
Product Sales	7						11
Respiratory, Others
Product sales
Product Sales	130	160	125	90	70	113
Respiratory, Others | World
Product sales
Product Sales	$ 130						$ 291
Actual %, year-on-year	85.00%						58.00%
CER %, year-on-year	70.00%						47.00%
Respiratory, Others | Emerging Markets
Product sales
Product Sales	$ 59						$ 135
Actual %, year-on-year							69.00%
CER %, year-on-year							55.00%
Respiratory, Others | US
Product sales
Product Sales	24						$ 60
Respiratory, Others | Europe
Product sales
Product Sales	$ 44						$ 89
Actual %, year-on-year	5.00%
CER %, year-on-year	(6.00%)						(9.00%)
Respiratory, Others | Established ROW
Product sales
Product Sales	$ 3						$ 7
Actual %, year-on-year	37.00%						(16.00%)
CER %, year-on-year	9.00%						(25.00%)
Total Other medicines
Product sales
Product Sales	$ 454	548	733	734	563	557
Total Other medicines | World
Product sales
Product Sales	$ 454						$ 1,003
Actual %, year-on-year	(19.00%)						(10.00%)
CER %, year-on-year	(23.00%)						(14.00%)
Total Other medicines | Emerging Markets
Product sales
Product Sales	$ 239						$ 536
Actual %, year-on-year	1.00%						10.00%
CER %, year-on-year	(4.00%)						5.00%
Total Other medicines | US
Product sales
Product Sales	$ 47						$ 100
Actual %, year-on-year	(27.00%)						(34.00%)
Total Other medicines | Europe
Product sales
Product Sales	$ 68						$ 145
Actual %, year-on-year	(41.00%)						(40.00%)
CER %, year-on-year	(45.00%)						(42.00%)
Total Other medicines | Established ROW
Product sales
Product Sales	$ 100						$ 222
Actual %, year-on-year	(31.00%)						(8.00%)
CER %, year-on-year	(32.00%)						(12.00%)
Nexium
Product sales
Product Sales	$ 336	403	377	401	377	338
Nexium | World
Product sales
Product Sales	$ 336						$ 739
Actual %, year-on-year	(11.00%)						4.00%
CER %, year-on-year	(14.00%)
Nexium | Emerging Markets
Product sales
Product Sales	$ 185						$ 419
Actual %, year-on-year	1.00%						13.00%
CER %, year-on-year	(4.00%)						9.00%
Nexium | US
Product sales
Product Sales	$ 35						$ 67
Actual %, year-on-year	(14.00%)						(17.00%)
Nexium | Europe
Product sales
Product Sales	$ 18						$ 36
Actual %, year-on-year	23.00%						(2.00%)
CER %, year-on-year	11.00%						(11.00%)
Nexium | Established ROW
Product sales
Product Sales	$ 98						$ 217
Actual %, year-on-year	(29.00%)						(4.00%)
CER %, year-on-year	(31.00%)						(8.00%)
Synagis
Product sales
Product Sales	$ 24	24	78	118	90	85
Synagis | World
Product sales
Product Sales	$ 24						$ 49
Actual %, year-on-year	(73.00%)						(72.00%)
CER %, year-on-year	(73.00%)						(72.00%)
Synagis | US
Product sales
Product Sales	$ 3						$ 5
Actual %, year-on-year	(78.00%)						(77.00%)
Synagis | Europe
Product sales
Product Sales	$ 21						$ 44
Actual %, year-on-year	(72.00%)						(71.00%)
CER %, year-on-year	(72.00%)						(71.00%)
Seroquel XR/IR
Product sales
Product Sales	$ 21	29	19	35	27	36
Seroquel XR/IR | World
Product sales
Product Sales	$ 21						$ 50
Actual %, year-on-year	(23.00%)						(21.00%)
CER %, year-on-year	(19.00%)						(21.00%)
Seroquel XR/IR | Emerging Markets
Product sales
Product Sales	$ 11						$ 25
Actual %, year-on-year	(26.00%)						(9.00%)
CER %, year-on-year	(27.00%)						(8.00%)
Seroquel XR/IR | US
Product sales
Product Sales	$ 3						$ 10
Actual %, year-on-year							(29.00%)
Seroquel XR/IR | Europe
Product sales
Product Sales	$ 7						$ 14
Actual %, year-on-year	(5.00%)						(4.00%)
CER %, year-on-year	2.00%						(3.00%)
Seroquel XR/IR | Established ROW
Product sales
Product Sales							$ 1
Actual %, year-on-year							(88.00%)
CER %, year-on-year	(87.00%)						(88.00%)
Losec/Prilosec
Product sales
Product Sales	$ 46	54	39	45	45	54
Losec/Prilosec | World
Product sales
Product Sales	$ 46						$ 100
Actual %, year-on-year	2.00%						1.00%
CER %, year-on-year	(6.00%)						(5.00%)
Losec/Prilosec | Emerging Markets
Product sales
Product Sales	$ 38						$ 84
Actual %, year-on-year	2.00%						4.00%
CER %, year-on-year	(7.00%)						(4.00%)
Losec/Prilosec | US
Product sales
Actual %, year-on-year	(68.00%)						(90.00%)
Losec/Prilosec | Europe
Product sales
Product Sales	$ 8						$ 15
Actual %, year-on-year	49.00%						56.00%
CER %, year-on-year	42.00%						55.00%
Losec/Prilosec | Established ROW
Product sales
Product Sales							$ 1
Actual %, year-on-year	(82.00%)						(90.00%)
CER %, year-on-year	(87.00%)						(92.00%)
FluMist
Product sales
Product Sales	$ 1	2	179	116
FluMist | World
Product sales
Product Sales	1						$ 3
FluMist | Emerging Markets
Product sales
Product Sales							1
FluMist | Europe
Product sales
Product Sales							2
FluMist | Established ROW
Product sales
Product Sales	1
Other, Others
Product sales
Product Sales	26	36	$ 41	$ 19	$ 24	$ 44
Other, Others | World
Product sales
Product Sales	$ 26						$ 62
Actual %, year-on-year	10.00%						(9.00%)
CER %, year-on-year	1.00%						(13.00%)
Other, Others | Emerging Markets
Product sales
Product Sales	$ 5						$ 7
Other, Others | US
Product sales
Product Sales	$ 6						$ 18
Actual %, year-on-year	(30.00%)						(46.00%)
Other, Others | Europe
Product sales
Product Sales	$ 14						$ 34
Actual %, year-on-year	14.00%						20.00%
CER %, year-on-year	(3.00%)						11.00%
Other, Others | Established ROW
Product sales
Product Sales	$ 1						$ 3
Actual %, year-on-year	39.00%						(16.00%)
CER %, year-on-year	55.00%						(14.00%)
COVID 19
Product sales
Product Sales	$ 862	275
COVID 19 | World
Product sales
Product Sales	862						$ 1,136
COVID 19 | Emerging Markets
Product sales
Product Sales	413						455
COVID 19 | Europe
Product sales
Product Sales	347						572
COVID 19 | Established ROW
Product sales
Product Sales	102						109
Pandemic COVID-19 Vaccine
Product sales
Product Sales	862	$ 275
Pandemic COVID-19 Vaccine | World
Product sales
Product Sales	862						1,136
Pandemic COVID-19 Vaccine | Emerging Markets
Product sales
Product Sales	413						455
Pandemic COVID-19 Vaccine | Europe
Product sales
Product Sales	347						572
Pandemic COVID-19 Vaccine | Established ROW
Product sales
Product Sales	$ 102						$ 109

Q2 2021 Product Sales year-on_3

Q2 2021 Product Sales year-on-year analysis (Unreviewed) (Details) - USD ($) $ in Millions	3 Months Ended						6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021
Product sales
Product Sales	$ 8,045	$ 7,257	$ 7,011	$ 6,520	$ 6,048	$ 6,311
World
Product sales
Product Sales	$ 8,045						$ 15,302
Actual %, year-on-year	33.00%						24.00%
CER %, year-on-year	27.00%						19.00%
Emerging Markets
Product sales
Product Sales	$ 2,834						$ 5,423
Actual %, year-on-year	38.00%						26.00%
CER %, year-on-year	31.00%						20.00%
US
Product sales
Product Sales	$ 2,470						$ 4,729
Actual %, year-on-year	23.00%						16.00%
Europe
Product sales
Product Sales	$ 1,704						$ 3,243
Actual %, year-on-year	55.00%						41.00%
CER %, year-on-year	39.00%						28.00%
Established ROW
Product sales
Product Sales	$ 1,037						$ 1,907
Actual %, year-on-year	17.00%						15.00%
CER %, year-on-year	12.00%						9.00%
Total Oncology
Product sales
Product Sales	$ 3,286	2,981	2,908	2,831	2,609	2,502
Total Oncology | World
Product sales
Product Sales	$ 3,286						$ 6,267
Actual %, year-on-year	26.00%						23.00%
CER %, year-on-year	21.00%						18.00%
Total Oncology | Emerging Markets
Product sales
Product Sales	$ 864						$ 1,626
Actual %, year-on-year	15.00%						11.00%
CER %, year-on-year	8.00%						6.00%
Total Oncology | US
Product sales
Product Sales	$ 1,301						$ 2,494
Actual %, year-on-year	33.00%						28.00%
Total Oncology | Europe
Product sales
Product Sales	$ 608						$ 1,183
Actual %, year-on-year	38.00%						33.00%
CER %, year-on-year	23.00%						20.00%
Total Oncology | Established ROW
Product sales
Product Sales	$ 513						$ 964
Actual %, year-on-year	18.00%						19.00%
CER %, year-on-year	15.00%						14.00%
Tagrisso
Product sales
Product Sales	$ 1,306	1,149	1,157	1,155	1,034	982
Tagrisso | World
Product sales
Product Sales	$ 1,306						$ 2,454
Actual %, year-on-year	26.00%						22.00%
CER %, year-on-year	21.00%						17.00%
Tagrisso | Emerging Markets
Product sales
Product Sales	$ 390						$ 697
Actual %, year-on-year	24.00%						17.00%
CER %, year-on-year	15.00%						10.00%
Tagrisso | US
Product sales
Product Sales	$ 438						$ 853
Actual %, year-on-year	24.00%						18.00%
Tagrisso | Europe
Product sales
Product Sales	$ 244						$ 468
Actual %, year-on-year	49.00%						44.00%
CER %, year-on-year	34.00%						30.00%
Tagrisso | Established ROW
Product sales
Product Sales	$ 234						$ 436
Actual %, year-on-year	16.00%						18.00%
CER %, year-on-year	13.00%						13.00%
Imfinzi
Product sales
Product Sales	$ 604	556	555	533	492	462
Imfinzi | World
Product sales
Product Sales	$ 604						$ 1,160
Actual %, year-on-year	23.00%						22.00%
CER %, year-on-year	19.00%						18.00%
Imfinzi | Emerging Markets
Product sales
Product Sales	$ 75						$ 133
CER %, year-on-year							99.00%
Imfinzi | US
Product sales
Product Sales	$ 305						$ 597
Actual %, year-on-year	6.00%						4.00%
Imfinzi | Europe
Product sales
Product Sales	$ 118						$ 227
Actual %, year-on-year	28.00%						36.00%
CER %, year-on-year	15.00%						23.00%
Imfinzi | Established ROW
Product sales
Product Sales	$ 106						$ 203
Actual %, year-on-year	30.00%						35.00%
CER %, year-on-year	26.00%						30.00%
Lynparza
Product sales
Product Sales	$ 588	543	496	464	419	397
Lynparza | World
Product sales
Product Sales	$ 588						$ 1,131
Actual %, year-on-year	40.00%						39.00%
CER %, year-on-year	35.00%						34.00%
Lynparza | Emerging Markets
Product sales
Product Sales	$ 99						$ 186
Actual %, year-on-year	54.00%						54.00%
CER %, year-on-year	47.00%						50.00%
Lynparza | US
Product sales
Product Sales	$ 269						$ 523
Actual %, year-on-year	29.00%						29.00%
Lynparza | Europe
Product sales
Product Sales	$ 153						$ 301
Actual %, year-on-year	59.00%						52.00%
CER %, year-on-year	43.00%						38.00%
Lynparza | Established ROW
Product sales
Product Sales	$ 67						$ 121
Actual %, year-on-year	35.00%						32.00%
CER %, year-on-year	30.00%						26.00%
Calquence
Product sales
Product Sales	$ 280	209	182	145	107	88
Calquence | World
Product sales
Product Sales	280						$ 490
Calquence | Emerging Markets
Product sales
Product Sales	5						7
Calquence | US
Product sales
Product Sales	250						445
Calquence | Europe
Product sales
Product Sales	22						32
Calquence | Established ROW
Product sales
Product Sales	3						6
Koselugo
Product sales
Product Sales	26	21	17	13	7
Koselugo | World
Product sales
Product Sales	26						48
Koselugo | US
Product sales
Product Sales	26						47
Koselugo | Europe
Product sales
Product Sales							1
Enhertu
Product sales
Product Sales	3	1
Enhertu | World
Product sales
Product Sales	3						4
Enhertu | Emerging Markets
Product sales
Product Sales	3						4
Zoladex
Product sales
Product Sales	244	221	216	230	217	225
Zoladex | World
Product sales
Product Sales	$ 244						$ 466
Actual %, year-on-year	12.00%						5.00%
CER %, year-on-year	5.00%						(1.00%)
Zoladex | Emerging Markets
Product sales
Product Sales	$ 159						$ 296
Actual %, year-on-year	14.00%						3.00%
CER %, year-on-year	7.00%						(3.00%)
Zoladex | US
Product sales
Product Sales	$ 3						$ 8
Actual %, year-on-year	2.00%						58.00%
Zoladex | Europe
Product sales
Product Sales	$ 37						$ 74
Actual %, year-on-year	12.00%						9.00%
CER %, year-on-year	(1.00%)						(1.00%)
Zoladex | Established ROW
Product sales
Product Sales	$ 45						$ 88
Actual %, year-on-year	6.00%						9.00%
CER %, year-on-year	2.00%						3.00%
Faslodex
Product sales
Product Sales	$ 105	122	130	138	146	166
Faslodex | World
Product sales
Product Sales	$ 105						$ 227
Actual %, year-on-year	(28.00%)						(27.00%)
CER %, year-on-year	(31.00%)						(31.00%)
Faslodex | Emerging Markets
Product sales
Product Sales	$ 38						$ 80
Actual %, year-on-year	(28.00%)						(20.00%)
CER %, year-on-year	(30.00%)						(22.00%)
Faslodex | US
Product sales
Product Sales	$ 7						$ 16
Actual %, year-on-year	(35.00%)						(52.00%)
Faslodex | Europe
Product sales
Product Sales	$ 30						$ 71
Actual %, year-on-year	(43.00%)						(39.00%)
CER %, year-on-year	(49.00%)						(45.00%)
Faslodex | Established ROW
Product sales
Product Sales	$ 30						$ 60
Actual %, year-on-year	(1.00%)						(3.00%)
CER %, year-on-year	(2.00%)						(6.00%)
Iressa
Product sales
Product Sales	$ 47	61	67	54	70	77
Iressa | World
Product sales
Product Sales	$ 47						$ 107
Actual %, year-on-year	(34.00%)						(27.00%)
CER %, year-on-year	(38.00%)						(31.00%)
Iressa | Emerging Markets
Product sales
Product Sales	$ 36						$ 89
Actual %, year-on-year	(38.00%)						(26.00%)
CER %, year-on-year	(43.00%)						(31.00%)
Iressa | US
Product sales
Product Sales	$ 3						$ 5
Actual %, year-on-year	(30.00%)						(27.00%)
Iressa | Europe
Product sales
Product Sales	$ 1						$ 3
Actual %, year-on-year	(61.00%)						(66.00%)
CER %, year-on-year	(68.00%)						(71.00%)
Iressa | Established ROW
Product sales
Product Sales	$ 7						$ 10
Actual %, year-on-year	30.00%						(10.00%)
CER %, year-on-year	27.00%						(13.00%)
Arimidex
Product sales
Product Sales	$ 29	44	36	42	58	50
Arimidex | World
Product sales
Product Sales	$ 29						$ 73
Actual %, year-on-year	(50.00%)						(32.00%)
CER %, year-on-year	(53.00%)						(35.00%)
Arimidex | Emerging Markets
Product sales
Product Sales	$ 20						$ 56
Actual %, year-on-year	(58.00%)						(37.00%)
CER %, year-on-year	(60.00%)						(40.00%)
Arimidex | Europe
Product sales
Product Sales	$ 1						$ 2
Actual %, year-on-year	14.00%						26.00%
CER %, year-on-year	(22.00%)						12.00%
Arimidex | Established ROW
Product sales
Product Sales	$ 8						$ 15
Actual %, year-on-year	(10.00%)						(10.00%)
CER %, year-on-year	(11.00%)						(13.00%)
Casodex
Product sales
Product Sales	$ 41	42	39	44	47	42
Casodex | World
Product sales
Product Sales	$ 41						$ 82
Actual %, year-on-year	(14.00%)						(7.00%)
CER %, year-on-year	(19.00%)						(13.00%)
Casodex | Emerging Markets
Product sales
Product Sales	$ 32						$ 64
Actual %, year-on-year	(14.00%)						(7.00%)
CER %, year-on-year	(21.00%)						(14.00%)
Casodex | Europe
Product sales
Product Sales							$ 1
Actual %, year-on-year							(29.00%)
CER %, year-on-year							(10.00%)
Casodex | Established ROW
Product sales
Product Sales	$ 9						$ 17
Actual %, year-on-year	(12.00%)						(7.00%)
CER %, year-on-year	(14.00%)						(10.00%)
Oncology, Others
Product sales
Product Sales	$ 13	12	13	13	12	13
Oncology, Others | World
Product sales
Product Sales	$ 13						$ 25
Actual %, year-on-year	12.00%						(1.00%)
CER %, year-on-year	6.00%						(4.00%)
Oncology, Others | Emerging Markets
Product sales
Product Sales	$ 7						$ 14
Actual %, year-on-year	24.00%						4.00%
CER %, year-on-year	18.00%						1.00%
Oncology, Others | Europe
Product sales
Product Sales	$ 2						$ 3
Actual %, year-on-year	46.00%						19.00%
CER %, year-on-year	(8.00%)						4.00%
Oncology, Others | Established ROW
Product sales
Product Sales	$ 4						$ 8
Actual %, year-on-year	(26.00%)						(13.00%)
CER %, year-on-year	(20.00%)						(13.00%)
BioPharmaceuticals: total CVRM
Product sales
Product Sales	$ 2,023	1,912	1,842	1,794	1,759	1,701
BioPharmaceuticals: total CVRM | World
Product sales
Product Sales	$ 2,023						$ 3,935
Actual %, year-on-year	15.00%						14.00%
CER %, year-on-year	9.00%						9.00%
BioPharmaceuticals: total CVRM | Emerging Markets
Product sales
Product Sales	$ 975						$ 1,921
Actual %, year-on-year	16.00%						19.00%
CER %, year-on-year	9.00%						14.00%
BioPharmaceuticals: total CVRM | US
Product sales
Product Sales	$ 525						$ 987
Actual %, year-on-year	6.00%
BioPharmaceuticals: total CVRM | Europe
Product sales
Product Sales	$ 363						$ 727
Actual %, year-on-year	31.00%						24.00%
CER %, year-on-year	18.00%						13.00%
BioPharmaceuticals: total CVRM | Established ROW
Product sales
Product Sales	$ 160						$ 300
Actual %, year-on-year	9.00%						9.00%
CER %, year-on-year	3.00%						3.00%
Farxiga
Product sales
Product Sales	$ 732	624	586	525	443	405
Farxiga | World
Product sales
Product Sales	$ 732						$ 1,356
Actual %, year-on-year	65.00%						60.00%
CER %, year-on-year	56.00%						53.00%
Farxiga | Emerging Markets
Product sales
Product Sales	$ 297						$ 557
Actual %, year-on-year	80.00%						82.00%
CER %, year-on-year	70.00%						77.00%
Farxiga | US
Product sales
Product Sales	$ 171						$ 302
Actual %, year-on-year	38.00%						27.00%
Farxiga | Europe
Product sales
Product Sales	$ 198						$ 372
Actual %, year-on-year	86.00%						67.00%
CER %, year-on-year	67.00%						51.00%
Farxiga | Established ROW
Product sales
Product Sales	$ 66						$ 125
Actual %, year-on-year	41.00%						53.00%
CER %, year-on-year	33.00%						44.00%
Brilinta
Product sales
Product Sales	$ 375	374	363	385	437	408
Brilinta | World
Product sales
Product Sales	$ 375						$ 749
Actual %, year-on-year	(14.00%)						(11.00%)
CER %, year-on-year	(18.00%)						(15.00%)
Brilinta | Emerging Markets
Product sales
Product Sales	$ 74						$ 180
Actual %, year-on-year	(52.00%)						(38.00%)
CER %, year-on-year	(55.00%)						(40.00%)
Brilinta | US
Product sales
Product Sales	$ 194						$ 360
Actual %, year-on-year	4.00%						2.00%
Brilinta | Europe
Product sales
Product Sales	$ 90						$ 178
Actual %, year-on-year	13.00%						3.00%
CER %, year-on-year	1.00%						(7.00%)
Brilinta | Established ROW
Product sales
Product Sales	$ 17						$ 31
Actual %, year-on-year	19.00%						6.00%
CER %, year-on-year							(7.00%)
Onglyza
Product sales
Product Sales	$ 99	101	105	110	115	141
Onglyza | World
Product sales
Product Sales	$ 99						$ 200
Actual %, year-on-year	(14.00%)						(22.00%)
CER %, year-on-year	(18.00%)						(25.00%)
Onglyza | Emerging Markets
Product sales
Product Sales	$ 51						$ 108
Actual %, year-on-year	(3.00%)						9.00%
CER %, year-on-year	(9.00%)						4.00%
Onglyza | US
Product sales
Product Sales	$ 26						$ 44
Actual %, year-on-year	(33.00%)						(58.00%)
Onglyza | Europe
Product sales
Product Sales	$ 15						$ 31
Actual %, year-on-year	12.00%						6.00%
CER %, year-on-year							(4.00%)
Onglyza | Established ROW
Product sales
Product Sales	$ 7						$ 17
Actual %, year-on-year	(31.00%)						(25.00%)
CER %, year-on-year	(39.00%)						(30.00%)
Bydureon
Product sales
Product Sales	$ 95	103	122	109	116	100
Bydureon | World
Product sales
Product Sales	$ 95						$ 198
Actual %, year-on-year	(18.00%)						(9.00%)
CER %, year-on-year	(20.00%)						(10.00%)
Bydureon | Emerging Markets
Product sales
Product Sales	$ 1						$ 2
Actual %, year-on-year	97.00%						(6.00%)
CER %, year-on-year	77.00%						(7.00%)
Bydureon | US
Product sales
Product Sales	$ 77						$ 162
Actual %, year-on-year	(24.00%)						(12.00%)
Bydureon | Europe
Product sales
Product Sales	$ 15						$ 29
Actual %, year-on-year	17.00%						20.00%
CER %, year-on-year	1.00%						7.00%
Bydureon | Established ROW
Product sales
Product Sales	$ 2						$ 5
Actual %, year-on-year	(19.00%)						(9.00%)
CER %, year-on-year	(34.00%)						(22.00%)
Byetta
Product sales
Product Sales	$ 16	16	19	15	15	20
Byetta | World
Product sales
Product Sales	$ 16						$ 32
Actual %, year-on-year	6.00%						(9.00%)
CER %, year-on-year							(12.00%)
Byetta | Emerging Markets
Product sales
Product Sales	$ 4						$ 8
Actual %, year-on-year							72.00%
CER %, year-on-year							79.00%
Byetta | US
Product sales
Product Sales	$ 7						$ 15
Actual %, year-on-year	(6.00%)						(20.00%)
Byetta | Europe
Product sales
Product Sales	$ 3						$ 5
Actual %, year-on-year	(19.00%)						(27.00%)
CER %, year-on-year	(35.00%)						(38.00%)
Byetta | Established ROW
Product sales
Product Sales	$ 2						$ 4
Actual %, year-on-year	(16.00%)						(17.00%)
CER %, year-on-year	(25.00%)						(26.00%)
Other diabetes
Product sales
Product Sales	$ 15	13	12	11	10	13
Other diabetes | World
Product sales
Product Sales	$ 15						$ 29
Actual %, year-on-year	49.00%						23.00%
CER %, year-on-year	40.00%						17.00%
Other diabetes | Emerging Markets
Product sales
Product Sales	$ 4						$ 8
Other diabetes | US
Product sales
Product Sales	$ 6						$ 11
Actual %, year-on-year	(4.00%)						(15.00%)
Other diabetes | Europe
Product sales
Product Sales	$ 5						$ 9
Actual %, year-on-year	71.00%						53.00%
CER %, year-on-year	47.00%						35.00%
Other diabetes | Established ROW
Product sales
Product Sales							$ 1
Actual %, year-on-year							25.00%
CER %, year-on-year							18.00%
Lokelma
Product sales
Product Sales	$ 39	33	28	21	17	11
Lokelma | World
Product sales
Product Sales	39						$ 72
Lokelma | Emerging Markets
Product sales
Product Sales	$ 1						2
Actual %, year-on-year	79.00%
CER %, year-on-year	78.00%
Lokelma | US
Product sales
Product Sales	$ 25						49
Lokelma | Europe
Product sales
Product Sales	3						5
Lokelma | Established ROW
Product sales
Product Sales	10						16
Roxadustat
Product sales
Product Sales	51	39
Roxadustat | World
Product sales
Product Sales	51						90
Roxadustat | Emerging Markets
Product sales
Product Sales	51						90
Crestor
Product sales
Product Sales	265	274	298	300	281	301
Crestor | World
Product sales
Product Sales	$ 265						$ 539
Actual %, year-on-year	(6.00%)						(7.00%)
CER %, year-on-year	(11.00%)						(11.00%)
Crestor | Emerging Markets
Product sales
Product Sales	$ 182						$ 372
Actual %, year-on-year	3.00%						1.00%
CER %, year-on-year	(3.00%)						(4.00%)
Crestor | US
Product sales
Product Sales	$ 19						$ 41
Actual %, year-on-year	10.00%						(10.00%)
Crestor | Europe
Product sales
Product Sales	$ 12						$ 32
Actual %, year-on-year	(61.00%)						(50.00%)
CER %, year-on-year	(67.00%)						(54.00%)
Crestor | Established ROW
Product sales
Product Sales	$ 52						$ 94
Actual %, year-on-year	(8.00%)						(10.00%)
CER %, year-on-year	(10.00%)						(12.00%)
Seloken/Toprol-XL
Product sales
Product Sales	$ 266	250	200	225	218	177
Seloken/Toprol-XL | World
Product sales
Product Sales	$ 266						$ 515
Actual %, year-on-year	22.00%						30.00%
CER %, year-on-year	14.00%						24.00%
Seloken/Toprol-XL | Emerging Markets
Product sales
Product Sales	$ 260						$ 503
Actual %, year-on-year	24.00%						34.00%
CER %, year-on-year	15.00%						27.00%
Seloken/Toprol-XL | US
Product sales
Product Sales							$ 1
Actual %, year-on-year	(83.00%)						(88.00%)
Seloken/Toprol-XL | Europe
Product sales
Product Sales	$ 3						$ 6
Actual %, year-on-year	(20.00%)						(23.00%)
CER %, year-on-year	(12.00%)						(20.00%)
Seloken/Toprol-XL | Established ROW
Product sales
Product Sales	$ 3						$ 5
Actual %, year-on-year	25.00%						3.00%
CER %, year-on-year	14.00%						(8.00%)
Atacand
Product sales
Product Sales	$ 23	34	63	54	59	66
Atacand | World
Product sales
Product Sales	$ 23						$ 57
Actual %, year-on-year	(62.00%)						(55.00%)
CER %, year-on-year	(61.00%)						(55.00%)
Atacand | Emerging Markets
Product sales
Product Sales	$ 15						$ 20
Actual %, year-on-year	(67.00%)						(79.00%)
CER %, year-on-year	(68.00%)						(79.00%)
Atacand | US
Product sales
Product Sales							$ 2
Actual %, year-on-year							(56.00%)
Atacand | Europe
Product sales
Product Sales	$ 8						$ 35
Actual %, year-on-year	31.00%
CER %, year-on-year	32.00%
CVRM, Others
Product sales
Product Sales	$ 47	51	46	39	48	59
CVRM, Others | World
Product sales
Product Sales	$ 47						$ 98
Actual %, year-on-year	(1.00%)						(7.00%)
CER %, year-on-year	(9.00%)						(13.00%)
CVRM, Others | Emerging Markets
Product sales
Product Sales	$ 35						$ 71
Actual %, year-on-year	20.00%						9.00%
CER %, year-on-year	10.00%						2.00%
CVRM, Others | Europe
Product sales
Product Sales	$ 11						$ 25
Actual %, year-on-year	(30.00%)						(19.00%)
CER %, year-on-year	(33.00%)						(22.00%)
CVRM, Others | Established ROW
Product sales
Product Sales	$ 1						$ 2
Actual %, year-on-year	(57.00%)						(20.00%)
CER %, year-on-year	(60.00%)						(23.00%)
BioPharmaceuticals: total Respiratory & Immunology
Product sales
Product Sales	$ 1,420	1,541	1,528	1,161	1,117	1,551
BioPharmaceuticals: total Respiratory & Immunology | World
Product sales
Product Sales	$ 1,420						$ 2,961
Actual %, year-on-year	27.00%						11.00%
CER %, year-on-year	21.00%						6.00%
BioPharmaceuticals: total Respiratory & Immunology | Emerging Markets
Product sales
Product Sales	$ 343						$ 885
Actual %, year-on-year	56.00%						17.00%
CER %, year-on-year	45.00%						10.00%
BioPharmaceuticals: total Respiratory & Immunology | US
Product sales
Product Sales	$ 597						$ 1,148
Actual %, year-on-year	27.00%						17.00%
BioPharmaceuticals: total Respiratory & Immunology | Europe
Product sales
Product Sales	$ 318						$ 616
Actual %, year-on-year	19.00%						5.00%
CER %, year-on-year	7.00%						(5.00%)
BioPharmaceuticals: total Respiratory & Immunology | Established ROW
Product sales
Product Sales	$ 162						$ 312
Actual %, year-on-year	3.00%						(8.00%)
CER %, year-on-year	(5.00%)						(14.00%)
Symbicort
Product sales
Product Sales	$ 680	691	680	599	653	790
Symbicort | World
Product sales
Product Sales	$ 680						$ 1,371
Actual %, year-on-year	4.00%						(5.00%)
CER %, year-on-year	(1.00%)						(9.00%)
Symbicort | Emerging Markets
Product sales
Product Sales	$ 141						$ 306
Actual %, year-on-year	5.00%						5.00%
CER %, year-on-year							2.00%
Symbicort | US
Product sales
Product Sales	$ 264						$ 530
Actual %, year-on-year	6.00%						(5.00%)
Symbicort | Europe
Product sales
Product Sales	$ 176						$ 344
Actual %, year-on-year	9.00%						(3.00%)
CER %, year-on-year	(2.00%)						(12.00%)
Symbicort | Established ROW
Product sales
Product Sales	$ 99						$ 191
Actual %, year-on-year	(9.00%)						(20.00%)
CER %, year-on-year	(17.00%)						(26.00%)
Pulmicort
Product sales
Product Sales	$ 167	330	368	151	97	380
Pulmicort | World
Product sales
Product Sales	$ 167						$ 497
Actual %, year-on-year	72.00%						4.00%
CER %, year-on-year	59.00%						(2.00%)
Pulmicort | Emerging Markets
Product sales
Product Sales	$ 119						$ 405
Actual %, year-on-year							9.00%
CER %, year-on-year	88.00%						2.00%
Pulmicort | US
Product sales
Product Sales	$ 18						$ 35
Actual %, year-on-year	40.00%						(2.00%)
Pulmicort | Europe
Product sales
Product Sales	$ 18						$ 34
Actual %, year-on-year	23.00%						(15.00%)
CER %, year-on-year	7.00%						(25.00%)
Pulmicort | Established ROW
Product sales
Product Sales	$ 12						$ 23
Actual %, year-on-year	5.00%						(24.00%)
CER %, year-on-year	(1.00%)						(30.00%)
Fasenra
Product sales
Product Sales	$ 320	260	283	240	227	199
Fasenra | World
Product sales
Product Sales	$ 320						$ 580
Actual %, year-on-year	41.00%						36.00%
CER %, year-on-year	36.00%						32.00%
Fasenra | Emerging Markets
Product sales
Product Sales	$ 5						$ 8
Actual %, year-on-year							25.00%
CER %, year-on-year							27.00%
Fasenra | US
Product sales
Product Sales	$ 201						$ 357
Actual %, year-on-year	32.00%						31.00%
Fasenra | Europe
Product sales
Product Sales	$ 73						$ 136
Actual %, year-on-year	72.00%						54.00%
CER %, year-on-year	55.00%						39.00%
Fasenra | Established ROW
Product sales
Product Sales	$ 41						$ 79
Actual %, year-on-year	28.00%						34.00%
CER %, year-on-year	21.00%						27.00%
Daliresp/Daxas
Product sales
Product Sales	$ 54	60	54	57	53	53
Daliresp/Daxas | World
Product sales
Product Sales	$ 54						$ 114
Actual %, year-on-year	3.00%						8.00%
CER %, year-on-year	3.00%						7.00%
Daliresp/Daxas | Emerging Markets
Product sales
Product Sales	$ 1						$ 2
Actual %, year-on-year	29.00%						20.00%
CER %, year-on-year	23.00%						18.00%
Daliresp/Daxas | US
Product sales
Product Sales	$ 49						$ 103
Actual %, year-on-year	10.00%						15.00%
Daliresp/Daxas | Europe
Product sales
Product Sales	$ 4						$ 8
Actual %, year-on-year	(37.00%)						(36.00%)
CER %, year-on-year	(36.00%)						(42.00%)
Daliresp/Daxas | Established ROW
Product sales
Product Sales							$ 1
Actual %, year-on-year	(85.00%)						(56.00%)
CER %, year-on-year	(80.00%)						(60.00%)
Bevespi
Product sales
Product Sales	$ 13	13	12	14	10	12
Bevespi | World
Product sales
Product Sales	$ 13						$ 26
Actual %, year-on-year	34.00%						20.00%
CER %, year-on-year	33.00%						18.00%
Bevespi | Emerging Markets
Product sales
Product Sales	$ 1						$ 2
Bevespi | US
Product sales
Product Sales	$ 10						$ 20
Actual %, year-on-year	6.00%						(5.00%)
Bevespi | Europe
Product sales
Product Sales	$ 2						$ 4
Breztri
Product sales
Product Sales	56	27	6	10	7	4
Breztri | World
Product sales
Product Sales	56						82
Breztri | Emerging Markets
Product sales
Product Sales	17						27
Breztri | US
Product sales
Product Sales	31						43
Breztri | Europe
Product sales
Product Sales	1						1
Breztri | Established ROW
Product sales
Product Sales	7						11
Respiratory, Others
Product sales
Product Sales	130	160	125	90	70	113
Respiratory, Others | World
Product sales
Product Sales	$ 130						$ 291
Actual %, year-on-year	85.00%						58.00%
CER %, year-on-year	70.00%						47.00%
Respiratory, Others | Emerging Markets
Product sales
Product Sales	$ 59						$ 135
Actual %, year-on-year							69.00%
CER %, year-on-year							55.00%
Respiratory, Others | US
Product sales
Product Sales	24						$ 60
Respiratory, Others | Europe
Product sales
Product Sales	$ 44						$ 89
Actual %, year-on-year	5.00%
CER %, year-on-year	(6.00%)						(9.00%)
Respiratory, Others | Established ROW
Product sales
Product Sales	$ 3						$ 7
Actual %, year-on-year	37.00%						(16.00%)
CER %, year-on-year	9.00%						(25.00%)
Total Other medicines
Product sales
Product Sales	$ 454	548	733	734	563	557
Total Other medicines | World
Product sales
Product Sales	$ 454						$ 1,003
Actual %, year-on-year	(19.00%)						(10.00%)
CER %, year-on-year	(23.00%)						(14.00%)
Total Other medicines | Emerging Markets
Product sales
Product Sales	$ 239						$ 536
Actual %, year-on-year	1.00%						10.00%
CER %, year-on-year	(4.00%)						5.00%
Total Other medicines | US
Product sales
Product Sales	$ 47						$ 100
Actual %, year-on-year	(27.00%)						(34.00%)
Total Other medicines | Europe
Product sales
Product Sales	$ 68						$ 145
Actual %, year-on-year	(41.00%)						(40.00%)
CER %, year-on-year	(45.00%)						(42.00%)
Total Other medicines | Established ROW
Product sales
Product Sales	$ 100						$ 222
Actual %, year-on-year	(31.00%)						(8.00%)
CER %, year-on-year	(32.00%)						(12.00%)
Nexium
Product sales
Product Sales	$ 336	403	377	401	377	338
Nexium | World
Product sales
Product Sales	$ 336						$ 739
Actual %, year-on-year	(11.00%)						4.00%
CER %, year-on-year	(14.00%)
Nexium | Emerging Markets
Product sales
Product Sales	$ 185						$ 419
Actual %, year-on-year	1.00%						13.00%
CER %, year-on-year	(4.00%)						9.00%
Nexium | US
Product sales
Product Sales	$ 35						$ 67
Actual %, year-on-year	(14.00%)						(17.00%)
Nexium | Europe
Product sales
Product Sales	$ 18						$ 36
Actual %, year-on-year	23.00%						(2.00%)
CER %, year-on-year	11.00%						(11.00%)
Nexium | Established ROW
Product sales
Product Sales	$ 98						$ 217
Actual %, year-on-year	(29.00%)						(4.00%)
CER %, year-on-year	(31.00%)						(8.00%)
Synagis
Product sales
Product Sales	$ 24	24	78	118	90	85
Synagis | World
Product sales
Product Sales	$ 24						$ 49
Actual %, year-on-year	(73.00%)						(72.00%)
CER %, year-on-year	(73.00%)						(72.00%)
Synagis | US
Product sales
Product Sales	$ 3						$ 5
Actual %, year-on-year	(78.00%)						(77.00%)
Synagis | Europe
Product sales
Product Sales	$ 21						$ 44
Actual %, year-on-year	(72.00%)						(71.00%)
CER %, year-on-year	(72.00%)						(71.00%)
Losec/Prilosec
Product sales
Product Sales	$ 46	54	39	45	45	54
Losec/Prilosec | World
Product sales
Product Sales	$ 46						$ 100
Actual %, year-on-year	2.00%						1.00%
CER %, year-on-year	(6.00%)						(5.00%)
Losec/Prilosec | Emerging Markets
Product sales
Product Sales	$ 38						$ 84
Actual %, year-on-year	2.00%						4.00%
CER %, year-on-year	(7.00%)						(4.00%)
Losec/Prilosec | US
Product sales
Actual %, year-on-year	(68.00%)						(90.00%)
Losec/Prilosec | Europe
Product sales
Product Sales	$ 8						$ 15
Actual %, year-on-year	49.00%						56.00%
CER %, year-on-year	42.00%						55.00%
Losec/Prilosec | Established ROW
Product sales
Product Sales							$ 1
Actual %, year-on-year	(82.00%)						(90.00%)
CER %, year-on-year	(87.00%)						(92.00%)
FluMist
Product sales
Product Sales	$ 1	2	179	116
FluMist | World
Product sales
Product Sales	1						$ 3
FluMist | Emerging Markets
Product sales
Product Sales							1
FluMist | Europe
Product sales
Product Sales							2
FluMist | Established ROW
Product sales
Product Sales	1
Seroquel XR/IR
Product sales
Product Sales	21	29	19	35	27	36
Seroquel XR/IR | World
Product sales
Product Sales	$ 21						$ 50
Actual %, year-on-year	(23.00%)						(21.00%)
CER %, year-on-year	(19.00%)						(21.00%)
Seroquel XR/IR | Emerging Markets
Product sales
Product Sales	$ 11						$ 25
Actual %, year-on-year	(26.00%)						(9.00%)
CER %, year-on-year	(27.00%)						(8.00%)
Seroquel XR/IR | US
Product sales
Product Sales	$ 3						$ 10
Actual %, year-on-year							(29.00%)
Seroquel XR/IR | Europe
Product sales
Product Sales	$ 7						$ 14
Actual %, year-on-year	(5.00%)						(4.00%)
CER %, year-on-year	2.00%						(3.00%)
Seroquel XR/IR | Established ROW
Product sales
Product Sales							$ 1
Actual %, year-on-year							(88.00%)
CER %, year-on-year	(87.00%)						(88.00%)
Other, Others
Product sales
Product Sales	$ 26	36	$ 41	$ 19	$ 24	$ 44
Other, Others | World
Product sales
Product Sales	$ 26						$ 62
Actual %, year-on-year	10.00%						(9.00%)
CER %, year-on-year	1.00%						(13.00%)
Other, Others | Emerging Markets
Product sales
Product Sales	$ 5						$ 7
Other, Others | US
Product sales
Product Sales	$ 6						$ 18
Actual %, year-on-year	(30.00%)						(46.00%)
Other, Others | Europe
Product sales
Product Sales	$ 14						$ 34
Actual %, year-on-year	14.00%						20.00%
CER %, year-on-year	(3.00%)						11.00%
Other, Others | Established ROW
Product sales
Product Sales	$ 1						$ 3
Actual %, year-on-year	39.00%						(16.00%)
CER %, year-on-year	55.00%						(14.00%)
COVID 19
Product sales
Product Sales	$ 862	275
COVID 19 | World
Product sales
Product Sales	862						$ 1,136
COVID 19 | Emerging Markets
Product sales
Product Sales	413						455
COVID 19 | Europe
Product sales
Product Sales	347						572
COVID 19 | Established ROW
Product sales
Product Sales	102						109
Pandemic COVID-19 Vaccine
Product sales
Product Sales	862	$ 275
Pandemic COVID-19 Vaccine | World
Product sales
Product Sales	862						1,136
Pandemic COVID-19 Vaccine | Emerging Markets
Product sales
Product Sales	413						455
Pandemic COVID-19 Vaccine | Europe
Product sales
Product Sales	347						572
Pandemic COVID-19 Vaccine | Established ROW
Product sales
Product Sales	$ 102						$ 109

Q2 2021 Product Sales quarter_3

Q2 2021 Product Sales quarterly sequential analysis (Unreviewed) (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Product sales
Product Sales	$ 8,045	$ 7,257	$ 7,011	$ 6,520	$ 6,048	$ 6,311
Actual %, quarter-on-quarter	11.00%	4.00%	8.00%	8.00%	(4.00%)	1.00%
CER %, quarter-on-quarter	12.00%	1.00%	6.00%	6.00%	(2.00%)	1.00%
Total Oncology
Product sales
Product Sales	$ 3,286	$ 2,981	$ 2,908	$ 2,831	$ 2,609	$ 2,502
Actual %, quarter-on-quarter	10.00%	3.00%	3.00%	8.00%	4.00%	10.00%
CER %, quarter-on-quarter	11.00%	1.00%	2.00%	6.00%	6.00%	10.00%
Tagrisso
Product sales
Product Sales	$ 1,306	$ 1,149	$ 1,157	$ 1,155	$ 1,034	$ 982
Actual %, quarter-on-quarter	14.00%	(1.00%)		12.00%	5.00%	11.00%
CER %, quarter-on-quarter	14.00%	(3.00%)	(1.00%)	9.00%	7.00%	11.00%
Imfinzi
Product sales
Product Sales	$ 604	$ 556	$ 555	$ 533	$ 492	$ 462
Actual %, quarter-on-quarter	9.00%		4.00%	8.00%	6.00%	9.00%
CER %, quarter-on-quarter	10.00%	(1.00%)	3.00%	6.00%	8.00%	9.00%
Lynparza
Product sales
Product Sales	$ 588	$ 543	$ 496	$ 464	$ 419	$ 397
Actual %, quarter-on-quarter	8.00%	9.00%	7.00%	11.00%	5.00%	13.00%
CER %, quarter-on-quarter	9.00%	8.00%	6.00%	8.00%	7.00%	13.00%
Calquence
Product sales
Product Sales	$ 280	$ 209	$ 182	$ 145	$ 107	$ 88
Actual %, quarter-on-quarter	34.00%	15.00%	25.00%	36.00%	21.00%	58.00%
CER %, quarter-on-quarter	34.00%	15.00%	25.00%	35.00%	23.00%	58.00%
Koselugo
Product sales
Product Sales	$ 26	$ 21	$ 17	$ 13	$ 7
Actual %, quarter-on-quarter	23.00%	23.00%	34.00%	75.00%
CER %, quarter-on-quarter	22.00%	23.00%	34.00%	75.00%
Enhertu
Product sales
Product Sales	$ 3	$ 1
Zoladex
Product sales
Product Sales	$ 244	$ 221	$ 216	$ 230	$ 217	$ 225
Actual %, quarter-on-quarter	10.00%	2.00%	(6.00%)	6.00%	(3.00%)	15.00%
CER %, quarter-on-quarter	11.00%		(7.00%)	3.00%		15.00%
Faslodex
Product sales
Product Sales	$ 105	$ 122	$ 130	$ 138	$ 146	$ 166
Actual %, quarter-on-quarter	(14.00%)	(6.00%)	(6.00%)	(5.00%)	(12.00%)
CER %, quarter-on-quarter	(12.00%)	(8.00%)	(7.00%)	(8.00%)	(9.00%)
Iressa
Product sales
Product Sales	$ 47	$ 61	$ 67	$ 54	$ 70	$ 77
Actual %, quarter-on-quarter	(23.00%)	(9.00%)	24.00%	(23.00%)	(9.00%)	(3.00%)
CER %, quarter-on-quarter	(22.00%)	(11.00%)	19.00%	(24.00%)	(7.00%)	(4.00%)
Arimidex
Product sales
Product Sales	$ 29	$ 44	$ 36	$ 42	$ 58	$ 50
Actual %, quarter-on-quarter	(34.00%)	22.00%	(14.00%)	(28.00%)	17.00%	(1.00%)
CER %, quarter-on-quarter	(33.00%)	18.00%	(16.00%)	(27.00%)	16.00%	(2.00%)
Casodex
Product sales
Product Sales	$ 41	$ 42	$ 39	$ 44	$ 47	$ 42
Actual %, quarter-on-quarter	(2.00%)	7.00%	(11.00%)	(7.00%)	14.00%	(2.00%)
CER %, quarter-on-quarter	(1.00%)	5.00%	(14.00%)	(8.00%)	12.00%	(3.00%)
Oncology, Others
Product sales
Product Sales	$ 13	$ 12	$ 13	$ 13	$ 12	$ 13
Actual %, quarter-on-quarter	13.00%	(4.00%)	2.00%	4.00%	(11.00%)	(52.00%)
CER %, quarter-on-quarter	11.00%	(6.00%)	2.00%	3.00%	(1.00%)	(52.00%)
BioPharmaceuticals: total CVRM
Product sales
Product Sales	$ 2,023	$ 1,912	$ 1,842	$ 1,794	$ 1,759	$ 1,701
Actual %, quarter-on-quarter	6.00%	4.00%	3.00%	2.00%	3.00%	(5.00%)
CER %, quarter-on-quarter	6.00%	1.00%	1.00%		6.00%	(5.00%)
Farxiga
Product sales
Product Sales	$ 732	$ 624	$ 586	$ 525	$ 443	$ 405
Actual %, quarter-on-quarter	17.00%	6.00%	11.00%	19.00%	9.00%	(3.00%)
CER %, quarter-on-quarter	18.00%	4.00%	10.00%	16.00%	13.00%	(3.00%)
Brilinta
Product sales
Product Sales	$ 375	$ 374	$ 363	$ 385	$ 437	$ 408
Actual %, quarter-on-quarter		3.00%	(6.00%)	(12.00%)	7.00%	(5.00%)
CER %, quarter-on-quarter	1.00%	1.00%	(6.00%)	(13.00%)	9.00%	(5.00%)
Bydureon
Product sales
Product Sales	$ 95	$ 103	$ 122	$ 109	$ 116	$ 100
Actual %, quarter-on-quarter	(8.00%)	(16.00%)	12.00%	(5.00%)	16.00%	(28.00%)
CER %, quarter-on-quarter	(7.00%)	(17.00%)	11.00%	(7.00%)	17.00%	(28.00%)
Onglyza
Product sales
Product Sales	$ 99	$ 101	$ 105	$ 110	$ 115	$ 141
Actual %, quarter-on-quarter	(2.00%)	(3.00%)	(4.00%)	(6.00%)	(19.00%)	8.00%
CER %, quarter-on-quarter	(2.00%)	(6.00%)	(5.00%)	(6.00%)	(17.00%)	8.00%
Byetta
Product sales
Product Sales	$ 16	$ 16	$ 19	$ 15	$ 15	$ 20
Actual %, quarter-on-quarter	(4.00%)	(14.00%)	26.00%	1.00%	(28.00%)	(24.00%)
CER %, quarter-on-quarter	(7.00%)	(15.00%)	24.00%	4.00%	(28.00%)	(24.00%)
Other diabetes
Product sales
Product Sales	$ 15	$ 13	$ 12	$ 11	$ 10	$ 13
Actual %, quarter-on-quarter	14.00%	7.00%	11.00%	9.00%	(21.00%)	(22.00%)
CER %, quarter-on-quarter	14.00%	1.00%	15.00%	6.00%	(19.00%)	(22.00%)
Lokelma
Product sales
Product Sales	$ 39	$ 33	$ 28	$ 21	$ 17	$ 11
Actual %, quarter-on-quarter	21.00%	16.00%	37.00%	22.00%	56.00%	42.00%
CER %, quarter-on-quarter	21.00%	18.00%	28.00%	26.00%	58.00%	42.00%
Roxadustat
Product sales
Product Sales	$ 51	$ 39
Actual %, quarter-on-quarter	32.00%
CER %, quarter-on-quarter	32.00%
Crestor
Product sales
Product Sales	$ 265	$ 274	$ 298	$ 300	$ 281	$ 301
Actual %, quarter-on-quarter	(3.00%)	(8.00%)	(1.00%)	7.00%	(7.00%)	2.00%
CER %, quarter-on-quarter	(3.00%)	(9.00%)	(4.00%)	5.00%	(4.00%)	1.00%
Seloken/Toprol-XL
Product sales
Product Sales	$ 266	$ 250	$ 200	$ 225	$ 218	$ 177
Actual %, quarter-on-quarter	6.00%	25.00%	(11.00%)	4.00%	23.00%	(6.00%)
CER %, quarter-on-quarter	7.00%	21.00%	(13.00%)	3.00%	27.00%	(6.00%)
Atacand
Product sales
Product Sales	$ 23	$ 34	$ 63	$ 54	$ 59	$ 66
Actual %, quarter-on-quarter	(35.00%)	(45.00%)	16.00%	(9.00%)	(11.00%)	11.00%
CER %, quarter-on-quarter	(32.00%)	(45.00%)	14.00%	(12.00%)	(5.00%)	12.00%
CVRM, Others
Product sales
Product Sales	$ 47	$ 51	$ 46	$ 39	$ 48	$ 59
Actual %, quarter-on-quarter	(7.00%)	12.00%	18.00%	(19.00%)	(18.00%)	(21.00%)
CER %, quarter-on-quarter	(10.00%)	10.00%	17.00%	(22.00%)	(16.00%)	(22.00%)
BioPharmaceuticals: total Respiratory & Immunology
Product sales
Product Sales	$ 1,420	$ 1,541	$ 1,528	$ 1,161	$ 1,117	$ 1,551
Actual %, quarter-on-quarter	(8.00%)	1.00%	32.00%	4.00%	(28.00%)	1.00%
CER %, quarter-on-quarter	(7.00%)	(1.00%)	29.00%	1.00%	(26.00%)	1.00%
Symbicort
Product sales
Product Sales	$ 680	$ 691	$ 680	$ 599	$ 653	$ 790
Actual %, quarter-on-quarter	(2.00%)	2.00%	13.00%	(8.00%)	(17.00%)	11.00%
CER %, quarter-on-quarter	(1.00%)		13.00%	(11.00%)	(15.00%)	11.00%
Fasenra
Product sales
Product Sales	$ 320	$ 260	$ 283	$ 240	$ 227	$ 199
Actual %, quarter-on-quarter	23.00%	(8.00%)	18.00%	5.00%	14.00%	(3.00%)
CER %, quarter-on-quarter	23.00%	(9.00%)	17.00%	4.00%	15.00%	(3.00%)
Pulmicort
Product sales
Product Sales	$ 167	$ 330	$ 368	$ 151	$ 97	$ 380
Actual %, quarter-on-quarter	(50.00%)	(10.00%)		56.00%	(74.00%)	(8.00%)
CER %, quarter-on-quarter	(49.00%)	(13.00%)		49.00%	(73.00%)	(9.00%)
Daliresp/Daxas
Product sales
Product Sales	$ 54	$ 60	$ 54	$ 57	$ 53	$ 53
Actual %, quarter-on-quarter	(10.00%)	11.00%	(4.00%)	8.00%	(1.00%)	(8.00%)
CER %, quarter-on-quarter	(9.00%)	10.00%	(6.00%)	11.00%	(3.00%)	(8.00%)
Bevespi
Product sales
Product Sales	$ 13	$ 13	$ 12	$ 14	$ 10	$ 12
Actual %, quarter-on-quarter	1.00%	7.00%	(16.00%)	47.00%	(19.00%)	9.00%
CER %, quarter-on-quarter	3.00%	8.00%	(17.00%)	46.00%	(21.00%)	9.00%
Breztri
Product sales
Product Sales	$ 56	$ 27	$ 6	$ 10	$ 7	$ 4
Actual %, quarter-on-quarter			(39.00%)	45.00%	58.00%
CER %, quarter-on-quarter			(38.00%)	48.00%	64.00%
Respiratory, Others
Product sales
Product Sales	$ 130	$ 160	$ 125	$ 90	$ 70	$ 113
Actual %, quarter-on-quarter	(19.00%)	28.00%	39.00%	27.00%	(38.00%)	(16.00%)
CER %, quarter-on-quarter	(19.00%)	25.00%	35.00%	22.00%	(36.00%)	(17.00%)
Total Other medicines
Product sales
Product Sales	$ 454	$ 548	$ 733	$ 734	$ 563	$ 557
Actual %, quarter-on-quarter	(17.00%)	(25.00%)		30.00%	1.00%	(15.00%)
CER %, quarter-on-quarter	(16.00%)	(26.00%)	(2.00%)	27.00%	4.00%	(15.00%)
Nexium
Product sales
Product Sales	$ 336	$ 403	$ 377	$ 401	$ 377	$ 338
Actual %, quarter-on-quarter	(17.00%)	7.00%	(6.00%)	6.00%	12.00%	(4.00%)
CER %, quarter-on-quarter	(15.00%)	5.00%	(7.00%)	4.00%	14.00%	(4.00%)
Synagis
Product sales
Product Sales	$ 24	$ 24	$ 78	$ 118	$ 90	$ 85
Actual %, quarter-on-quarter	1.00%	(69.00%)	(34.00%)	31.00%	6.00%	35.00%
CER %, quarter-on-quarter	1.00%	(69.00%)	(33.00%)	29.00%	7.00%	35.00%
Seroquel XR/IR
Product sales
Product Sales	$ 21	$ 29	$ 19	$ 35	$ 27	$ 36
Actual %, quarter-on-quarter	(29.00%)	51.00%	(45.00%)	32.00%	(26.00%)	(12.00%)
CER %, quarter-on-quarter	(22.00%)	38.00%	(42.00%)	29.00%	(23.00%)	(12.00%)
Losec/Prilosec
Product sales
Product Sales	$ 46	$ 54	$ 39	$ 45	$ 45	$ 54
Actual %, quarter-on-quarter	(14.00%)	39.00%	(15.00%)		(15.00%)	18.00%
CER %, quarter-on-quarter	(15.00%)	36.00%	(18.00%)		(15.00%)	17.00%
FluMist
Product sales
Product Sales	$ 1	$ 2	$ 179	116
Actual %, quarter-on-quarter	(51.00%)	(99.00%)	55.00%
CER %, quarter-on-quarter	(71.00%)	(99.00%)	50.00%
Other, Others
Product sales
Product Sales	$ 26	$ 36	$ 41	$ 19	$ 24	$ 44
Actual %, quarter-on-quarter	(28.00%)	(6.00%)		(17.00%)	(46.00%)	(71.00%)
CER %, quarter-on-quarter	(32.00%)	(4.00%)		(19.00%)	(42.00%)	(70.00%)
COVID 19
Product sales
Product Sales	$ 862	$ 275
Pandemic COVID-19 Vaccine
Product sales
Product Sales	$ 862	$ 275

FY 2020 Product Sales quarter_3

FY 2020 Product Sales quarterly sequential analysis (Unreviewed) (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Product sales
Product Sales	$ 8,045	$ 7,257	$ 7,011	$ 6,520	$ 6,048	$ 6,311
Actual %, quarter-on-quarter	11.00%	4.00%	8.00%	8.00%	(4.00%)	1.00%
CER %, quarter-on-quarter	12.00%	1.00%	6.00%	6.00%	(2.00%)	1.00%
Total Oncology
Product sales
Product Sales	$ 3,286	$ 2,981	$ 2,908	$ 2,831	$ 2,609	$ 2,502
Actual %, quarter-on-quarter	10.00%	3.00%	3.00%	8.00%	4.00%	10.00%
CER %, quarter-on-quarter	11.00%	1.00%	2.00%	6.00%	6.00%	10.00%
Tagrisso
Product sales
Product Sales	$ 1,306	$ 1,149	$ 1,157	$ 1,155	$ 1,034	$ 982
Actual %, quarter-on-quarter	14.00%	(1.00%)		12.00%	5.00%	11.00%
CER %, quarter-on-quarter	14.00%	(3.00%)	(1.00%)	9.00%	7.00%	11.00%
Imfinzi
Product sales
Product Sales	$ 604	$ 556	$ 555	$ 533	$ 492	$ 462
Actual %, quarter-on-quarter	9.00%		4.00%	8.00%	6.00%	9.00%
CER %, quarter-on-quarter	10.00%	(1.00%)	3.00%	6.00%	8.00%	9.00%
Lynparza
Product sales
Product Sales	$ 588	$ 543	$ 496	$ 464	$ 419	$ 397
Actual %, quarter-on-quarter	8.00%	9.00%	7.00%	11.00%	5.00%	13.00%
CER %, quarter-on-quarter	9.00%	8.00%	6.00%	8.00%	7.00%	13.00%
Calquence
Product sales
Product Sales	$ 280	$ 209	$ 182	$ 145	$ 107	$ 88
Actual %, quarter-on-quarter	34.00%	15.00%	25.00%	36.00%	21.00%	58.00%
CER %, quarter-on-quarter	34.00%	15.00%	25.00%	35.00%	23.00%	58.00%
Koselugo
Product sales
Product Sales	$ 26	$ 21	$ 17	$ 13	$ 7
Actual %, quarter-on-quarter	23.00%	23.00%	34.00%	75.00%
CER %, quarter-on-quarter	22.00%	23.00%	34.00%	75.00%
Zoladex
Product sales
Product Sales	$ 244	$ 221	$ 216	$ 230	$ 217	$ 225
Actual %, quarter-on-quarter	10.00%	2.00%	(6.00%)	6.00%	(3.00%)	15.00%
CER %, quarter-on-quarter	11.00%		(7.00%)	3.00%		15.00%
Faslodex
Product sales
Product Sales	$ 105	$ 122	$ 130	$ 138	$ 146	$ 166
Actual %, quarter-on-quarter	(14.00%)	(6.00%)	(6.00%)	(5.00%)	(12.00%)
CER %, quarter-on-quarter	(12.00%)	(8.00%)	(7.00%)	(8.00%)	(9.00%)
Iressa
Product sales
Product Sales	$ 47	$ 61	$ 67	$ 54	$ 70	$ 77
Actual %, quarter-on-quarter	(23.00%)	(9.00%)	24.00%	(23.00%)	(9.00%)	(3.00%)
CER %, quarter-on-quarter	(22.00%)	(11.00%)	19.00%	(24.00%)	(7.00%)	(4.00%)
Arimidex
Product sales
Product Sales	$ 29	$ 44	$ 36	$ 42	$ 58	$ 50
Actual %, quarter-on-quarter	(34.00%)	22.00%	(14.00%)	(28.00%)	17.00%	(1.00%)
CER %, quarter-on-quarter	(33.00%)	18.00%	(16.00%)	(27.00%)	16.00%	(2.00%)
Casodex
Product sales
Product Sales	$ 41	$ 42	$ 39	$ 44	$ 47	$ 42
Actual %, quarter-on-quarter	(2.00%)	7.00%	(11.00%)	(7.00%)	14.00%	(2.00%)
CER %, quarter-on-quarter	(1.00%)	5.00%	(14.00%)	(8.00%)	12.00%	(3.00%)
Oncology, Others
Product sales
Product Sales	$ 13	$ 12	$ 13	$ 13	$ 12	$ 13
Actual %, quarter-on-quarter	13.00%	(4.00%)	2.00%	4.00%	(11.00%)	(52.00%)
CER %, quarter-on-quarter	11.00%	(6.00%)	2.00%	3.00%	(1.00%)	(52.00%)
BioPharmaceuticals: total CVRM
Product sales
Product Sales	$ 2,023	$ 1,912	$ 1,842	$ 1,794	$ 1,759	$ 1,701
Actual %, quarter-on-quarter	6.00%	4.00%	3.00%	2.00%	3.00%	(5.00%)
CER %, quarter-on-quarter	6.00%	1.00%	1.00%		6.00%	(5.00%)
Farxiga
Product sales
Product Sales	$ 732	$ 624	$ 586	$ 525	$ 443	$ 405
Actual %, quarter-on-quarter	17.00%	6.00%	11.00%	19.00%	9.00%	(3.00%)
CER %, quarter-on-quarter	18.00%	4.00%	10.00%	16.00%	13.00%	(3.00%)
Brilinta
Product sales
Product Sales	$ 375	$ 374	$ 363	$ 385	$ 437	$ 408
Actual %, quarter-on-quarter		3.00%	(6.00%)	(12.00%)	7.00%	(5.00%)
CER %, quarter-on-quarter	1.00%	1.00%	(6.00%)	(13.00%)	9.00%	(5.00%)
Onglyza
Product sales
Product Sales	$ 99	$ 101	$ 105	$ 110	$ 115	$ 141
Actual %, quarter-on-quarter	(2.00%)	(3.00%)	(4.00%)	(6.00%)	(19.00%)	8.00%
CER %, quarter-on-quarter	(2.00%)	(6.00%)	(5.00%)	(6.00%)	(17.00%)	8.00%
Bydureon
Product sales
Product Sales	$ 95	$ 103	$ 122	$ 109	$ 116	$ 100
Actual %, quarter-on-quarter	(8.00%)	(16.00%)	12.00%	(5.00%)	16.00%	(28.00%)
CER %, quarter-on-quarter	(7.00%)	(17.00%)	11.00%	(7.00%)	17.00%	(28.00%)
Byetta
Product sales
Product Sales	$ 16	$ 16	$ 19	$ 15	$ 15	$ 20
Actual %, quarter-on-quarter	(4.00%)	(14.00%)	26.00%	1.00%	(28.00%)	(24.00%)
CER %, quarter-on-quarter	(7.00%)	(15.00%)	24.00%	4.00%	(28.00%)	(24.00%)
Other diabetes
Product sales
Product Sales	$ 15	$ 13	$ 12	$ 11	$ 10	$ 13
Actual %, quarter-on-quarter	14.00%	7.00%	11.00%	9.00%	(21.00%)	(22.00%)
CER %, quarter-on-quarter	14.00%	1.00%	15.00%	6.00%	(19.00%)	(22.00%)
Lokelma
Product sales
Product Sales	$ 39	$ 33	$ 28	$ 21	$ 17	$ 11
Actual %, quarter-on-quarter	21.00%	16.00%	37.00%	22.00%	56.00%	42.00%
CER %, quarter-on-quarter	21.00%	18.00%	28.00%	26.00%	58.00%	42.00%
Roxadustat
Product sales
Product Sales	$ 51	$ 39
Actual %, quarter-on-quarter	32.00%
CER %, quarter-on-quarter	32.00%
Crestor
Product sales
Product Sales	$ 265	$ 274	$ 298	$ 300	$ 281	$ 301
Actual %, quarter-on-quarter	(3.00%)	(8.00%)	(1.00%)	7.00%	(7.00%)	2.00%
CER %, quarter-on-quarter	(3.00%)	(9.00%)	(4.00%)	5.00%	(4.00%)	1.00%
Seloken/Toprol-XL
Product sales
Product Sales	$ 266	$ 250	$ 200	$ 225	$ 218	$ 177
Actual %, quarter-on-quarter	6.00%	25.00%	(11.00%)	4.00%	23.00%	(6.00%)
CER %, quarter-on-quarter	7.00%	21.00%	(13.00%)	3.00%	27.00%	(6.00%)
Atacand
Product sales
Product Sales	$ 23	$ 34	$ 63	$ 54	$ 59	$ 66
Actual %, quarter-on-quarter	(35.00%)	(45.00%)	16.00%	(9.00%)	(11.00%)	11.00%
CER %, quarter-on-quarter	(32.00%)	(45.00%)	14.00%	(12.00%)	(5.00%)	12.00%
CVRM, Others
Product sales
Product Sales	$ 47	$ 51	$ 46	$ 39	$ 48	$ 59
Actual %, quarter-on-quarter	(7.00%)	12.00%	18.00%	(19.00%)	(18.00%)	(21.00%)
CER %, quarter-on-quarter	(10.00%)	10.00%	17.00%	(22.00%)	(16.00%)	(22.00%)
BioPharmaceuticals: total Respiratory & Immunology
Product sales
Product Sales	$ 1,420	$ 1,541	$ 1,528	$ 1,161	$ 1,117	$ 1,551
Actual %, quarter-on-quarter	(8.00%)	1.00%	32.00%	4.00%	(28.00%)	1.00%
CER %, quarter-on-quarter	(7.00%)	(1.00%)	29.00%	1.00%	(26.00%)	1.00%
Symbicort
Product sales
Product Sales	$ 680	$ 691	$ 680	$ 599	$ 653	$ 790
Actual %, quarter-on-quarter	(2.00%)	2.00%	13.00%	(8.00%)	(17.00%)	11.00%
CER %, quarter-on-quarter	(1.00%)		13.00%	(11.00%)	(15.00%)	11.00%
Pulmicort
Product sales
Product Sales	$ 167	$ 330	$ 368	$ 151	$ 97	$ 380
Actual %, quarter-on-quarter	(50.00%)	(10.00%)		56.00%	(74.00%)	(8.00%)
CER %, quarter-on-quarter	(49.00%)	(13.00%)		49.00%	(73.00%)	(9.00%)
Fasenra
Product sales
Product Sales	$ 320	$ 260	$ 283	$ 240	$ 227	$ 199
Actual %, quarter-on-quarter	23.00%	(8.00%)	18.00%	5.00%	14.00%	(3.00%)
CER %, quarter-on-quarter	23.00%	(9.00%)	17.00%	4.00%	15.00%	(3.00%)
Daliresp/Daxas
Product sales
Product Sales	$ 54	$ 60	$ 54	$ 57	$ 53	$ 53
Actual %, quarter-on-quarter	(10.00%)	11.00%	(4.00%)	8.00%	(1.00%)	(8.00%)
CER %, quarter-on-quarter	(9.00%)	10.00%	(6.00%)	11.00%	(3.00%)	(8.00%)
Bevespi
Product sales
Product Sales	$ 13	$ 13	$ 12	$ 14	$ 10	$ 12
Actual %, quarter-on-quarter	1.00%	7.00%	(16.00%)	47.00%	(19.00%)	9.00%
CER %, quarter-on-quarter	3.00%	8.00%	(17.00%)	46.00%	(21.00%)	9.00%
Breztri
Product sales
Product Sales	$ 56	$ 27	$ 6	$ 10	$ 7	$ 4
Actual %, quarter-on-quarter			(39.00%)	45.00%	58.00%
CER %, quarter-on-quarter			(38.00%)	48.00%	64.00%
Respiratory, Others
Product sales
Product Sales	$ 130	$ 160	$ 125	$ 90	$ 70	$ 113
Actual %, quarter-on-quarter	(19.00%)	28.00%	39.00%	27.00%	(38.00%)	(16.00%)
CER %, quarter-on-quarter	(19.00%)	25.00%	35.00%	22.00%	(36.00%)	(17.00%)
Total Other medicines
Product sales
Product Sales	$ 454	$ 548	$ 733	$ 734	$ 563	$ 557
Actual %, quarter-on-quarter	(17.00%)	(25.00%)		30.00%	1.00%	(15.00%)
CER %, quarter-on-quarter	(16.00%)	(26.00%)	(2.00%)	27.00%	4.00%	(15.00%)
Nexium
Product sales
Product Sales	$ 336	$ 403	$ 377	$ 401	$ 377	$ 338
Actual %, quarter-on-quarter	(17.00%)	7.00%	(6.00%)	6.00%	12.00%	(4.00%)
CER %, quarter-on-quarter	(15.00%)	5.00%	(7.00%)	4.00%	14.00%	(4.00%)
Synagis
Product sales
Product Sales	$ 24	$ 24	$ 78	$ 118	$ 90	$ 85
Actual %, quarter-on-quarter	1.00%	(69.00%)	(34.00%)	31.00%	6.00%	35.00%
CER %, quarter-on-quarter	1.00%	(69.00%)	(33.00%)	29.00%	7.00%	35.00%
FluMist
Product sales
Product Sales	$ 1	$ 2	$ 179	$ 116
Actual %, quarter-on-quarter	(51.00%)	(99.00%)	55.00%
CER %, quarter-on-quarter	(71.00%)	(99.00%)	50.00%
Losec/Prilosec
Product sales
Product Sales	$ 46	$ 54	$ 39	45	$ 45	$ 54
Actual %, quarter-on-quarter	(14.00%)	39.00%	(15.00%)		(15.00%)	18.00%
CER %, quarter-on-quarter	(15.00%)	36.00%	(18.00%)		(15.00%)	17.00%
Seroquel XR/IR
Product sales
Product Sales	$ 21	$ 29	$ 19	$ 35	$ 27	$ 36
Actual %, quarter-on-quarter	(29.00%)	51.00%	(45.00%)	32.00%	(26.00%)	(12.00%)
CER %, quarter-on-quarter	(22.00%)	38.00%	(42.00%)	29.00%	(23.00%)	(12.00%)
Other, Others
Product sales
Product Sales	$ 26	$ 36	$ 41	$ 19	$ 24	$ 44
Actual %, quarter-on-quarter	(28.00%)	(6.00%)		(17.00%)	(46.00%)	(71.00%)
CER %, quarter-on-quarter	(32.00%)	(4.00%)		(19.00%)	(42.00%)	(70.00%)

Collaboration Revenue (Details)

Collaboration Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Revenues
Total collaboration revenue	$ 175	$ 227	$ 238	$ 270	$ 727	$ 819
Nexium | Initial Collaboration Revenue | Japan
Revenues
Total collaboration revenue			75
Crestor | Ongoing Collaboration Revenue | Spain
Revenues
Total collaboration revenue						39
Lynparza | Ongoing Collaboration Revenue | Regulatory milestones
Revenues
Total collaboration revenue				135	160	60
Lynparza | Ongoing Collaboration Revenue | Sales milestones
Revenues
Total collaboration revenue					300	450
Lynparza/Koselugo | Ongoing Collaboration Revenue | Option payments
Revenues
Total collaboration revenue						100
Enhertu | Ongoing Collaboration Revenue | Share of gross profits
Revenues
Total collaboration revenue			83	36	94
Roxadustat | Ongoing Collaboration Revenue | Share of gross profits
Revenues
Total collaboration revenue			3	11	30
Royal income | Ongoing Collaboration Revenue
Revenues
Total collaboration revenue			69	34	62	62
Other Ongoing Collaboration Revenue
Revenues
Total collaboration revenue			$ 8	$ 54	$ 81	$ 108

Operating profit - Other operat

Operating profit - Other operating income and expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Operating profit, other operating income and expense
Total other operating income and expense	$ 128	$ 121	$ 1,308	$ 601	$ 1,528	$ 1,541
Brazikumab licence termination funding
Operating profit, other operating income and expense
Total other operating income and expense			51		107
Monetisation of an asset previously licensed
Operating profit, other operating income and expense
Total other operating income and expense					120
Atacand
Operating profit, other operating income and expense
Total other operating income and expense					400
Other operating income and expense
Operating profit, other operating income and expense
Total other operating income and expense			132	200	446	389
Europe ex UK and Spain | Crestor
Operating profit, other operating income and expense
Total other operating income and expense			309
Ex-US, India and Japan | Hypertension medicines
Operating profit, other operating income and expense
Total other operating income and expense				350	350
India | Oxra and Oxramet
Operating profit, other operating income and expense
Total other operating income and expense			40
Japan | Inderal, Tenormin, Seloken and Omepral
Operating profit, other operating income and expense
Total other operating income and expense				$ 51	51
US | Synagis
Operating profit, other operating income and expense
Total other operating income and expense						515
Ex-China, Japan, US and Mexico | Losec
Operating profit, other operating income and expense
Total other operating income and expense						243
US, Canada, Europe and Russia | Seroquel and Seroquel XR
Operating profit, other operating income and expense
Total other operating income and expense						213
Various countries | Arimidex and Casodex
Operating profit, other operating income and expense
Total other operating income and expense						$ 181
Europe and ex-US | Nexium and Vimovo
Operating profit, other operating income and expense
Total other operating income and expense					$ 54
Viela Bio
Operating profit, other operating income and expense
Total other operating income and expense			$ 776